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Fungal immunomodulatory protein (FIP)-fve is isolated from the edible golden 
needle mushroom, Flammulina velutipes. FIP-fve consists of 114 amino acids, 
with the molecular weight of 12.7 kDa. Since its discovery, FIP-fve has been 
shown to play immunomodulatory and adjuvant roles in tumor immunology 
and allergy. However, a comprehensive molecular and cellular mechanism by 
which FIP-fve modulates the immune response to exert its biological effect 
remains unclear. I hypothesized that FIP-fve could mitogenically potentiate T 
cell function by up-regulating T cell surface marker expressions and 
cytokine/chemokine productions, thereby creating a microenvironment 
favoring the initiation and enhancement of adaptive immunity. As an initial 
approach, I examined the effect of FIP-fve on several major immune cell 
types, such as bone-marrow derived dendritic cells (BM-DCs), CD4
+
 T cells, 
and CD8
+
 T cells in vitro. Interestingly, I found that FIP-fve could directly up-
regulate CD69, CD25, and CD137 (4-1BB) expressions on both CD4
+
 T and 
CD8
+
 T cells, whereas the expressions of CD27 and CD28 were mainly up-
regulated on CD8
+ 
T cells. Nevertheless, the ability of FIP-fve to enhance the 
T cell proliferation and secretions of IFN-γ, IP-10, MIG, MIP-1α, and MIP-1β 
appeared to be dependent on the presence of accessory cells (i.e. BM-DCs in 
my study). My subsequent in vitro study showed that addition of anti-CD70 
and anti-OX-40L monoclonal antibodies to  BM-DCs and FIP-fve-stimulated -
total T cells, -CD4
+
 T cells or -CD8
+
 T cells co-cultures resulted in significant 
attenuation of T cell proliferation and cytokine/chemokine production by 
CD8
+
 T cells. Results suggest that the binding of CD70 and OX-40L with their 
cognate receptors on T cells may be involved in mediating the biological 
XI 
 
effect of FIP-fve. Next, when OT-I CD8
+
 T cells were pre-stimulated with 
FIP-fve in vitro, FIP-fve was shown to accelerate as well as enhance the 
magnitude and function of antigen-specific CD8
+
 T cell responses, as 
demonstrated by significant increases in their proliferation, IFN-γ production, 
and killing function towards OVA-pulsed EL4 cells. For in vivo studies, I 
demonstrated that footpad injection of FIP-fve into mice led to significant 
increase in the number of proliferating CD4
+
 T and CD8
+
 T cells as well as the 
recruitment of B cells and NK cells into the draining lymph nodes.  Moreover, 
to confirm T cell activation in draining lymph nodes, FIP-fve was also shown 
to up-regulate the expression of co-stimulatory molecules, CD27 and CD28 on 
CD8
+
 T cells. Furthermore, more importantly, co-immunization of mice with 
FIP-fve and OVA peptide in my short-term immunization regime appeared to 
significantly increase the number and the percentage of antigen-specific CD8
+
 
T cells in vivo. Hence, the results from my in vitro and in vivo studies may 
help to explain how FIP-fve activates and modulates the immune system. 
Since FIP-fve is shown to be capable of eliciting and enhancing antigen-
specific CD8
+
 T cell responses, my results also reaffirm the potential 
application of FIP-fve as a vaccine adjuvant for immunotherapy against cancer 
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Vaccines are among the greatest inventions in history and most successful life-
saving instruments in modern medicine owing to their extremely efficient and 
cost-effective prevention of infectious diseases. The main components of 
traditional vaccines usually comprise of whole-inactivated or live-attenuated 
pathogens. However, there is a potential safety issue when live pathogens are 
given to immunocompromised individuals. To overcome this issue, 
recombinant, synthetic or highly purified subunit antigens have been used to 
substitute the whole pathogen. Unfortunately, these recombinant antigens tend 
to demonstrate weak immunogenicities. Hence, any substances or compounds 
which can help to enhance the immunogenicity of these weak antigens will be 
highly desired. 
1.1 Purposes, classification, and modes of action of adjuvants 
The term adjuvant was coined by Ramon in 1926 to describe substances which 
he used to increase the immunogenicity against tetanus and diphtheria toxins. 
The name adjuvant was derived from the latin adjuvare, meaning to help or to 
aid (Speil and Rzepka, 2011). Thereafter, adjuvants are defined as molecules, 
compounds or macromolecular complexes incorporated into vaccines to boost 
the immunogenicity against a specific antigen. Adjuvants by themselves 
should not pose any significant toxicity or induce long lasting immune effects 
on their own (Wack and Rappuoli, 2005). Due to their main capability of 
enhancing the immunogenicity of weak antigens, adjuvants have been 
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employed in various vaccination strategies and immunotherapy to serve a 
range of purposes. Most of the adjuvants have been characterized and 
classified according to their source, physiochemical properties or stimulatory 
actions. These classifications will be elaborated further in the later section of 
this chapter. 
1.1.1  Different purposes of adjuvants 
Modern immunization uses antigens which are derived from recombinant 
purified proteins or biosynthetic materials. These proteins or materials 
typically result in a modest antibody response with little or no T cell response 
due to the lack of an innate immune stimulus (Petrovsky and Aguilar, 2004; 
Song and Hu, 2009). For instance, although an enormous effort has been put to 
develop the recombinant Influenza vaccines to better prepare for a pandemic, 
it still remains a challenge to supply the candidate vaccines globally. This is 
due to the low immunogenicity of recombinant antigens and thereofore a large 
dose is required per immunization. The incorporation of adjuvants in the 
vaccines design may provide a way to greatly expand the vaccines supply by 
lowering their effective doses. In general, adjuvants may act via modulation of 
immune system to: (1) boost the immune responses against weak antigens; (2) 
speed up the kinetics of immune responses; (3) modulate the specificity, 
function, and isotype distribution of antibody; (4) stimulate cell-mediated 
immunity; (5) enhance the induction of mucosal immunity; (6) promote 
immune responses in immune-deficient individuals; (7) as well as to decrease 
the dose of antigen to be incorporated in the vaccine, thereby reducing its cost 




1.1.1.1 Increase the magnitude and functionality of antibody response. 
Some adjuvants which greatly enhance the magnitude of antibody response 
against vaccine antigens include alum salts, CpG (TLR9 agonist), and oil-in-
water emulsions. The mechanisms of these adjuvants involve the activation of 
danger signal uric acid (Kool et al., 2008), the activation and maturation of 
plasmacytoid dendritic cells and enhanced differentiation of B cells into 
antibody-secreting plasma cells (Vollmer and Krieg, 2009), and formation of 
an “immunocompetent environment” within the muscle that may facilitate the 
development of antigen-specific immune responses (De Gregorio et al., 2013). 
In certain cases, the use of these adjuvants in combination may potentially 
enhance the magnitude and avidity of antibody responses due to their 
synergistic actions. For instance, a CpG adjuvant is included into a 
3′aminomethylnicotine-diphtheria toxoid-conjugate (3′AmNic-DT) of anti-
nicotine vaccine together with alum salts. The combination of these two 
adjuvants results in a significant increase in both the titer and the avidity of 
anti-nicotine IgG in the blood of mice immunized with 3′AmNic-
DT/Al(OH)3/CpG as compared to the group immunized with the Al(OH)3 
adjuvanted vaccine only (McCluskie et al., 2013). Furthermore, it is worth to 
note that the capacity of adjuvants to enhance the amount of functional 
antibodies (antibodies with higher affinity to vaccine antigens) is more 
beneficial as compared to a mere increase of the overall titer of antibodies 
(Kasturi et al., 2011).  
1.1.1.2 Stimulate effective T cell responses.  
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One of the key challenges with many currently available adjuvants is their 
inability to induce optimal T cell responses. A novel adjuvant which is able to 
facilitate the engagement of T helper cells more effectively; hence, enhancing 
the quality and length of antibody responses as well as to induce effector 
CD4
+
 T or CD8
+
 T cells to kill intracellular pathogens will be highly desirable. 
The importance of this property is clearly seen in the design of vaccine against 
diseases which require cellular immune responses to control pathogens, such 
as in malaria, tuberculosis, and leishmaniasis (Reed et al., 2013). Recently, a 
glycolypid adjuvant (7DW8-5), a novel analog of α-galactosylceramide in 
which its adjuvanticity was shown to be mediated by the CD1d molecule, 
iNKT cells, IFN-γ, type I interferon, and CD40-CD40L interaction (Fujii et 
al., 2003; Gonzalez-Aseguinolaza et al., 2002; Silk et al., 2004), was 
incoporarted into a human malaria vaccine. This vaccine, AdPfCA (NMRC-
M3V-Ad-PfCA), consists of two non-replicating recombinant adenoviral (Ad) 
vectors which expressed the circumsporozoite protein (CSP) and the apical 
membrane antigen-1 (AMA1) of Plasmodium falciparum. Results from this 
vaccination demonstrated a significant enhancement in malaria-specific CD8
+
 
T cell responses by about 9-fold after priming and boosting phases in 25 
rhesus macaques; thus providing a promising prospect for further clinical 
development (Padte et al., 2013). 
1.1.1.3 Speed up the immune responses.  
A single-shot of vaccine against pandemic diseases, such as flu, anthrax or 
other potential bioterrorism weapons is always the gold standard of 
vaccination. The effort to shorten the vaccination regimen includes the 
incorporation of an adjuvant to the vaccine antigen. This is demonstrated by 
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the use of the AS04 adjuvant (a combination of TLR4 agonist MPL (3-O-
desacyl-4′-monophosphoryl lipid A) and aluminum salt, which induce local 
NF-κB activity and cytokine production, in hepatitis B vaccine 
(GlaxoSmithKline’s Fendrix). This vaccination strategy resulted in an 
enhanced adaptive immunity (Didierlaurent et al., 2009)) with a shortened 
regimen from three doses to two doses. Moreover, the open-label randomized 
study showed that administration of hepatitis B surface antigen (HBsAg) 
vaccine formulated with a novel adjuvant (HBsAg/AS04) to healthy subjects 
at months 0 and 6 led to a 100% seroprotection rate (anti-HBs ≥ 10 mIU/ml) 
as compared to a 99% response rate in individuals vaccinated with the 
standard licensed recombinant HBsAg vaccine at months 0, 1 and 6. As 
expected, the geometric mean titres of antibodies in groups vaccinated with 
the novel adjuvant (15,468 and 2,745 mIU/ml at months 7 and 12 respectively) 
were indeed significantly higher than those vaccinated with the standard 
adjuvant (6,274 and 1,883 mIU/ml at months 7 and 12 respectively). Thus, the 
use of adjuvants in the vaccine design may simplify the vaccination schedule, 
improve subject compliance and reduce the cost (Chiew Tong et al., 2005; 
Levie et al., 2002).  
1.1.1.4 Broaden the antibody response.  
The capability of adjuvants to expand an immune response profile could 
significantly increase vaccine efficacy against some targets, especially 
influenza viruses, human papilloma virus (HPV), human immunodeficiency 
virus (HIV), and the malaria parasite which showed substantial strain 
variations, antigenic drift or both. The broadening effect of adjuvants was 
experimentally shown to be mediated by the expansion of B cell diversity 
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instead of merely via the increase in antibody titer. In an animal study of 
malaria vaccine against the well-established Plasmodium vivax antigen, the 
incorporation of toll-like receptor (TLR) agonists in the vaccination strategy 
appeared to increase the diversity of the variable region sequences as 
compared to the use of an oil-in-water emulsion adjuvant alone. Analyses of 
the IgG sequences showed that immunization of mice with both TLR4 and 
TLR7/8 agonists resulted in the highest diversity, followed by immunization 
with TLR4 agonist alone. Immunization with TLR7/8 formulation or vehicle 
alone resulted in the least diversity. Hence, the use of adjuvants, such as TLR 
agonists in the vaccine design may be considered as a strategy to generate 
antibodies with high efficacy against a broad range of polymorphic variants 
(Wiley et al., 2011). 
1.1.1.5 Reduce the dose of antigen to be incorporated into a vaccine. 
An effective strategy to meet the global demand of the vaccine against a 
pandemic disease, such as flu will be to reduce the amount of antigen required 
or to employ recombinant vaccines. Despite its manufacturing advantages, a 
recombinant vaccine is weakly immunogenic on its own; hence, requiring a 
large amount of antigen. Fortunately, the amount of recombinant antigen 
needed to induce the target antibody titers could still be reduced with the 
addition of adjuvants to the recombinant protein. For instance, the 
incorporation of glucopyranosyl lipid adjuvant–stable emulsion (GLA-SE) to 
the recombinant influenza H5 protein was shown to reduce the amount of 
antigen required to reach 40% seroconversion. This was achieved with only 
one immunization and the level was greater than 30-fold as compared to the 
antigen alone (Treanor et al., 2013). 
7 
 
1.1.2 Different classifications of adjuvants and their examples 
Due to their potential application and contribution to vaccine development, the 
interest in adjuvant research has been gaining popularity recently. As a first 
step to understand how adjuvants act and shape the immune system, a rational 
classification of different types of adjuvants based on the current knowledge 
will be helpful. There are several different criteria to classify adjuvants to 
allow their rational comparison. Earlier, two different broad groups which can 
be allocated to classify adjuvants are particulate and non-particulate (Cox and 
Coulter, 1997). More recently, adjuvants are grouped according to their 
particulate and non-particulate properties, physiochemical properties or 
mechanism of action, as well as their stimulatory action (Reed et al., 2009; 
Ribeiro and Schijns, 2010).  
1.1.2.1 Classification of adjuvants based on their particulate and non-
particulate properties 
The activity of particulate adjuvants is partly contributed by the property of 
their microscopic structure. The effects of particulate adjuvants are only 
generally seen when the immunogen can be incorporated into or at least 
associated with the particulate. Some examples of particulate adjuvants 
include aluminium salts (insoluble, gel-like precipitate of aluminium 
hydroxide, aluminium phosphate or alum with a particle size from 100 to 1000 
nm) (Gupta and Rost, 2000), water-in-oil or oil-in-water emulsions, immune 
stimulating complexes (ISCOM™ adjuvant-Iscotec AB), liposomes (single or 
multilamellar bilayer membrane vesicles comprising of cholesterol and 
phospholipid, with the sizes ranging from 20 nm to 3 µm), nano- and 
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microparticles (small solid particles, with the sizes of 10 to 1000 nm for 
nanoparticles, and 1 to 100 µm for microparticles, which form a range of 
biocompatible and biodegradable polymers, typically cyanoacrylates and the 
polylactide-co-glycolide (PLG) copolymers), virosomes (liposomes which 
contains fusogenic viral proteins), and niosomes (vesicles consisting of 
nonionic surfactants instead of phospholipids) (Cox and Coulter, 1997; Reed 
et al., 2013). A study suggested that particulate adjuvants could enhance the 
survival of murine bone marrow-derived macrophages. Moreover, in the 
presence of GM-CSF and CSF-1, these adjuvants were shown to 
synergistically induce DNA synthesis and proliferation of bone-marrow-
derived macrophages, suggesting that particulate adjuvants may exert their 
function by increasing the frequency of cells available for subsequent antigen 
presentation and cytokine production (Hamilton et al., 2000). 
In contrast, the activity of non-particulate adjuvants does not rely on their 
particulate or multimeric nature. They generally exert their 
immunomodulatory function by improving targeting; however, the benefit can 
only be seen when they are in association with an antigen. Several examples of 
non-particulate adjuvants are muramyl dipeptide (MDP) and derivatives, non-
ionic block copolymers, saponins, lipid A, cytokines, carbohydrate polymers, 
derivatized polysaccharides, and bacterial toxins (Cox and Coulter, 1997; 
Grant et al., 1994).  
1.1.2.2 Classification of adjuvants based on their physiochemical or 
mechanisms of action properties 
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To date, the mechanisms of action of most adjuvants are still not well 
characterized; nonetheless, adjuvants are generally classified into two classes  
including (1) immunostimulants which will have effects on immune system 
directly to enhance the responses to antigens, examples include toll-like 
receptors (TLR) ligands, cytokines, saponins, and bacterial toxins; (2) vehicles 
which will enhance the presentation of antigens to the immune system in an 
optimal manner via controlled release and depot delivery systems; in addition, 
the vehicle can also be used to deliver the immunostimulants, examples 
include emulsions, mineral salts, liposome, virosomes, and biodegradable 
polymer microspheres (Reed et al., 2009). 
1.1.2.3 Classification of adjuvants based on their stimulatory actions 
properties 
The T cell response is known to be activated and maintained by three different 
signals (i.e. signal 0, 1, and 2) (Fig. 1.1). Signal 1 refers to the specific peptide 
presentation by major histocompatibility complex (MHC) molecules to the T 
cell receptor (TCR). With the presence of signal 1 alone, T cells may undergo 
anergy and abortive responses; hence, an additional co-stimulatory signal 
(referred to as signal 2) has to be given to sustain the immune responses. This 
signal 2 includes the interaction between the receptors on T cells and their 
respective ligands on antigen presenting cells (APCs), such as CD40 – CD40L 
(CD154), OX40 (CD134) – OX40L (CD134L), CD80 (B7.1) or CD86 (B7.2) 
– CD28 bindings. A later discovery demonstrates that an additional earlier 
signal (referred to as signal 0) is essential for activation of APCs and 
subsequent TH responses. Signal 0 occurs when the pathogen-recognition 
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receptors (PRRs), such as TLRs on APCs recognize the pathogen-associated 
molecular patterns (PAMPs) on microbes (Bianchi, 2007; Guy, 2007). 
Based on the requirement for these different signals, adjuvants can be 
classified as follows: 
 Signal 1 facilitators; this group of adjuvants may improve the 
immunoavailability by ensuring the presence of constant amount of 
antigens at the vaccination sites via their antigen depot function, which 
ultimately leads to the enhancement of adaptive T cell and B cell 
responses. Examples include alum-containing adjuvants and oil-based 
emulsions. 
 Signal 2 facilitators; this group of adjuvants improves the co-
stimulation pathways by up-regulating the expression of co-stimulatory 
molecules, such as CD40, CD80, CD86, and major histocompatibility 
complex (MHC). Examples include recombinant cytokines or co-
stimulatory molecules (Ribeiro and Schijns, 2010). 
 Signal 0 facilitators; this group of adjuvants improves the targeting of 
antigens to antigen presenting cells (APCs); thus, resulting in enhanced 
uptake of antigens and subsequent activation of APCs. Examples 
include the coupling of antigens to the TLR-5 agonist flagellin (Mizel 














Figure 1.1 Adjuvants may act either alone or in combination on three 
different signals, commonly referred to as signal 0, 1, and 2. Signal 0 is 
activated during antigen recognition and APCs activation, signal 1 is involved 
in antigen presentation to T helper (TH) cells, whereas signal 2 is related to the 
engagement of co-stimulatory molecules on activated T cells. (Source: Guy, B. 
(2007). "The perfect mix: recent progress in adjuvant research." Nat Rev 
Micro 5(7): 505-517) 
 
Adjuvants may act on the three essential signals for initiation, activation, and 
maintenance of T cell immune responses (referred to as signal 0, 1, and 2), 
either alone or in combination. Most currently developed adjuvants act on 
signal 0 and indirectly on signal 2 which in turn lead to the activation of 
antigen presenting cells (APCs) and the secretion of some cytokines, such as 
interleukin (IL)- 12 and -4. The TLR agonists are categorized under this group 
of adjuvants which are also known as type A adjuvants.  
Another group of adjuvants, known as type B adjuvants, mainly enhance the 
antigen presentation to T cells by favoring antigen capture; thus, activating 
signal 1. Nonetheless, stimulating signal 1 alone is not sufficient; thus, an 
immunostimulatory signal needs to be co-delivered for an optimal response. 
Liposomes, microspheres, and some emulsions fall under this group. Lastly, 
the type C adjuvants are the ligands of co-stimulatory molecules which can 
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directly enhance signal 2; however, these molecules have to be used with 
caution as there is a possibility for them to induce non-specific overreactions 
(Guy, 2007). 
1.1.3 Mechanisms of action of commonly used adjuvants 
In the past decades, Dr. C Janeway Jr. named vaccines as “dirty little secret” 
of immunology as vaccines only showed efficacy because of the “dirt” in them 
(Janeway, 1989). This “dirt” which he referred to was actually the microbial or 
natural products that functioned as adjuvants by stimulating the immune 
system which subsequently led to long-term protective immunity. Some 
adjuvants which are currently licensed for use in human vaccines include 
aluminum salts (mostly used in US), oil-in-water emulsions (MF59, AS03 and 
AF03, mostly employed in Europe), virosomes and AS04 (monophosphoryl 
lipid A preparation (MPL) with aluminum salt) (Reed et al., 2013).  One of the 
best known mechanisms of adjuvants is to serve as the depot formation which 
is commonly observed in particulate adjuvants, such as alum, emulsion-based, 
and insoluble adjuvants (Cox and Coulter, 1997). The mechanism of depot 
formation involved sequestration of antigens and adjuvants from their 
injection site, allowing a slow release of the mixture to stimulate APCs, such 
as dendritics cells (DCs) and macrophages at a constant rate (Marciani, 2003).  
A more comprehensive understanding on the mode of action of adjuvants 
involves the classification of adjuvants into innate immunity adjuvants and 
adaptive immunity adjuvants. Innate immunity adjuvants may bind to broadly 
specific TLRs and PRRs on APCs, resulting in activation of NF-κB and 
enhanced B7 ligands expressions as well as increased production of 
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inflammatory cytokines. While, adaptive immunity adjuvants may bind to 
specific surface receptors on T cells, resulting in activation of T cells via up-
regulation of co-stimulatory signals and induction of cytokine-regulated genes 
(Table 1.1). 










Bind to broadly specific 
TLRs and PRRs on APCs 
Bind to specific surface 
receptors on T cells 
Mode of action 
Activate Nuclear Factor-
κB to: 
• Produce inflammatory 
cytokines 
• Increase B7 ligands 
production 
Adaptive immunity will 
then be activated 
Activate T cell by: 
• Co-stimulatory signals 
• Induction of cytokine-
regulated genes 
Examples 
Microbial products or 
PAMPs, e.g. CpG-DNA 
and LPS 
Natural or synthetic 
products, such as 
cytokines, quillaja 
saponins, and tucaresol 
 
(Source: Marciani, D. J. (2003). "Vaccine adjuvants: role and mechanisms of 
action in vaccine immunogenicity." Drug Discovery Today 8(20): 934-943) 
 
Moreover, several putative mechanisms of action of adjuvants have been 
proposed recently (Fig 1.2). Many adjuvants may act as ligands for PRRs to 
activate innate immune responses. The activated receptors will then trigger 
downstream signaling pathways leading to the activation of transcription 
factors and production of some cytokines and chemokines which are essential 
for T cells polarization as well as recruitment of other immune cells to the site 
of administration. Other mechanisms include the activation of inflammasome 
which will induce the production of pro-inflammatory cytokines IL-1β and IL-
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18, as well as the enhancement of antigen presentation by MHC molecules. 
Furthermore, it is likely that some adjuvants may act via multiple mechanisms, 
such as alum which has been suggested to induce antigen uptake and stimulate 
PRR signaling, inflammasome activation, and recruitment of immune cells. 







                                
Figure 1.2 Current postulations on mechanisms of action of adjuvants. 
Many adjuvants may act as the ligands for pathogen recognition receptors 
(PRRs) to activate the innate immune response. The downstream signaling 
from these receptors may activate the transcription factors, leading to 
production of various cytokines and chemokines. The activation of 
inflammasome which involves the production of pro-inflammatory cytokines 
IL-1β and IL-18 has also been implicated as a mechanism for some adjuvants. 
Some adjuvants also act on MHC molecules to enhance antigen presentation. 
It is also possible for the adjuvants to act via these different mechanisms 
simultaneously. (Source: Reed, S. G., M. T. Orr and C. B. Fox (2013). "Key 
roles of adjuvants in modern vaccines." Nat Med 19(12): 1597-1608). 
 
1.1.3.1  Modes of action of aluminum salts 
Due to its history of excellent safety profile and capability to induce protective 
humoral immune responses, aluminum hydroxide (alum) has been widely used 
as an adjuvant in human prophylactic vaccines; however, since its first 
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discovery in the 1920s, its mechanism of action is still not fully elucidated 
although million of doses of alum-containing vaccines have been given to a 
large human population (Naim et al., 1997). There are three suggested 
mechanisms on how alum may function as an adjuvant to boost the humoral 
immunity, (1) via a depot formation which allows slow release of antigen to 
enhance humoral immunity; (2) via an induction of inflammation which 
recruits the activated DCs for antigen capture; (3) via the conversion of 
soluble antigen into particulate form which may be phagocytosed by DCs, 
macrophages or B cells (Brewer, 2006). 
Recent studies haveshown that the hypothesis of alum to function as a depot is 
debatable. White et al. demonstrated that immunization of rabbits with antigen 
and alum salts resulted in the presence of B cell blasts in the draining lymph 
nodes at day 7 post-immunization and at the site of the granuloma by day 14. 
However, after 3 weeks, only few B cell blasts remained in the draining lymph 
nodes, suggesting that antigen was no longer present or circulating through the 
lymph nodes, therefore it raised a question of whether alum salts could simply 
function by providing a long-lived antigen depot (Marrack et al., 2009; White 
et al., 1955).Another study by Lambrecht B.N. et al. suggested that the 
presence of alum resulted in antigen uptake, processing, and presentation by 
inflammatory monocytes which originated from peritoneum. These monocytes 
would subsequently become inflammatory DCs that induced a persistent Th2 
response. A conditional depletion of CD11c
+
 monocytes and DCs was shown 
to abolish the adjuvant effect of alum. In addition, the DC-driven responses 
were also abolished in MyD88-deficient mice as well as after treatment with 
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uricase, suggesting the involvement of the endogenous danger signal uric acid 
(Kool et al., 2008).  
Recently, a new mechanism on how alum may work as an adjuvant has also 
been proposed by Flach et al. which involves (1) the interaction of alum 
crystals with sphingomyelin and cholesterol lipids on the DCs membrane at 
the vaccination site which will subsequently induce clustering of ITAM-
containing receptors and downstream Syk and PI3K signaling; (2) 
internalization of antigen by DCs in the absence of alum uptake, followed by 
up-regulation of MHC class II, ICAM-1 and co-stimulatory molecules such as 
CD80 expressions on the DCs surface; (3) dissociation of activated antigen-
loaded DCs from the alum crystals and migration of DCs to lymph nodes 
where they will activate antigen-specific CD4
+
 T cells, leading to the 
enhancement of humoral immune responses (M Lamine Mbow, 2011). These 
findings have uncovered a novel key mechanism in which the interaction of 
alum with lipid rather than protein receptors may drive immune stimulation. 
This new insight may facilitate a better vaccine design. 
1.2 Safety of adjuvants and their potential side effects 
To accelerate the development of novel vaccine adjuvants which are safe for 
human use, it is important to understand the mechanism of action of each 
vaccine adjuvant. However, most of these studies are usually performed in 
animal models which may not accurately mimic the outcome in humans. The 
intrinsic discrepancies between different species may limit the ability of 
animal models to predict the effect of vaccine adjuvants in humans. These 
discrepancies include the differences in innate immune receptors, in cellular 
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sources of some pro-inflammatory cytokines, and also in anatomical structure 
of the skin and mucous membranes.  
Since the size of clinical trial conducted prior to the licensure of a new vaccine 
adjuvant is usually not very large, it is important to collect the data from post-
marketing and follow-up studies. If possible, a large database of immune 
profiles can be established from both healthy and immunocompromised 
populations. The immunocompromised population may include the individual 
with some underlying conditions, such as pregnancy, transplantation, HIV 
infection, autoimmune diseases or old age. The result from this large dataset 
may assist in identifying potential biomarkers, such as cytokines, pro-
inflammatory mediators or molecular profiling which may predict the onset or 
exacerbation of immune disorders and any link between the adjuvant and 
short- or long-term adverse events (Mastelic et al., 2010). 
Some of the local adverse events triggered by the vaccine adjuvants include 
local inflammation at the injection site and, very seldom, the induction of 
granuloma or sterile abscess formation. In addition, some of the systemic 
reactions to adjuvants have also been found in laboratory animals, including 
malaise, fever, adjuvant arthritis and anterior uveitis (Waters et al., 1986). 
These reactions may be due to the responses, such as the cytokine profile 
produced by the adjuvant against an antigen. Hence, animal models must 
always be used and developed to predict the effectiveness and safety of the 
vaccine adjuvants in humans as accurately as possible, despite the intrinsic 




1.3 Future direction and limitation of current adjuvants 
Recent advancement in proteomics and genomics has facilitated the 
formulation of recombinant and synthetic vaccines molecules; however, it has 
also imposed a demand for the development of novel adjuvants. One of the 
major interests is to design a vaccine with the capability of inducing a strong 
immune response by both cytotoxic and TH-1 helper T cells as well as the 
production of immuno-stimulatory cytokines, such as IFN-γ. This is 
particularly needed for vaccines against chronic viral infection, infections 
linked to intracellular pathogens, and cancer (therapeutic vaccines) (Seder and 
Hill, 2000). Moreover, the ability of adjuvants to induce mucosal and 
polarized (e.g. TH-1 or TH-2) immune responses without eliciting unacceptable 
local reactions or toxicity is also highly desired.  
Despite recent mechanistic studies have shed considerable light on how some 
adjuvants (e.g. alum and oil-in-water emulsion) exert their function, similar 
work has to be done as well on the next-generation adjuvants to determine the 
type of immune responses being elicited (i.e. cell-mediated or humoral 
immunity). In addition, the effort to find alternative routes of delivery will also 
allow high-throughput, rational screening of potential adjuvant candidates as 
well as facilitate the optimization and development of new adjuvants. Another 
new key area to explore in adjuvant research is targeting the dendritic cells 





 myeloid DCs were found to cross-present 
exogenous antigens proficiently via MHC Class I, hence inducing robust 
CD8
+ 





 DCs were shown to induce the formation of 
CXCL13-secreting follicular helper cells which enhanced class switching but 
were incompetent in driving cytotoxic T lymphocyte formation (Klechevsky et 
al., 2008). Thus, future studies have to assess the feasibility and make a 
rational selection of the adjuvant and the route of administration to activate 
certain DCs subsets depending on the type of desired immune responses. 
1.4 Mushrooms and their potential adjuvanticity properties 
1.4.1 Mushrooms – nutritional and medicinal values 
From a taxonomy perspective, mushrooms refer to mainly Basidiomycetes as 
well as some species of Ascomycetes. Mushrooms are defined as macrofungi 
with typical fruiting bodies. They are either epigeous (with fruiting bodies 
located above the ground) or hypogeous (with fruiting bodies located under 
the ground) and sufficiently noticeable by naked eyes to be hand-picked 
(Chang and Miles, 1992). Many types of mushrooms are edible and rich in 
nutritional as well as bioactive metabolites of high medicinal values, such as 
lectins, polysaccharides, phenolic and polyphenolics, terpenoids, ergosterols, 
and volatile organic compounds (Chang and Buswell, 1996). The nutrient 
composition and biological active compounds in mushrooms vary greatly 
depending on mushroom types, growing medium, moisture content, 
developmental stage, and the age of mushrooms (Feeney, 2006). To date, 
mushrooms consist of at least 14,000 known species. There is an estimated 
140,000 mushroom species exist on earth, suggesting that only about 10% of 
mushroom species are known. Assuming that only 5% of the undiscovered and 
unexamined mushrooms are beneficial, there will still be about 7,000 species 
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which may provide potential nutritional and medicinal values to mankind 
(Hawksworth, 2001). Of the mushroom species that have been identified 
currently, about 650 species are reported to possess medicinal values (Minato, 
2010). Some extensive clinical studies, primarily in China and Japan, have 
explicitly demonstrated that mushroom extracts exhibit immunomodulatory, 
medicinal, and therapeutic values in prevention or treatment of cancer, viral-
related diseases, hypercholesterolaemia, blood platelet aggregation, 
hypertension, as well as in prevention of cardiovascular diseases owing to 
their effects as antiatherosclerosis agents (Mu et al., 2012; Zong et al., 2012).  
1.4.2 Mushrooms as immunomodulators 
Mushroom immunomodulators have been shown to stimulate both innate and 
adaptive immunities. They have been shown to activate innate immune cells: 
DCs, natural kiler (NK) cells, monocyte/macrophages and induce 
cytokine/chemokines production. These cytokines may in turn activate 
adaptive immune cells by polarizing the T cells into T helper (TH)-1 or TH-2 
effector cells and stimulating the differentiation of B cells for antibody 
production (Borchers et al., 2008). To date, mushroom immunomodulators are 
categorized into four broad groups, namely lectins, terpenes and terpenoids, 
polysaccharides as well as fungal immunomodulatory proteins (FIPs) (El 
Enshasy and Hatti-Kaul, 2013).  
1.4.3 Lectins 
Lectins are typically recognized as the proteins with specific binding 
capacities towards a diverse group of carbohydrates. They are widely present 
in various organisms, such as animals, plants, fungi, bacteria, and viruses. 
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Interestingly, the mushroom-derived lectins display immunomodulatory and 
anti-tumor activities (Sze et al., 2004). A thermostable lectin (18 kDa), derived 
from Ganoderma capense, shows higher mitogenic activity than concanavalin 
A toward mouse splenocytes but anti-proliferative activity against leukemia 
and hepatoma cells (Ngai and Ng, 2004). Another novel 15.9-kDa 
homodimeric, lactose-binding, ricin-B-like lectin which is purified from the 
basidiomycete Clitocybe nebularis also suppresses the proliferation of human 
leukemic T cells by binding to carbohydrate receptors on human leukemic T 
cells (Pohleven et al., 2009). In addition, this lectin is capable of inducing 





 T cells towards TH-1 phenotypes, as shown by the 
increased percentage of IFN-γ-producing cells after 5 days of Clitocybe 
nebularis lectin-treated DCs and naïve CD4
+
 T cells co-culture (Švajger et al., 
2011). In addition, a lectin (20 kDa) is also extracted from the fruiting bodies 
of Flammulina velutipes with phosphate buffer, purified by zinc acetate 
treatment and CM-cellulose column chromatography. The lectin is dissociated 
into two subunits, namely FVA-L (12 kDa) and FVA-S (8 kDa), in the 
presence of 6 M guanidine-HCl. The haemagglutinating and mitogenic 
activities are mainly elicited by the FVA-L subunit and not altered by the 
common simple sugars, suggesting that the F. velutipes lectin may not have 
affinity for more complex carbohydrate structures on the cell surface (Tsuda, 
1979). 
1.4.4 Terpenes and terpenoids 
A diversified group of organic compounds, known as terpenes, consist of 
isoprene five-carbon subunits ((C5H6)n) as building blocks. These compounds 
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are widely present in plants as the main constituent of resin and essential oil. 
Terpenes are found in modified form in mushrooms. The fruiting bodies 
extract of Ganoderma sp. contains various terpenes and terpene derivatives, 
such as ganodermic and ganoderic acids, ganoderals, ganoderols, 
ganodermanontriol, lucidone, and ganodermanondiol, which may stimulate the 
nuclear factor (NF)-κB pathway and mitogen-activated protein kinases as well 
as prevent drug nephrotoxicity and inflammation (Gao et al., 2002; Pillai et al., 
2011).  
1.4.5 Polysaccharides 
Different types of polysaccharides from mushroom extracts possess 
immunomodulatory properties. These polysaccharides are homoglycans or 
heteroglycans which may combine with other proteins to form peptidoglycan 
(Enshasy, 2011). Lentinan (a β-1,3-D-glucan with β-1,6 branches), isolated 
from the fruiting body of Lentinus edodes in the late 1960s in Japan, is the first 
known polysaccharide with potential immunomodulatory and anti-cancer 
activities (Ikekawa et al., 1969). Furthermore, lentinan is also the first 
mushroom polysaccharide which is approved to be used clinically as an 
immune adjuvant to chemotherapy for stomach cancer treatment in Japan 
since 1985 (Higashi et al., 2012). A few of mushroom polysaccharides, such 
as β-glucan type, schizophyllan from Schizophyllum commune and the protein-
bound polysaccharide Krestin from Coriolus versicolor are successfully 
marketed by nutraceutical and pharmaceutical companies as biological 
response modifier drugs due to their efficacies in enhancing immune responses 
in both in vitro and in vivo models (Mu et al., 2012). Nevertheless, the 
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understanding of chemical structures and exact immunomodulatory effects of 
mushroom polysaccharides on the immune system remains incomplete.  
1.4.6 Fungal immunomodulatory proteins (FIPs) 
FIPs family consists of different immunomodulatory proteins derived from 
higher Basidiomycetes. To date, there are 11 members of FIPs family since the 
first discovery of Ling-Zhi-8 (FIP-LZ-8 or FIP-glu) from Ganoderma lucidum 
in 1989 (Tanaka et al., 1989), including FIP-fve from Flammulina velutipes 
(Ko et al., 1995a), FIP-gts from Ganoderma tsugae (Hsiao et al., 2008), FIP-
gsi from Ganoderma sinensis (Li et al., 2010), FIP-pcp from Poria cocos 
(Chang et al., 2009) , FIP-vvo and FIP-vvl from Volvariella volvacea (Hsu et 
al., 1997b), FIP-aca from Antrodia camphorate (Sheu et al., 2009), FIP-gja 
from Ganoderma japonicum, FIP-gmi from Ganoderma microsporum (Lin et 
al., 2010), and the new FIP family member, namely FIP-tvc from Trametes 
versicolor (Li et al., 2011a). Most of the FIPs share some homology in their 
amino acid sequences (Fig 1.3) as well as display structural and functional 






















Figure 1.3 Alignment of amino acid sequences from members of FIPs: 
LZ-8, FIP-gts, FIP-gja, FIP-gmi, FIP-fve, FIP-vvo, FIP-tvc, FIP-aca, and 
FIP-pcp. Identical amino acids are represented by [*], while partial identical 
amino acids are indicated by [:] and [.]. 
 
 
1.4.6.1 Characteristics of FIPs 
Most FIPs consist of 110 to 114 amino acids with the molecular weight of 
approximately 13 kDa. They are poor in His, Cys, and Met but rich in Asp and 
Val and are acetylated at the N-terminus (Hsu et al., 1997b; Ko et al., 1995a; 
Lin et al., 2010). FIPs mostly exist as a dimer in nature. Using single 
anomalous diffraction, Paaventhan et al. reported that the NaBr-soaked crystal 
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structure of FIP-fve was a dumb-bell shaped homodimer. Each monomer 
contains an N-terminal α-helix followed by a fibronectin III (FNIII) fold 
which is a transition between the seven β-stranded s-type and the eight β-
stranded h-type topologies (Paaventhan et al., 2003a). Among the FIP family 
members, FIP-LZ-8 (FIP-glu), FIP-fve, FIP-vvo and FIP-gts have been better 
characterized. The analysis of primary structure from the four FIPs indicates 
that LZ-8 (FIP-glu) has the similar amino acid sequence as FIP-gts where both 
of them share 60–70% homology with FIP-fve and FIP-vvo. Furthermore, four 
completely conserved amino acid segments are also found in the hydrophilic 
β-sheet that are directly related to its function (Li et al., 2011b).  
1.4.6.2 Recombinant FIPs and their expression systems 
One of the key challenges for potential exploitation of FIPs as medicinal or 
nutritional supplements is their extremely low yield from natural sources. 
Only few milligrams amount of FIPs can be obtained from one kilogram of 
macrofungi. Several reports showed that 35 mg of FIP-fve can be obtained 
from 400 g fruiting bodies of F. velutipes (Ko et al., 1995a), 5 to 10 mg of 
FIP-LZ-8 (FIP-glu) from 340 g of G. lucidum mycelium (Tanaka et al., 1989), 
and 115 mg FIP-vvo from 3 kg fresh fruiting bodies of Volvariella volvacea 
(Hsu et al., 1997b). Thus, a lot of efforts have been invested in improving the 
yield of FIPs for practical use by different genetic engineering approaches.  
To date, several reports have demonstrated that the genes encoding FIPs have 
been successfully expressed in both prokaryotic and eukaryotic systems. In 
prokaryotic system, FIP-LZ-8 (FIP-glu) gene is expressed using pET-30 
vector with the yield of 36.46 mg/L of recombinant FIP-LZ-8 protein (Ye et 
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al., 2002). A fusion protein of glutathione S-transferase (GST) and FIP-gts is 
also expressed in E. coli TG1 with the yield of 20 mg/L of recombinant 
protein after being cleaved by thrombin (Lin et al., 1997). Similarly, FIP-fve is 
fused with GST and expressed using the pGEX-2T in E. coli with the yield of 
5 mg/L (Ko et al., 1997). In eukaryotic system, FIP-LZ-8 is successfully 
expressed in Pichia pastoris where it yield 191.2 μg/L of recombinant FIP-
LZ-8 protein (Lin et al., 2009a). Using the insect cells Sf21 expression system, 
FIP-gts is expressed as a fusion protein with 6xHis-tag with the yield of 47.2 
μg of recombinant protein per 3x106 infected cells (Jinn et al., 2006). Similarly 
for FIP-fve, the insect cells expression system can yield 6.25 mg/L of 
recombinant FIP-fve protein (3.1 μg per 106 infected cells). However, in this 
system, recombinant FIP-fve protein is highly glycosylated, possibly due to the 
two potential N-linked glycosylation sites on FIP-fve (Wu et al., 2008). All 
recombinant FIPs are shown to retain their capabilities of inducing 
lymphocyte proliferation and cytokines expression.  
Besides the expression of individual FIPs in different systems, a novel strategy 
of in vitro shuffling of four FIPs genes is performed by PCR technique. The 
rationale underlying this strategy is that DNA shuffling can be utilized to 
generate evolved recombinant proteins with increased expression, improved 
bioactivity and enhanced stability. The first shuffled library contain the 
intrageneric group of shuffled FIP-glu and FIP-gsi genes; while the second 
library of intergeneric group contain the shuffled FIP-glu, FIP-fve, and FIP-
vvo genes. The shuffled genes have higher protein expression as compared to 
their native counterparts and maintain the original bioactivity, such as 
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induction of IL-2, IL-4, IFN-γ, IL-2R, and LT expressions in a dose-dependent 
manner (Wang et al., 2013).  
1.4.6.3 Biological functions and proof-of-concept studies on FIPs 
1.4.6.3.1 Haemagglutination activity 
Most FIPs demonstrate the ability to agglutinate the red blood cells from 
human, mouse, sheep, and rat. FIP-LZ-8 was shown to haemagglutinate sheep 
red blood cells at a concentration of greater than 6.25 μg/ml but no similar 
activity was observed toward human erythrocytes (Tanaka et al., 1989). While 
FIP-vvo is able to agglutinate the red blood cells from Wistar rats, Balb/c 
mice, and rabbits at the minimal concentrations of 0.52 μg/ml, 1.11 μg/ml, and 
0.13 μg/ml respectively, it does not demonstrate any haemagglutination 
activity on human erythrocytes (Hsu et al., 1997b). On the other hand, FIP-fve 
was shown to haemagglutinate all types of human red blood cells, i.e. A, B, 
AB, and O types (Ko et al., 1995a).   
Since lectin has also been known for its haemagglutination activity, it is 
speculated that FIPs belong to lectin family. However, FIPs are actually 
different from lectins in several ways, such as (1) FIPs consist of mostly 
proteins without carbohydrate (except FIP-LZ-8 with 1.3% of sugar amount); 
whereas, lectins exist as mostly glycoproteins or sugar-binding proteins; (2) 
the bioactivities of FIPs are not inhibited by common simple sugars, i.e. 
monosaccharides or oligosaccharides (Li et al., 2011b). 
1.4.6.3.2 Mitogenic activity 
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One of the well known immunological properties of FIPs is to function as 
mitogens which activate and promote the proliferation of lymphoid cells, such 
as mouse spleen cells and human peripheral blood lymphocytes (hPBL) in a 
dose-dependent manner. FIP-fve and FIP-vvo were shown to stimulate the 
proliferation of hPBL at concentrations of 100 μg/ml and 5 μg/ml respectively 
(Hsu et al., 1997b; Ko et al., 1995a); whereas FIP-LZ-8 was reported to show 
maximal stimulatory activity on mouse spleen cells at a concentration of 3.13 
μg/ml (Kino et al., 1989).  
1.4.6.3.3 Induction of cytokines expression 
Cytokines have been regarded as new biological response modifiers due to 
their ability to regulate the body’s physiological processes and enhance the 
immune system to fight some human diseases, such as cancers (Leung et al., 
2006). Various reports showed that FIPs could enhance the expression of 
several cytokines which are essential for immune modulation (Hsu et al., 
1997a; Kino et al., 1989; Ko et al., 1995a). Stimulation of murine splenocytes 
with FIP-fve resulted in increased transcript levels of IL-2 and IFN-γ. In 
addition, oral administration of FIP-fve into ovalbumin (OVA)-immunized 
mouse model resulted in enhancement of TH-1-predominant cytokines profile 
in which the level of serum IFN-γ was  significantly higher and the level of 
IL-5 was significantly lower in the FIP-fve-fed mice as compared to the PBS 
control group (Hsieh et al., 2003). When mouse splenocytes were stimulated 
with various concentrations of FIP-vvo for 4 hours, the transcripts of IL-2, IL-
4, TNF-α, IFN-γ, lymphotoxin, and IL-2 receptor were enhanced in a dose-
dependent manner. Thus, FIP-vvo appeared to exert its immunomodulatory 
effect via cytokine regulation (Hsu et al., 1997a). Moreover, it is speculated 
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that FIPs act indirectly to modulate the immune responses by initially 
mediating the cell-cell agglutination or cell-fundus which in turn promotes 
cellular proliferation and enhance the production of cytokines; these cytokines 
will subsequently regulate or polarize the immune cells (Li et al., 2011b).  
1.4.6.3.4 Anti-tumor activity  
In recent years, immunotherapy has become an attractive alternative for the 
treatment of cancer patients. Studies have focused on the use of cancer vaccine 
to provide active immunization for the treatment of growing tumors 
(Rosenberg et al., 2004). Several studies have demonstrated that FIPs is able 
to exert anti-tumor activity both in vitro and in vivo; thus, they may serve as 
potent adjuvants for tumor vaccines or anti-tumor medicines with high 
efficacy, specificity, and low toxicity. The addition of 32 μg/ml of FIP-LZ-8 
was shown to induce 35% of human leukemia-NB4 cells undergoing apoptosis 
(Lin et al., 2009a). Besides, FIP-gts was also shown to inhibit the proliferation 
of human lung adenocarcinoma A549 cells by arresting the cells at G1 phase 
and turning some cells apoptotic (Yeh et al., 2008). Further investigation on 
FIP-gts suggested that it could significantly reduce cervical cancer cell 
migration in SiHa and non-metastatic clone 23 type 1 (nm23-H1) transfected 
Caski cells. In addition, it could also suppress telomerase activity in A549 
cells via nucleus export mechanism which could be mediated by endoplasmic 
reticulum stress-induced intracellular calcium levels (Liao et al., 2006; Liao et 
al., 2007; Wang et al., 2007). When FIP-fve was co-administered with human 
papillomavirus (HPV)-16 E7 oncoprotein in the TC-1-inoculated tumor mouse 
model, FIP-fve appeared to serve as a potent adjuvant which enhanced 
antigen-specific humoral and cellular immunities. Besides the significant 
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increase in HPV-16 E7-specific antibodies production and expansion of HPV-
16 E7-specific IFN-γ-producing CD4+ and CD8+ T cells, FIP-fve was also 
shown to stimulate the maturation of splenic dendritic cells in vivo. From 
tumor protection assay, 60% of mice receiving HPV-16 E7 and FIP-fve co-
immunization remained tumor-free for up to 167 days post-challenge with 
tumor cells as compared to 20% of mice receiving HPV-16 E7 immunization. 
Furthermore, the tumor therapeutic assays also demonstrated that co-
immunization of mice with HPV-16 E7 plus FIP-fve could significantly 
prolong the survival of tumor-bearing mice as compared to the control group 
(Ding et al., 2009).  Recently, a newly discovered FIP, namely FIP-gmi, has 
also been shown to suppress tumor invasion and metastasis by inhibiting 
epidermal growth factor (EGF)-induced migration and invasion. FIP-gmi 
inhibits phosphorylation and activation of EGF receptor as well as AKT 
kinases pathway upon EGF induction. In addition, FIP-gmi also inhibits 
activation of Cdc42 GTPase and microfilament depolymerization upon EGF 
induction (Rosenberg et al., 2004). 
1.4.6.3.5 Anti-allergy and anaphylaxis activity 
Anaphylaxis is an acute serious allergic reaction with rapid onset and may 
cause death (Sampson et al., 2005). The episodes of anaphylaxis are usually 
triggered by allergen which crosslinks immunoglobulin E (IgE) bound to the 
high affinity IgE receptor (FcεRI) on the mast cells and basophil. FcεRI 
crosslinking will lead to mast cells and basophil activation with subsequent 
release of pro-inflammatory mediators, such as histamines, leukotrienes, 
tryptase, and prostaglandins (Kim and Fischer, 2011). Interestingly, treatment 
with FIP-LZ-8 and FIP-fve has been shown to suppress the bovine serum 
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albumin-induced systemic anaphylaxis reactions in mice, whereas little effect 
was found when FIP-vvo was administered (Hsu et al., 1997b; Ko et al., 
1995a; Tanaka et al., 1989). In an ovalbumin (OVA)-induced food allergy 
animal model, mice receiving oral administration of FIP-fve during 
sensitization to OVA showed significant reduction in the the symptoms of 
anaphylaxis reaction as compared to those mice receiving OVA sensitization 
alone. Furthermore, FIP-fve-treated mice also displayed significantly lower 
plasma histamine level as well as very mild mucosal edema and epithelial 
damage in the lamina propria and intestine. Whereas in the PBS-control group, 
the mice showed severe vascular congestion and damage in the epithelial 
lining of lamina propria (Hsieh et al., 2003). 
1.4.6.4 Mechanism of action of FIPs 
Being the most extensively studied, LZ-8 (isolated from Ganoderma lucidum), 
has been shown to activate human monocyte-derived dendritic cells via NF-κB 
and MAPK pathways. It significantly enhanced OVA-specific IgG2a, IFN-γ, 
and IL-2 in mice immunized with OVA (Lin et al., 2009b). Moreover, LZ-8 
could also induce the expansion of both murine and human CD4
+
 T cells into 
FOXP3
+
 regulatory T (Treg) cells via CD45-mediated signaling pathway. 
Adoptive transfer of LZ-8-treated CD4
+
 T cells alleviated acute intestinal 
inflammation in mice (Hsu et al., 2013). The anti-tumor activities of LZ-8 
were demonstrated by its capability to arrest the growth of A549 human lung 
cancer cells at G1 phase via ribosomal protein S7-MDM2-p53 pathway (Wu et 
al., 2011). LZ-8 also induced autophagic cell death in SGC-7901 human 
gastric cancer cells by triggering endoplasmic reticulum (ER) stress and the 
ATF4-CHOP pathway. In addition, it also triggered subsequent degradation of 
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the aggregated recombinant LZ-8 in ER via ubiquitine/proteasome ER-
associated degradation (ERAD) system (Liang, 2012). Furthermore, the 
adjuvant effect of LZ-8 had also been tested recently. Co-treatment of mice 
with HER-2/neu DNA vaccine and LZ-8 strongly improved the therapeutic 
effect of the DNA vaccine against MBT-2 tumor. The anti-tumor activity was 
mediated by TLR4 signaling on dendritic cells as well as enhancement in 
vaccine-induced TH-1 and cytotoxic T lymphocytes responses (Chu et al., 
2011; Lin et al., 2011). 
FIP-fve was shown to stimulate human peripheral blood lymphocytes, 
suppress systemic anaphylaxis reactions and mice hind-paw edema as well as 
enhance transcriptional expression of IL-2 and IFN-γ (Ko et al., 1995b). 
Several studies have attempted to explore the molecular mechanisms 
underlying the immunomodulatory properties of FIP-fve. By employing 
SB203580, a p38 MAPK inhibitor, the production of IFN- γ induced by FIP-
fve was fully abolished. The progression of lymphocytes through the cell 
cycles in the presence of FIP-fve could also be partially inhibited, suggesting 
the involvement of p38 MAPK signaling during FIP-fve stimulation (Wang et 
al., 2004). Besides, using fluo-3 AM, a fluorescent calcium-specific dye, FIP-
fve was shown to induce a rapid elevation in calcium concentration as well as 
PKC-α activation in PBMCs (Ou et al., 2009). Furthermore, recent report 
suggested that the binding of carbohydrate binding module family 34 (CBM-
34) and the ligand-like glycoproteins on the surface of human PBMCs was 
required to induce the physiological immunomodulatory effects of FIP-fve 
(Liu et al., 2012).  
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1.5 Rational, objectives and significance of the study 
1.5.1 Rational of the study 
Besides the biochemical and structural studies, numerous proof-of-concept 
studies have also been performed to explore the potential applications of FIP-
fve. Oral administration of FIP-fve could inhibit the development of food-
allergic reactions, allergen (OVA)-induced chronic airway inflammation and 
alleviate the Dermatophagoides microceras-induced allergy in mice (Chang et 
al., 2014; Hsieh et al., 2003; Lee et al., 2013; Su et al., 2012b). In vitro studies 
showed that FIP-fve could inhibit IL-5-mediated survival of eosinophils 
through modulation of cytokine receptor expression and apoptotic signal 
protein production (Hsieh et al., 2007). Moreover, the percentage of IL-10
+
 
and TGF-β+ cells in Foxp3 + CD4 + CD25 + T cells was also up-regulated by 
Der f 2 N-peptides in conjunction with FIP-fve only in D. farinae allergic 
individuals (Wu et al., 2009). Co-administration of FIP-fve as an adjuvant 
together with human papillomavirus type-16 (HPV-16) E7 oncoprotein 
conferred anti-tumor effects against HPV-16 E7-expressing TC-1 cells in a 
mouse model. The anti-tumor activities were mainly attributed by enhanced 





 T, and activated  dendritic cells (Ding et al., 2009). An almost 
similar observation was also seen in murine hepatocellular carcinoma model 
where oral administration of FIP-fve induced anti-tumor activity via activation 
of innate and adaptive immunity (Chang et al., 2010). A recent report also 
demonstrated that FIP-fve could inhibit A549 lung cancer cell proliferation 
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and migration via activation of p53 signaling pathway and suppression of 
RacGAP1 (Chang et al., 2013).   
Despite all those studies, the molecular and cellular mechanisms by which 
FIP-fve modulates immune responses are yet to be elucidated. Although 
previous studies have shown that FIP-fve stimulation may significantly 
enhance T cells proliferation and induce the secretion of IFN-γ, the specific 
subset of T cells that preferentially respond to FIP-fve stimulation is still 
unknown. Moreover, complete profiles of surface expressions and 
cytokine/chemokine production by the FIP-fve-stimulated cells still await to be 
revealed. In this study, I will investigate the effect of FIP-fve on bone marrow-
derived dendritic cells (BM-DCs) and T cell subsets, both in vitro and in vivo. 
I hypothesize that FIP-fve may mitogenically potentiate T cell function by up-
regulating the T cell surface expressions and cytokine/chemokine production, 
thereby creating a microenvironment favoring the initiation and enhancement 
of adaptive immunity. 
1.5.2    Objectives of the study 
The specific aims of this research project were separated into two major parts: 
A. In vitro studies 
1. To examine the surface expression, cytokine/chemokine as well as 
cellular proliferation profiles of  mouse T cell subsets and BM-DCs 
upon stimulation with FIP-fve 
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2.  To investigate the role of tumor necrosis factor receptor (TNFR) 
family member, CD27, OX40 and 4-1BB on FIP-fve-induced-
cellular proliferation and -cytokine/chemokine production  
3. To evaluate the outcome of FIP-fve pre-stimulation on the 
potentiation of antigen-specific CD8
+
 T cell responses 
B. In vivo studies 
1. To assess the cellular  immune responses  in the draining lymph 
nodes upon footpad injection with FIP-fve in mice 
2. To evaluate the adjuvant effect of FIP-fve on the enhancement of 
antigen-specific CD8
+
 T cell responses in OVA-immunized mice 
1.5.3 Significance of the study 
Most of the previous works in vaccine development were focused on 
discovering novel protective antigens and the ways to present them, instead of 
optimizing the responses against the existing antigens. As a consequence, only 
very few adjuvants, such as aluminum salts and oil in water emulsion (MF59) 
are currently approved for human use in prophylactic vaccines (Fang and 
Hora, 2000; Lindblad, 2004). To date, there is no immune potentiator which 
has been licensed for use as an adjuvant in human vaccines; and, this may be 
due to the perceived risks of toxicity as well as the lack of a comprehensive 
approach in adjuvant research (Gupta and Siber, 1995; Pashine et al., 2005). 
The knowledge on how FIP-fve stimulates and modulates the immune system 
may be useful for finding a good match adjuvant for an antigen to achieve 
desired immune responses. For instance, vaccination with an adjuvant which 
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induced TH-1 skewing effect may inhibit the development of allergen-induced 
TH-2 type responses. Also, for a cancer vaccine, an adjuvant which could 
potentially trigger a strong elicitation of antigen-specific CD8
+
 T cell 









Female C57BL/6J and C57BL/6NTac mice, 6-8 weeks of age, were purchased 
from Centre for Animal Resources (CARE) and InVivos at Lim Chu Kang, 
Singapore respectively. Breeding pairs of OT-I mice having transgenic 
Vα2Vβ5 TCRs specific for OVA257−264 epitope in the context of H-2K
b
 were 
acquired from Prof David Mike Kemeny’s laboratory (Department of 
Microbiology, National University of Singapore). All mice were housed under 
specific-pathogen-free (SPF) condition (temperature 22ºC and relative 
humidity 65%) in the Animal Holding Unit, National University of Singapore. 
Food and water were available ad libitum. All breeding and experimental 
procedures were performed according to approved protocols and in 
accordance with the guidelines from Institutional Animal Care & Use 
Committee (IACUC). 
2.1.2  FIP-fve protein 
FIP-fve protein has been previously isolated and purified from Flammulina 
velutipes (golden needle mushroom) in my laboratory according to the 
protocol from previous study (Paaventhan et al., 2003b). Briefly, two 
kilograms of Flammulina velutipes was purchased. The fresh fruit bodies of 
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mushroom were homogenized with 2 L of 5 % acetic acid (v/v) in the presence 
of 0.1 % (v/v) 2-mercaptoetheanol. The homogenate was centrifuged for 20 
min at 10,000 g and soluble proteins in the supernatant were precipitated by 
addition of ammonium sulphate to 95 % saturation. After stirring for an 
overnight, the precipitate was collected by centrifuge for 20 min again. The 
pellet was then dissolved and dialyzed against 4.5 L of 10 mM Tris-HCl (pH 
8.0) at 4 °C for 4 days with 6 to 9 changes of dialysis solution. The dialyzed 
solution was firstly applied to Q column, which had been pre-equilibrated with 
10mM Tris-HCl (pH 8.0). The flows through fractions were then further 
purified by SP column, which was pre-equilibrated with 10 mM sodium 
acetate (pH 5.0). The column was washed with 10 mM equilibration buffer 
and then eluted with a linear gradient of 0-1 M NaCl in 10 mM sodium acetate 
(pH 5.0). The fractions were then further purified on a Q column (pH 8.0) and 
SP column (pH 5.0). Purified FIP-fve was dialyzed with 2 L of 10 mM PBS 
(pH 7.4) and stores at -80°C. The purity of FIP-fve was determined by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by 
coomassie blue staining. Concentration of FIP-fve was determined based on its 
absorbance at 280 nm. In our studies, we managed to extract 150 mg of FIP-
fve from two kilograms of fresh Flammulina velutipes. 
2.1.3 Reagents for cell culture 
Hanks’ balanced salt solution (HBSS) without calcium and magnesium was 
purchased from Sigma-Aldrich, St. Loius, MO, USA. Dulbecco's Modified 
Eagle Medium (DMEM), RPMI 1640 medium, penicillin, streptomycin, L-
glutamine and sodium pyruvate were purchased from Hyclone (Logan, Utah, 
USA). Fetal bovine serum was purchased from PAA Laboratories GmbH 
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(Haidmannweg, Pasching, Austria). 2-mercaptoethanol was purchased from 
Gibco (Grand Island, NY, USA). OptiPrep™ density gradient media was 
purchased from Axis Shield Poc AS (Oslo, Norway).  
To prepare for complete media, DMEM and RPMI 1640 media were 
supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum, 100 
U/ml of penicillin, 100 μg/ml of Streptomycin, 2 × 10-3 M L-glutamine, 1 × 
10
-3
 M sodium pyruvate and 5.5 × 10
-5
 M 2-mercaptoethanol. Complete RPMI 
1640 medium was used for all cell culture experiments except for bone 
marrow-derived dendritic cells (BM-DCs) culture. Complete DMEM was used 
for BM-DCs culture. 
2.1.4 Cell line 
The carcinogen-induced lymphoma cell line, EL4, was purchased from 
American Type Culture Collection (ATCC), Manassas, Virginia, USA.  The 
cells were grown in complete RPMI 1640 at 37 °C with 5% CO2. The cells 
were seeded at a density of 2 × 10
5
 cells/ml for the initial culture and 
subsequently maintained at a density between 1 × 10
5
 to 1 × 10
6
 cells/ml. 
2.1.5 Antibodies and microbeads 
For T cell surface markers staining, anti-CD4-APC (clone RM4-5), anti-
CD62L-PerCP (clone MEL-14) and anti-CD30-biotin (clone mCD30.1) 
monoclonal antibodies (mAbs) were purchased from Biolegend (San Diego, 
CA, USA). Anti-CD3ε- BD Horizon™ V500 (clone 500A2), anti-CD3ε-APC 
(clone 145-2C11), anti-CD8-biotin (clone 53-5.8), anti-CD8a-Pacific Blue™ 
(clone 53-6.7), anti-CD40L-PE (clone MR1), anti-CD27-R-PE (clone 
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LG.3A10), anti-CD27-APC (clone LG.3A10), anti-CD28-PE-Cy7 (clone 
37.51), anti-CD25-biotin (clone PC61) mAbs, streptavidin -PE, and 
streptavidin -PerCP were purchased from BD Bioscience (San Jose, CA, 
USA). Anti-CD137 (4-1BB)-PE (clone 17B5), anti-CD8-FITC (clone 
eBioH35-17.2), anti-CD134 (OX-40)-PE (clone OX-86), CD134 (OX-40)-
APC (clone OX-86) and anti-CD69-biotin (clone H1.2F3) mAbs were 
purchased from eBioscience (San Diego, CA, USA). For isotype controls, rat 
IgG1-κ-PE, rat IgM-κ, hamster IgG group 1-PE, hamster IgG-biotin, and 
armenian hamster IgG1-biotin were purchased from BD Pharmingen (San 
Diego, CA, USA). For NK cells, anti-CD49b-PE (clone DX5) mAb was 
purchased from Biolegend. 
For B cells, BM-DCs, and macrophages surface markers staining, anti-CD19-
APC (clone 1D3), anti-CD40-FITC (clone 3123), anti-I-A
b
-FITC (AF6-
120.1), CD86-PE (clone GL1), and streptavidin -FITC were purchased from 
BD Bioscience. Anti-CD11c-APC (clone N418) and anti-CD70-biotin (clone 
FR70) mAbs were purchased from Biolegend. Anti-4-1BBL-PE (clone TKS-
1), anti-OX-40L (clone RM134L), anti-CD11b-PE (clone M1/70), anti-F4/80-
Alexa Fluor
®
 488 (clone BM8), and anti-CD11c-PE-Cy7 (clone N418) mAbs 
were purchased from eBioscience. Anti-CD80-FITC (clone 1G10) mAb was 
purchased from SouthernBiotech (Birmingham, USA). For isotype controls, 
rat IgG2a-κ-FITC, rat IgG2a-κ-PE, mouse IgG2a-κ-FITC, and rat IgG2b-κ 
were purchased from BD Pharmingen. 
Furthermore, anti-CD49b (Pan-NK)-PE (clone DX5) was purchased from 
Biolegend. Anti-CD45-PerCP-Cy5.5 (clone 30-F11), anti-CD11b-PE (clone 







, and Pan T cells isolation kits (Miltenyi 




, and T 
cells from splenocytes by AutoMACS respectively. 
2.1.6 Primer sequences for validation of gene expression profile from 
array studies 
The primer sequences for CCL3, CCL4, CD160, CD274, CRTAM, CX3CL1, 
CXCL10, EGR1, IRF4, LTA, PLK3, SH3BP2, SHMT1, SHMT2, STAT1, 
TNFRSF9, TNFRSF19, TNFSF14, TNFSF15, XCL1, β-actin were designed 
using The Primer Express® Software v3.0.1 (Life Technologies, Carlsbad, 
CA, USA). The primer sequences which covered the middle region of target 
genes were chosen. All the oligonucleotide primers were synthesized by 
AITbiotech Pte Ltd, Singapore. The sizes of PCR genes products for CCL3, 
CCL4, CD160, CD274, CRTAM, CX3CL1, CXCL10, EGR1, IRF4, LTA, 
PLK3, SH3BP2, SHMT1, SHMT2, STAT1, TNFRSF9, TNFRSF19, 
TNFSF14, TNFSF15, XCL1, and β-actin were 59 bp, 56 bp, 63 bp, 62 bp, 60 
bp, 64 bp, 57 bp, 64 bp, 69 bp, 59 bp, 61 bp, 56 bp, 61 bp, 57 bp, 74 bp, 55 bp, 
61 bp, 58 bp, 76 bp, 66 bp, and 154 bp respectively.  
Table 2.1 Primers used for validation of gene expression profile by real-
time qPCR 
Primers Sequences 
CCL3-F 5' - TCCCAGCCAGGTGTCATTTT - 3' 
CCL3-R 5' - TTGGAGTCAGCGCAGATCTG - 3' 
CCL4-F 5' - CAGCACCAATGGGCTCTGA - 3' 
CCL4-R 5' - GCCGGGAGGTGTAAGAGAAAC - 3' 
CD160-F 5' - CAAGCCAACAGTTCCCATAAGC - 3' 
CD160-R 5' - AGCGAGCCCCAGCAATC - 3' 
CD274-F 5' - ACACAATTCGAGGAGACGTAAGC - 3' 
CD274-R 5' - GACCACAAGCTGCCAATCG - 3' 
CRTAM-F 5' - ACACCAGCAGCATGCTCATC - 3' 
CRTAM-R 5' - ATAATGCAGTGCACGGTTGAGT - 3' 
CX3CL1-F 5' - GCTTGCGAGAGGGTTTAAAGTGT - 3' 
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CX3CL1-R 5' - AGACGCAGCATGCCTTCAC - 3' 
CXCL10-F 5' - CCCAGTGGATGGCTAGTCCTAA - 3' 
CXCL10-R 5' - CCACGGCTGGTCACCTTT - 3' 
EGR1-F 5' - CCATGAACGCCCATATGCTT - 3' 
EGR1-R 5' - GCTCATCCGAGCGAGAAAAG - 3' 
IRF4-F 5' - AGCCTGGTATAGATGGACTTTTGC - 3' 
IRF4-R 5' - TTCTCTTGTCAGGGATTCATGCT - 3' 
LTA-F 5' - GCACACGAGGTCCAGCTCTT - 3' 
LTA-R 5' - CGCACTGAGGAGAGGCACAT - 3' 
PLK3-F 5' - GCCTCTCCTTGTGACCTTCGT - 3' 
PLK3-R 5' - GGTGGGAAGCGAGGTAAGTACA - 3' 
SH3BP2-F 5' - TGCCCAACCTCCGGAAA - 3' 
SH3BP2-R 5' - GTTCTAGGCCGGGATTCACA - 3' 
SHMT1-F 5' - CCTCATCAACTCTGCCGTGTT - 3' 
SHMT1-R 5' - CAGCAATGGCATGGTTGTG - 3' 
SHMT2-F 5' - GAGACAAGCCAGCGTTTGG - 3' 
SHMT2-R 5' - AGCCCCTGGCAAACTGTTC - 3' 
STAT1-F 5' - GACCACGCCTTTGGGAAGTA - 3' 
STAT1-R 5' - TCGCTTAGGGTCGTCAAGCT - 3' 
TNFRSF9-F 5' - TGCAGGTCCTTACCTTGTTCCT - 3' 
TNFRSF9-R 5' - GATCAGGGCCAGCAGCAA - 3' 
TNFRSF19-F 5' - CTGTCAGTATCACCGGGACTCA - 3' 
TNFRSF19-R 5' - ACAAGGACGGAATCAGGTGAA - 3' 
TNFSF14-F 5' - CCAGACTTGCCACCACACTCT - 3' 
TNFSF14-R 5' - TGGCTGGAAACCAATGCA - 3' 
TNFSF15-F 5' - GGCCACTTTTTCTGTCTTCAACTT - 3' 
TNFSF15-R 5' - GAAGGCGACCTCACCTTTCC - 3' 
XCL1-F 5' - ACTAAAAATTTGTGCTGATCCAGAAG - 3' 
XCL1-R 5' - CCTGCCATCCACAGTCTTGA - 3' 
β-actin-F 5' - GGCTGTATTCCCCTCCATCG - 3' 
β-actin-R 5' - CCAGTTGGTAACAATGCCATGT - 3' 
 
2.2  Methods 
2.2.1 Preparation of immune cells 
2.2.1.1  Preparation of bone marrow-derived dendritic cells (BM-DCs) 
The method for deriving dendritic cells from bone marrow cells was adapted 
from previous study (Lutz et al., 1999) with some modification. The femora 
and tibiae of female 6 to 8-week-old C57BL/6 mice were removed and 
stripped of muscles and tendons. Both ends of the bones were cut. The bone 
marrow was then flushed with HBSS using a 27-gauge needle. Cell suspension 
was centrifuged at 1380 rpm for 8 minutes. Red blood cells (RBCs) were 
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subsequently lysed with 1.5 ml of pre-warmed RBC lysis buffer (10 mM Tris, 
0.83% NH4Cl, pH 8.3) for 90 seconds. Next, cells were washed for three times 
with HBSS and finally re-suspended in complete DMEM. The cell number 
was determined using hemocytometer. 
Five millions of cells were cultured in a 10 cm Petri dish in 10 ml of complete 
DMEM containing 40 ng/ml of GM-CSF (Peprotech, Rocky Hill, NJ). Cells 
were incubated at 37°C in a 5% CO2 humidified incubator. At day 3, an 
additional 10 ml of freshly complete DMEM containing 40 ng/ml of GM-CSF 
was added into each plate. At day 5, non-adherent cells were harvested by 
gentle pipetting. BM-DCs were subsequently enriched using OptiPrep
TM
 
gradient centrifugation according to the manufacturer’s recommendation (Axis 
Shield PoC AS, Oslo, Norway). Cells were washed for 3 times with HBSS and 
finally re-suspended in complete DMEM. The cell number was determined by 
using a hemocytometer. The purity of DCs was more than 70%. 
2.2.1.2  Preparation of single cell suspension from spleen 
A spleen was removed from C57BL/6 mouse and placed in a 10 cm Petri dish 
(92 mm × 17 mm; Nunc, Roskilde, Denmark) containing 10 ml of HBSS. The 
spleen was then homogenized using two frosted-slides to obtain the single 
splenocyte suspension. After centrifugation, supernatant was discarded and red 
blood cells were lysed with 1.5 ml of RBC lysis buffer (10 mM Tris, 0.83% 
NH4Cl, PH8.2-8.4) for 90 seconds. Next, after three times washing of 
splenocytes with HBSS, the cell number was determined using 
haemocytometer. The splenocytes were then either used for in vitro culture or 
subjected to further purification steps.  
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2.2.1.3  Isolation of T cells, CD4
+
 T cells, and CD8
+
 T cells from mouse 
splenocytes 
Splenic T cells, CD4
+
 T cells, and CD8
+
 T cells were purified via negative 
selection using autoMACS Separator according to manufacturer’s protocol 
(Miltenyi Biotec GmbH Bergisch Gladback, Germany). Every 10
7
 cells were 
re-suspended in 40 μL of staining buffer (0.5% bovine serum albumin (BSA) 
(Sigma-Aldrich, USA)), 2 mM EDTA (1st BASE, Singapore) in PBS, pH 7.4) 
and 10 μL of biotinylated-antibodies cocktail were added. After mixing and 
incubation for 10 minutes at 4 °C, another 30 μL of staining buffer per 107 
total cells and 20 μL of anti-biotin microBeads per 107 total cells were added. 
The mixtures were then incubated for 15 minutes at 4°C, followed by 
extensive washing. Finally, the cells were subjected to magnetic separation 
with the autoMACS Separator. Purities of splenic T cells, CD4
+
 T cells, and 
CD8
+
 T cells were above 97%, 95%, and 91% respectively. 




 cells/ml) were stimulated with 20 µg/ml, 40 µg/ml, and 100 
µg/ml of FIP-fve as well as 1 µg/ml of LPS (Sigma-Aldrich, USA) as the 
positive control for 18 hours. The cells were then harvested, washed, and 
stained with anti-CD11c-APC, anti-CD40-FITC, anti-I-A
b
-FITC, anti-CD80-
FITC, anti-CD86-PE, anti-CD70-biotin plus streptavidin-FITC, anti-OX-40L-
PE, anti-4-1BBL-PE monoclonal antibodies, as well as their corresponding 
isotype controls. 7-Amino-actinomycin D (7-AAD) was added to exclude the 
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dead cells.  Data collection was performed using FACSCalibur. The data was 
analyzed by using CellQuest Pro software. 
For co-culture of BM-DCs and T cells experiment, the enriched DCs were co-
cultured with the purified T cells at a ratio of T : DC = 10 : 1 in the presence 
of 40 µg/ml of FIP-fve for 18 hours. Next, the cells were harvested and stained 
with the similar abovementioned markers. 
For co-culture of BM-DCs and FIP-fve-pre-stimulated T cells experiment, 1.5 
× 10
6
 /ml of purified T cells were either cultured in medium alone or pre-
stimulated with 40 µg/ml of FIP-fve for 24 hours. Subsequently, each group of 
T cells were washed thoroughly and further co-cultured with the BM-DCs at a 
ratio of T : DC = 10 : 1, in the presence or absence of 40 µg/ml of FIP-fve for 
another 18 hours. Next, the cells were harvested and again stained with the 
similar abovementioned markers. 
2.2.3 Surface markers staining and flow cytometry analysis of FIP-fve-
stimulated T cells  
Purified T (2 × 10
6
 cells/ml) were stimulated with increasing concentration of 
FIP-fve, starting from 0 µg/ml, 20 µg/ml, 40 µg/ml, and 100 µg/ml in the 
presence of absence BM-DCs at a T to DC ratio of 10 to 1 for 48 hours. Next, 
cells were harvested, washed with the staining buffer (1% BSA in PBS) and 
stained with anti-CD4-FITC, anti-CD8-APC, anti-CD69-biotin plus 
streptavidin -PE, anti-CD28-biotin plus streptavidin -PerCP, anti-CD25-biotin 
plus streptavidin -PE, and antibodies against TNF receptor family members, 
including anti-CD27-R-PE, anti-CD30-biotin plus streptavidin -PerCP, anti-
CD40L-PE, anti-CD134 (OX-40)-PE, anti-CD137 (4-1BB)-PE monoclonal 
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antibodies as well as their corresponding isotype control antibodies. After 20 
minutes of incubation at 4°C, followed by two times washing steps, the cells 
were then analyzed using FACSCalibur (Becton Dickinson immunocytometry 
systems, San Jose, CA). 7-Amino-actinomycin D was added (BD Pharmingen, 
San Diego, CA, USA) to exclude the dead cells before data acquisition. 
2.2.4 In vitro culture of T cells and subsets of T cells with FIP-fve for 
cytokine/chemokine analysis 
The culture supernatants were collected at day 2 or day 3 from purified T (2 × 
10
6





 T cells stimulated with 40 µg/ml of FIP-fve in the presence of 
BM-DCs at a T to DC ratio of 10 to 1. Subsequently, the culture supernatants 
were stored at -20°C, and the profile of cytokine/chemokine was analyzed by 
Multiplex immunoassay. 
2.2.5 In vitro blocking experiment  
CD4
+
 T cells, CD8
+
 T cells, and total T cells were purified from mouse 
splenocytes separately; subsequently, each cell type was co-cultured with BM-
DCs at the ratio of 10 : 1 (T : DC) in the presence of 40 μg/ml of FIP-fve. In 
addition to this, 1 μg/ml or 10 μg/ml of blocking antibodies, including anti-
mouse CD70 (clone FR70, Biolegend, San Diego, CA, USA), anti-mouse 
CD252 (OX-40L) (clone RM134L, Biolegend, San Diego, CA, US), and anti-
mouse CD137L (4-1BBL) (clone TKS-1, eBioscience, San Diego, CA, USA) 
were added either separately or in combination according to the experimental 
setups. Culture supernatants were collected after 48 and 72 hours of culture 
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and the cytokine/chemokines profile was analyzed by Multiplex 
immunoassay. Cells were harvested at day 2 for proliferation assay. 
2.2.6 [
3
H]-thymidine incorporation assay 
Eighteen hours before harvesting the cells, [
3
H]-thymidine (PerkinElmer, 
Waltham, Massachusetts, USA) was added into each well of a 96-well plate to 
a final concentration of 1 μCi. Next, the cells were harvested onto a glass fiber 
filter (Skatron instruments AS, Lier, Norway). After adding the scintillation 
fluid (Amersham Biosciences Corp), the cellular proliferation was measured 
by the liquid scintillation counter (Beckman Coulter, Inc. Fullerton, CA). The 
stimulation index was calculated by dividing the count per minute (cpm) 
values in the FIP-fve-stimulated group by the cpm values in the medium 
control group. 
2.2.7 Proliferation assay by CFSE staining 
Splenocytes from C57BL/6J mouse were labeled with 5 μM of CFSE (Life 
Technologies, USA). Briefly, the cells were resuspended at a concentration of 
5 × 10
7
 cells/ml in HBSS. Next, an equal volume of 10 μM of CFSE were 
added to the cells and further incubated at 37°C in the dark for 10 minutes. 
The reaction was subsequently stopped with the addition of 10 times volume 
of 1% BSA in PBS. Finally, the labeled cells were washed for three times with 
HBSS and further stimulated with 40 μg/ml of FIP-fve, 2 μg/ml of PHA or 1 
μg/ml of LPS for 48 hours. After harvesting the cells, they were stained with 
anti-CD4-PE, anti-CD8-PerCP, and anti-CD19-APC mAbs. 
2.2.8 Immunoassays  
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2.2.8.1  Measurement of cytokine/chemokine secretion by multiplex 
assay 
The multiplex assay kit was purchased from Millipore, Billerica, USA. 
Briefly, the microtiter filter plate was pre-wetted with 200 µl of wash buffer 
per well, followed by shaking for 10 minutes at room temperature. After 
removing the wash buffer by vacuum, 25 µl of serial diluted standard protein 
were added to the appropriate wells. In addition, 25 µl of assay buffer were 
also added to the sample wells. After the addition of 25 µl of culture medium 
to the standard and background wells, 25 µl of culture supernatant sample was 
added to the appropriate sample wells. Subsequently, 25 µl of premixed beads 
was added to each well. The filter plate was then covered, sealed, and shaked 
for overnight (16 to 18 hours) at 4°C with agitation. 
Next, the fluid was removed by vacuum, and the plate was then washed twice 
with 200 µl of wash buffer per well. Subsequently, 25 µl of detection 
antibodies was added into each well and the plate was incubated with shaking 
at room temperature for 1 hour. After that, another 25 µl of Streptavidin-
Phycoerythrin was added to each well and the plate was further incubated with 
shaking for 30 minutes at room temperature. After removing all contents by 
vacuum, followed by two times of washing steps with 200 µl of wash buffer 
per well, 150 µl of sheath fluid was added into each well. The plate was then 
shaked for 5 minutes to resuspend the beads before running it on Bio-Plex® 
200 Systems (Bio-Rad, CA, USA).  
2.2.8.2  Measurement of IFN-γ secretion by enzyme-linked 
immunosorbent assay (ELISA) 
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Briefly, the 96-well high-binding plate (Costar Corning, NY, USA) was 
coated with 50 µl of purified rat anti-mouse IFN-γ monoclonal antibody 
(mAb) (2 µg/ml) (clone R4-6A2) (R&D Systems, Minneapolis, MN, USA) 
diluted in coating buffer (0.1 M NaHCO3, pH 8.2) and incubated at 4°C 
overnight. After washing the plate with washing buffer (0.05% Tween 20 
(Sigma-Aldrich, USA) in TBS) three times, the wells were then blocked with 
blocking buffer (0.05% Tween-20 and 1% BSA in TBS) at room temperature 
for 1 hour. After another three times of washing steps, 50 µl of culture 
supernatants were added to wells and the plate was incubated at 4°C 
overnight. In addition, 50 µl of recombinant mouse IFN-γ at different 
concentrations were also added to several wells to generate a standard curve. 
After overnight incubation, followed by three times washing steps, 50 µl of 
biotinylated anti-mouse IFN-γ (2 µg/ml) mAb (clone XMG1.2) (R&D 
Systems, Minneapolis, MN, USA) were added to each well, followed by 
incubation at room temperature for 1 hour. Again, after another three times of 
washing steps, 50 µl of ExtraAvidin-alkaline phosphatase (1:2000) (Sigma-
Aldrich, USA) diluted in blocking buffer were added and incubated at room 
temperature for another 1 hour. Subsequently, the signal was developed by 
addition of p-Nitrophenyl Phosphate (pNPP) substrate (Sigma-aldrich, USA) 
and read with a microplate reader at 405 nm (BioTek, Winooski, VT, USA). 





 T cells (2 × 10
6
 cells/ml) were remained 
unstimulated or stimulated with 20 µg/ml of FIP-fve for 2 hours and 8 hours. 
Subsequently, the cells were harvested and their total RNA was extracted 
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using miRNeasy mini kit (Qiagen, Valencia, CA, USA). The total RNA for 
each sample was sent for quality check using Bioanalyzer RNA6000 Nano kit 
(Agilent Technologies, Inc., Santa Clara, CA, USA). Next, microarray 
experiment was performed with mouse 8x60K GX array (Agilent 
Technologies, Inc., USA). The data from gene array experiment was analyzed 
using GeneSpring GX software (Agilent Technologies, Inc., USA). 
2.2.10 Validation of gene expression profile from array studies using real-
time quantitative PCR 
For validation of gene expression profile from microarray results, the sample 
RNA which was previously used for microarray studies was converted to first-
strand cDNA using the SuperScript® III First-Strand Synthesis SuperMix 
(Life Technologies, Carlsbad, CA, USA). Briefly, about 100 ng of total RNA 
was mixed with random hexamers, annealing buffer, RNase/DNase-free water 
to a final volume of 8 μl, followed by a short incubation in a thermal cycler at 
65°C for 5 minutes. Next, the sample was chilled on ice for 1 minute before 
being added with 10 μl of 2X First-Strand Reaction Mix and 2 μl of 
SuperScript® III /RNaseOUT™ Enzyme Mix. The sample was subsequently 
incubated at 25°C for 10 minutes, followed by second incubation at 50°C for 
50 minutes. The reaction was finally terminated with incubation at 85°C for 5 
minutes and stored at -20°C. The generated first-strand cDNA was then used 
as the template for the subsequent real-time qPCR step using KAPA SYBR® 
FAST qPCR Kits (Kapa Biosystems, Inc., Woburn, MA, USA). Briefly, about 
5 ng of template cDNA was mixed with 10 μl of 2X KAPA SYBR® FAST 
qPCR Master Mix, 0.8 μl of 5 μM Forward Primer and Reverse Primer Mix, 
and DNase-free water to a final volume of 20 μl. The protocol for the real-time 
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qPCR was summarized in Table 2.2. The fluorescent signal of the reactions 
and the data were read and analyzed using ABI 7500 Real-Time PCR System 
and its software (Applied Biosystems, Carlsbad, CA, USA). The quantitative 
real-time PCR of each sample was performed in triplicate. Normalized Ct 
(ΔCt) values for each sample were calculated by subtracting the Ct value 
obtained from each target gene with the Ct value obtained from the β-actin. 
Using ΔΔCt values (calculated from ΔCt in FIP-fve-stimulated group – ΔCt in 
unstimulated group) and the formula, 2
-( ΔΔCt)
, the relative quantity (RQ) of 
mRNA levels in FIP-fve-stimulated sample and unstimulated sample were 
determined.  
Table 2.2 Protocol for real-time qPCR 
Step Temperature Duration Cycles 
Enzyme activation 95°C 1 minute 1 
Denature 95°C 3 seconds 
40 
Anneal/extend 60°C 30 seconds 
 
2.2.11 In vitro priming of OVA-specific CD8
+
T cells by FIP-fve 
CD8
+
 T cells were purified from OT-I mouse splenocytes using the 
microbeads (Miltenyi Biotec, Germany) as mentioned previously. The purified 
CD8
+
 T cells (2 × 10
6
/ml) were then cultured in medium only, 20 μg/ml or 40 
μg/ml of FIP-fve for 18 hours. Upon overnight incubation, the pre-stimulated 
CD8
+
 T cells were washed three times to remove the residual amount of FIP-
fve. The pre-stimulated cells were subsequently co-cultured with purified bone 
marrow-derived dendritic cells (BM-DCs) at a ratio of 10 : 1 (CD8
+
 T : BM-
DCs) in the presence of various concentration of OVA257–264 peptide 





cells was measured using [
3
H]-thymidine incorporation assay from day 1 until 
day 5 of culture. In addition, the culture supernatant from day 1, 2, 3, and 5 of 
culture were also collected and used to assay for the level of IFN-γ secretion 
by ELISA. 
2.2.12 In vitro cytotoxicity assay 
The protocol to establish in vitro cytotoxicity assay was adopted from 
previous study (van Stipdonk et al., 2001) with some modifications. Briefly, 
purified OT-I CD8
+
 T cells were cultured in either medium alone or 40 μg/ml 
of FIP-fve for 18 hours. Subsequently, the pre-stimulated cells were washed 
thoroughly to remove the residual amount of FIP-fve. The cells were 
subsequently co-cultured with mitomycin-c-treated splenocytes to serve as 
accessory cells (ACs) at CD8
+
T to ACs ratio of 1 to 5, and further stimulated 
with 0.78 μM of OVA257-264 peptide for 7 days. At day 3 and day 5 of culture, 
mouse IL-2 was added to a final concentration of 10 U/ml. At day 7, the cells 
were harvested and subjected to Ficoll-density gradient centrifugation (GE 
Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) to remove the dead 
cells. As the target cells, EL4 cells were first labeled with 0.5 M Calcein-AM 
(Biomed Diagnostics Pte Ltd, Singapore) for 10 minutes at room temperature 
and washed three times with HBSS.  Half of the Calcein-AM labelled cells 
were then pulsed with 10 μM of OVA257-264 peptide for 3 hours at 37°C. 
Target cells were resuspended in culture media at the density of 3×10
5
 cells 
per ml. Subsequently, effector cells were co-cultured with target cells at E : T 
ratio of 10 : 1, 5 : 1, 1 : 1, and 1 : 2 in a 96-well U bottom plate for 4 hours at 
37°C. Labeled EL4 cells alone (3x10
4
 cells/well) served as the reference 
control. At the end of 4 hours incubation, the content from each well was 
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transferred to each 5 ml round-bottom tubes (BD Falcon, BD Biosciences, 
USA). Two microliter of propidium iodide solution (50 g/ml) was added into 
each tube. Data collection was performed on BD FACSCalibur™. The BD 
FACSCalibur™ was set to collect the sample run at high sample flow rate for 





was calculated. The percentage of specific lysis was calculated as follows:  
[(No. of live un-pulsed EL4 cells – No. of live pulsed EL4 cells) / No. of EL4 
control] × 100% 
2.2.13 In vivo T cell activation assay 
C57BL/6J mice were subcutaneously injected with either 30 µl of PBS or 10 
μg of FIP-fve in 30 µl PBS on their footpad. At day 1, 2, 3, 4, and 5 post-
injection (3 mice were used for each time point), the popliteal lymph nodes 
(PLN) were harvested and the total cell number obtained from each mouse 
was determined. To measure the activation profile of T cells, at day 3 post-
injection, the lymph node cells were stained with LIVE/DEAD® Fixable Dead 
Cell Stain Kit (Life Technologies, Carlsbad, CA, USA) to exclude the dead 
cells, anti-CD45-PerCP-Cy5.5, anti-CD3ε- BD Horizon™ V500, anti-CD4-
FITC, anti-CD8-Pacific Blue™, anti-CD27-APC, anti-CD28-PE-Cy7, anti-
CD134 (OX-40)-APC, and anti-CD137 (4-1BB)-PE. In addition, to identify 
the cellular composition in the lymph nodes, the cells were stained with 
LIVE/DEAD® Fixable Dead Cell Stain Kit, anti-CD45-PerCP-Cy.5.5, anti-
CD3ε- BD Horizon™ V500, anti-CD4-FITC, anti-CD8-Pacific Blue™, anti-
CD49b (Pan-NK)-PE, anti-CD19-APC, anti-CD11b-PE, anti-F4/80-Alexa 
Fluor
®
 488, and anti-CD11c-PE-Cy7. The surface expressions were measured 
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by BD LSRFortessa™ cell analyzer (BD Biosciences, San Jose, CA, USA) 
and the data was analyzed using FlowJo analysis software (Tree Star Inc., 
Ashland, Oregon, USA). 
2.2.14 In vivo bromodeoxyuridine (BrdU) incorporation assay 
Similar to previous protocol, C57BL/6J mice were injected with either 30 µl 
of PBS or 10 µg of FIP-fve in 30 µl PBS on their footpad. At day 2 post 
injection, the mice were intraperitoneally (i.p.) injected with 1 mg of BrdU (in 
50 μl solution) per mouse for three times at 4 hours interval. The PLN was 
harvested on the next day. The BrdU intracellular staining was performed with 
BrdU flow kit according to the manufacturer’s instruction (BD PharMingen, 
San Diego, CA, USA). Briefly, the cells were first stained with LIVE/DEAD® 
Fixable Dead Cell Stain Kit, followed by staining with antibodies against 
various surface markers, such as, anti-CD45-PerCP-Cy5.5, anti-CD3ε-V500, 
anti-CD4-APC, anti-CD8-Pacific Blue™, anti-CD49b (Pan-NK)-PE, and anti-
CD19-PE. After that, the cells were fixed and permeabilized with 100 µl of 
Cytofix/Cytoperm buffer for 16 to 18 hours at 4°C. Next, the cells were 
washed once with 1 ml of 1x Perm/Wash buffer. After washing, the cells were 
then incubated with 100 µl of Cytoperm Plus buffer at 4°C for 10 minutes. 
Next, after another round of washing, the cells were again re-fixed with 100 µl 
of Cytofix/Cytoperm buffer for 5 minutes at 4°C. Subsequently, the cells were 
washed again and treated with 30 µg of DNase for 1 hour at 37°C. After being 
washed once, the cells were then stained with anti-BrdU-FITC for 1 hour at 
4°C, followed by another washing step again. Finally, the cells were 
resuspended in 500 µl of staining buffer (1% BSA in PBS) and further 
analyzed using BD LSRFortessa™ cell analyzer. 
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2.2.15 Mouse immunization protocols 
CD8
+
 T cells were purified from OT-I mouse splenocytes using the 
microbeads (Miltenyi Biotec, Germany) as mentioned previously. One day 
before immunization, two millions of OT-I CD8
+
 T cells was adoptively 
transferred into each C57BL/6J mouse by intravenous injection. The OVA 
peptide (AVHAAHAEINEAGSIINFEKL) was synthesized and purchased 
from Axil Scientific Pte Ltd, Singapore.  Incomplete Freund’s adjuvant (IFA) 
was purchased from Sigma-Aldrich, USA. For short term immunization 
experiment, mice (n = 5 for each group) were subcutaneously injected with, 20 
µg of FIP-fve, 50 µg of OVA peptide, 20 µg of FIP-fve + 50 µg of OVA 
peptide, 50 µg of OVA peptide in IFA or 20 µg of FIP-fve + 50 µg of OVA 
peptide in IFA or PBS. At day 3 post-injection, the skin lymph nodes, 
including proper axillary, accessory axillary, and subiliac lymph nodes were 
harvested and stained.  
For long term immunization experiment, mice (n = 5 for each group) were 
subcutaneously injected with 50 µg of OVA peptide, 20 µg of FIP-fve + 50 µg 
of OVA peptide or 50 µg of Polyinosinic-polycytidylic acid (Poly (I:C)) 
(Sigma-Aldrich, St. Louis, MO, USA) + 50 µg of OVA peptide or PBS. At 
day 20 post-injection, spleens and skin lymph nodes were harvested and 
stained. R-PE-labeled H-2K
b
/SIINFEKL (OVA) recombinant murine 
pentamer was purchased from ProImmune, Oxford, UK. Anti-CD3ε- BD 
Horizon™ V500 (clone 500A2), anti-CD19-FITC (clone 1D3), anti-CD27-
APC (clone LG.3A10), anti-CD8-Pacific Blue™ (clone 53-6.7) were 
purchased from BD Biosciences, San Jose, CA, USA. Anti-CD62L-PerCP-
Cyanine5.5 (clone MEL-14), anti-CD44-APC (clone IM7), CD197 (CCR7)-
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PE-Cyanine7 (clone 4B12), anti-CD69-PerCP-Cyanine5.5 (clone H1.2F3), 
anti-CD28-PE-Cyanine7 (clone 37.51), anti-CD134 (OX-40)-APC (clone OX-







Immunomodulatory effect of FIP-fve on immune cells in vitro 
 
3.1 Introduction 
Fungal immunomodulatory protein (FIP)-fve is isolated from the golden 
needle mushroom, Flammulina velutipes. FIP-fve was demonstrated to be able 
to hemagglutinate human red blood cells, stimulate human peripheral blood 
lymphocytes, and suppress systemic anaphylaxis reactions and mice hind-paw 
edema, enhance transcriptional expression of interleukin-2 and interferon-γ 
(Ko et al., 1995b). Since then, some attempts have been made by several 
studies to explain the possible mechanisms underlying the immunomodulatory 
properties of FIP-fve. By employing SB203580, a p38 MAPK inhibitor, the 
production of IFN- γ induced by FIP-fve could be fully abolished and also the 
progression of lymphocytes through the cell cycles in the presence of FIP-fve 
could be partially inhibited (Wang et al., 2004). Another study employing 
fluo-3 AM, a fluorescent calcium-specific dye, demonstrated that FIP-fve 
could induce a rapid elevation in calcium concentration. Further investigations 
by ELISA, real-time PCR, and western blot assays showed significant 
increases in the production and mRNA expression of IFN-γ and PKC-α 
activation in FIP-fve stimulated-peripheral blood mononuclear cells (PBMCs), 




In addition, numerous proof-of-concept studies have also demonstrated the 
potential applications of FIP-fve in several contexts. In relation to allergy, oral 
administration of FIP-fve could inhibit the development of food-allergic 
reactions in mice (Hsieh et al., 2003); while, in vitro studies showed that FIP-
fve could inhibit IL-5-mediated survival of eosinophils through the modulation 
of cytokine receptor expression and apoptotic signal protein production (Hsieh 
et al., 2007). In addition, previous study also showed that the percentage of 
IL-10
+
 and TGF-β+ cells in Foxp3 + CD4 + CD25 + T cells could be up-
regulated by Der f 2 N-peptides in conjunction with FIP-fve only in D. farinae 
allergic individuals (Wu et al., 2009). In tumor immunology, co-
administration of FIP-fve as an adjuvant together with human papillomavirus 
type-16 (HPV-16) E7 oncoprotein conferred anti-tumor effects against the 
inoculation of HPV-16 E7-expressing TC-1 cells in a mouse model. The anti-
tumor activities were mainly attributed by the enhanced HPV-16 E7-specific 
IgG1, IgG2c, IFN-γ productions as well as the responses from CD4+ T and 
CD8
+
 T cells (Ding et al., 2009). An almost similar observation was also seen 
in murine hepatocellular carcinoma model where oral administration of FIP-
fve was shown to induce anti-tumor activity via activation of innate and 
adaptive immunity (Chang et al., 2010). Furthermore, a recent report 
demonstrated that FIP-fve could inhibit A549 lung cancer cell proliferation 
and migration via activation of p53 signaling pathway and suppression of 
RacGAP1 respectively (Chang et al., 2013).  
Despite the previous studies on the potential exploitation of FIP-fve as an 
adjuvant, the complete molecular and cellular mechanisms by which FIP-fve 
can modulate the immune response is yet to be elucidated. To approach this 
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important question, I attempted to unveil the direct or indirect immunological 
effect of FIP-fve on the main players in the immune system, such as dendritic 
cells, CD4
+
 T cells, CD8
+
 T cells, and B cells. In this chapter, I performed 
various in vitro studies and employed different immunological techniques to 
identify, demonstrate, and measure the surface expression, cellular 
proliferation as well as cytokines/chemokines production profiles of the 



















3.2.1 Immunomodulatory effect of FIP-fve on major immune cells 
3.2.1.1 Effect of FIP-fve on the maturation of BM-DCs 
Some adjuvants have been shown to exert their effects by enhancing the 
activation and maturation of DCs or macrophages. Since the earlier data from 
our laboratory showed that FIP-fve could up-regulate the expression of I-A
b
, 
CD86 on splenic DCs in vivo (data not shown), I then would like to 
understand whether FIP-fve could directly induce or augment the maturation 
of BM-DCs. As a first approach, I examined the expression profiles of 
conventional DC maturation markers, CD40, I-A
b
, CD80, CD86 as well as the 
markers of tumor necrosis factor ligand (TNFL) superfamily, 4-1BBL, OX-
40L, and CD70 on DCs by flow cytometry. The interaction of TNFL with 
their receptors is important for the survival of T cells. BM-DCs were 
stimulated with 20, 40 or 100 g/ml of FIP-fve for 18 hours, results showed 
that FIP-fve did not up-regulate any of the surface markers (Fig. 3.1A). In 
contrast, LPS, as positive control, up-regulated the expression CD40, I-A
b
, 
CD80, CD86, and 4-1BBL. To address why FIP-fve could induce splenic DCs 
maturation in vivo, BM-DCs were then co-cultured with purified T cells. In the 
presence of purified T cells, FIP-fve significantly up-regulated the expression 
of I-A
b
 and CD86, moderately up-regulated CD40 and CD80 expressions but 
did not up-regulate CD70, 4-1BBL, and OX-40L expressions on BM-DCs 




To strengthen the hypothesis, purified T cells were cultured in either medium 
alone or pre-simulated with 40 µg/ml of FIP-fve for 24 hours. T cells were 
then washed thoroughly with HBSS to remove residual FIP-fve. The non-
stimulated and pre-stimulated T cells were then co-cultured with purified BM-
DCs in the presence or absence of 40 µg/ml of FIP-fve for another 18 hours. 
Results demonstrated that in the presence of FIP-fve pre-stimulated T cells, the 
expression of I-A
b
 and CD86 on BM-DCs could be up-regulated even in the 
absence of FIP-fve during T and BM-DCs co-culture (mean fluorescence 
intensity, I-A
b
: 168.79 vs 105.50; CD86: 303.53 vs 195.89) and the expression 
profile was similar to that of when FIP-fve was present during T and BM-DCs 
co-culture (Fig. 3.2), suggesting that FIP-fve-stimulated T cells played an 
















































Figure 3.1 Phenotype of BM-DCs upon FIP-fve stimulation. A. FIP-fve did 
not directly induce BM-DCs maturation. Purified BM-DCs were stimulated 
with 20 µg/ml (—), 40 µg/ml (—), and 100 µg/ml (—) of FIP-fve, 1 µg/ml of 
LPS (—) or remained unstimulated (—) for 18 hours. B. T cells helped BM-
DCs maturation. Purified T cells were co-culured with BM-DCs in the 
presence (—) or absence (—) of 40 µg/ml of FIP-fve. Isotype control was 
represented by filled grey histrogram. Representative data from three 
independent experiments were shown.  
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Figure 3.2 Pre-stimulation of T cells with FIP-fve significantly drive the 
up-regulation of I-A
b
 and CD86 expression on BM-DCs. Purified T cells 
were cultured in either medium alone (T (M)) or 40 µg/ml of FIP-fve (T (FIP-
fve)) for 24 hours; the pre-stimulated and non-stimulated T cells were then 
washed thoroughly and co-cultured with purified BM-DCs in the presence or 
absence of 40 µg/ml of FIP-fve for another 18 hours. Co-culture of non-
stimulated T cells and BM-DCs in medium alone (—) or in 40 µg/ml of FIP-
fve (—) and co-culture of pre-stimulated T cells and BM-DCs in medium 
alone (—) or in 40 µg/ml of FIP-fve (—) were represented by the indicated 
colors. The numbers represent mean fluorescence intensity (MFI). 





















































(—)  T (M) + DCs in Medium 
(—)  T (M) + DCs in FIP-fve 
(—)  T (FIP-fve) + DCs in Medium 
(—)  T (FIP-fve) + DCs in FIP-fve 
64 
 
3.2.1.2 Effect of FIP-fve on T cell potentiation 
Previous study in our laboratory showed that FIP-fve induced T cell 
proliferation were APC dependent (Ding et al., 2009). Since the presence of T 
cells was crucial for BM-DCs maturation during FIP-fve stimulation (Fig 3.1 
and 3.2), I then hypothesized that FIP-fve could provide direct stimulation to T 
cells. Purified mouse splenic T cells were stimulated with 20 µg/ml, 40 µg/ml 
or 100 µg/ml of FIP-fve for 48 hours in the presence or absence of purified 
BM-DCs. The expression of T cell activation or survivial markers CD25, 





 T cells were analyzed by flow cytometry. Results showed that 
even in the absence of BM-DCs, FIP-fve still up-regulated the expression of 
CD27, 4-1BB, early T cells activation marker (CD69), and alpha chain of IL-2 
receptor (CD25) on both CD4
+
 T and CD8
+
 T cells as well as CD28 
expression on CD8
+
 T cells in a dose-dependent manner. Notably, FIP-fve 
induced a more dramatic up-regulation of CD27 and CD28 on CD8
+
 T than 
CD4
+
 T cells. The expression of CD30, CD40L, and OX-40 did not show any 
significant change in both CD4
+
 T and CD8
+
 T cells (Fig. 3.3). When BM-
DCs were present in the co-culture, a dose-dependent up-regulation of 4-1 BB, 
CD25 and CD69 on both CD4
+
 T and CD8
+
 T cells were observed again and 
the up-regulation of 4-1 BB, CD25 and CD69 on T cells were much more 
prominent than that in the absence of BM-DCs. In contrast, up-regulation of 
CD27 was still observed but there was no dose-dependent effect. OX-40 of 
which did not show changes on T cells in the absence of BM-DCs was up-
regulated by FIP-fve on CD4
+
 T cells in the presence of BM-DCs. The 





 T and CD8
+
 T cells (Fig. 3.4). Furthermore, since 40 µg/ml of FIP-fve 
was sufficient to enhance T cell surface expression, this working concentration 
would be used for subsequent in vitro studies.  
Besides the expression profile of T cell activation markers, I also performed 
immunoassays to examine the profile of soluble mediators 
(cytokines/chemokines) secreted by T cells in the presence or absence BM-
DCs upon FIP-fve activation. In the presence of T cells alone, FIP-fve induced 
elevated production of MIP-1α and MIP-1β (Table 3.1, Fig. 3.5A). In co-
culture of T cells and BM-DCs, FIP-fve also induced the secretion of MIP-1α 
and MIP-1β by T cells. However, the levels of MIP-1α and MIP-1β in this co-
culture were more enhanced than that of T cells alone on both day 2 and day 3 
of co-culture. Besides, FIP-fve also induced secretions of IFN-γ, IP-10, and 
MIG in T cells and BM-DCs co-culture (Table 3.1, Fig. 3.5B). Next, to further 
delineate the subset of cytokine producing T cell, CD4
+
 T and CD8
+
 T cells 
were purified and stimulated with FIP-fve in the presence of BM-DCs. Results 
showed that cytokine/chemokine profiles were different between the two 
subsets upon FIP-fve stimulation. The cytokine/chemokine level from CD4
+
 T 
cells and BM-DCs co-culture was lower compared to that of CD8
+
 T cells and 
BM-DCs co-culture (Table 3.1, Fig. 3.6). Nonetheless, the levels of IP-10, 
MIP-1α, and MIP-1β in FIP-fve-stimulated CD4+ T cell co-culture were still 
significantly enhanced on both day 2 and day 3 of stimulation (Table 3.1, Fig. 
3.6A). In comparison to CD4
+
 T cell co-culture, the secretion of IFN-γ, IP-10, 
MIG, MIP-1α, and MIP-1β in CD8+ T cell co-culture was greatly elevated by 




Having demonstrated the differential effects of FIP-fve on cytokine/chemokine 










 T cell proliferation. Purified total T cells, CD4
+
 T cells or 
CD8
+
 T cells were stimulated with 40 µg/ml of FIP-fve, either alone or in the 
presence of BM-DCs for 48 hours. [
3
H]-thymidine incorporation assay results 
demonstrated that in the absence of BM-DCs, total T cells, CD4
+
 T cells, and 
CD8
+
 T cells proliferated to a stimulation index of 4.7, 1.5, and 9.7 
respectively upon FIP-fve stimulation. In the presence of BM-DCs, the 
proliferation index of total T cells, CD4
+
 T cells, and CD8
+
 T cells was 
increased to 8.7, 6.4, and 21.5 respectively (Fig. 3.7). BM-DCs alone did not 
show any significant increase in proliferation after FIP-fve stimulation (data 
not shown). 
In summary, my results demonstrated that FIP-fve directly activated T cells by 
up-regulating their surface markers, increasing production of 
cytokine/chemokine as well as enhancing their proliferation. More 





 T cell subsets. CD8
+
 T cells responded better to FIP-fve 
stimulation than CD4
+


































 T cells in the 
absence of BM-DCs. Purified splenic T cells alone were stimulated with 
20µg/ml (—), 40µg/ml (—), and 100µg/ml (—) of FIP-fve or remained 
unstimulated (Medium (—)). Forty eight hours later, cells were harvested, the 
expression of CD25, CD69, CD28, CD40L as well as TNF receptor family 





 cells were analyzed by flow cytometry. The numbers 
represent mean fluorescence intensity (MFI). Representative data from three 
independent experiments were shown. 
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(—)  Medium   (—)  20 μg/ml of FIP-fve 
(—)  40 μg/ml of FIP-fve  (—) 100 μg/ml of FIP-fve 
CD4+T Cells CD8+T Cells CD4+T Cells CD8+T Cells 
CD4+T Cells CD8+T Cells CD4+T Cells CD8+T Cells 

































 T cells in the 
presence of BM-DCs. Purified splenic T cells were co-cultured with BM-DCs 
and stimulated with 20µg/ml (—), 40µg/ml (—), and 100µg/ml (—) of FIP-fve 
or remained unstimulated (Medium (—)). Forty eight hours later, cells were 
harvested, the expression of CD25, CD69, CD28, CD40L as well as TNF 
receptor family members (CD27, CD30, CD134 (OX-40), and CD137 (4-




 cells were analyzed by flow cytometry. The 
number represented the mean fluorescence intensity. Representative data from 




































































5.1      234.2     243.3 
73.0                  380.4 
 
 












































(—)  Medium   (—)  20 μg/ml of FIP-fve 
(—)  40 μg/ml of FIP-fve  (—) 100 μg/ml of FIP-fve 
CD4+T Cells CD8+T Cells CD4+T Cells CD8+T Cells 
CD4+T Cells CD8+T Cells CD4+T Cells CD8+T Cells 
CD4+T Cells CD8+T Cells CD4+T Cells CD8+T Cells 









Day 2 Day 3 
Mean ± SD (pg/ml) Mean ± SD (pg/ml) 
FIP-fve Medium FIP-fve Medium 
T cells alone 
MIP-1α 70.4 ± 13.3 43.8 ± 5.3 107.5 ± 2.6 *** 42.4 ± 5.7 
MIP-1β 69.9 ± 11.4 * 41.3 ± 4.2 110.4 ± 11.1 ** 40.1 ± 6.9 
T cells  
+  
BM-DCs 
IFN-γ 46.6 ± 11.4 * 11.2 ± 1 71.5 ± 3.7 *** 11.8 ± 1.6 
IP-10 248.9 ± 45.1 * 70.8 ± 7.9 275.4 ± 26.7 ** 68.1 ± 10.6 
MIG 78.8 ± 6.5 ** 47.9 ± 7.1 132.5 ± 11.8 ** 50.4 ± 4.6 
MIP-1α 218.8 ± 13.4 ** 51.9 ± 3.7 358.9 ± 60.9 * 59.9 ± 10.9 
MIP-1β 319.6 ± 81.7 * 48.8 ± 4.5 617.9 ± 197.5 * 57.6 ± 9.5 
CD4
+
 T cells  
+  
BM-DCs 
IP-10 222.9 ± 27.4 ** 94.1 ± 23.1 191.1 ± 43.3 * 61.8 ± 14.8 
MIP-1α 190.8 ± 15.6 ** 71.5 ± 7.1 257.3 ± 79.8 73.4 ± 14.6 
MIP-1β 253.9 ± 54.9 * 75.1 ± 9.2 368.1 ± 134.5 70.2 ± 10.9 
CD8
+
 T cells  
+  
BM-DCs 
IFN-γ 2615.4 ± 237.4 ** 24.4 ± 12.4 389.9 ± 32.9 *** 47.1 ± 42.5 
IP-10 834 ± 90.6 ** 122.9 ± 31.4 702.3 ± 38.2 ** 171.7 ± 76.9 
MIG 481 ± 13.3 *** 54.4 ± 7.4 542.3 ± 58.4 *** 81.8 ± 37.4 
MIP-1α 1640.4 ± 179.6 ** 91.8 ± 16.9 1148.6 ± 111 *** 153.9 ± 59.4 
MIP-1β 2679.4 ± 443.5 ** 90.6 ± 16.9 2998.4 ± 417.8 ** 230.1 ± 118.4 
 
a) Total T cells alone, co-culture of total T cells, CD4+ T cells or CD8+ T 
cells and BM-DCs were stimulated with 40µg/ml of FIP-fve; culture 
supernatant was collected at day 2 and day 3 post-stimulation to assay for 
the cytokine/chemokine profile by multiplex immunoassay. Data were 
presented as mean±SD. Two-tailed student’s t-test was used to calculate 
the significant difference in the level of cytokine/chemokine between the 
FIP-fve-stimulated and medium control groups. *, P<0.05; **, P<0.01; 





















































































Figure 3.5 FIP-fve enhanced the secretion of cytokine/chemokine by 
activated T cells. Purified T cells alone (A) as well as co-culture of total T 
cells with BM-DCs (B) were stimulated with 40µg/ml of FIP-fve; culture 
supernatant was collected at day 2 and day 3 post-stimulation to assay for the 
cytokine/chemokine profile by multiplex immunoassay. Data were presented 
as mean±SD. Two-tailed student’s t-test was used to calculate the significant 
difference in the level of cytokine/chemokine between the FIP-fve-stimulated 
and medium control groups. *, P<0.05; **, P<0.01; ***, P<0.001. 
Representative data from two independent experiments were shown.   
















































































































 T cells. CD4
+
 T cells (A) or CD8
+
 T cells (B) 
were stimulated with 40µg/ml of FIP-fve in the presence of BM-DCs; culture 
supernatant was collected at day 2 and day 3 post-stimulation to assay for the 
cytokine/chemokine profile by multiplex immunoassay. Data were presented 
as mean±SD. Two-tailed student’s t-test was used to calculate the significant 
difference in the level of cytokine/chemokine between the FIP-fve-stimulated 
and medium control groups. *, P<0.05; **, P<0.01; ***, P<0.001. 
Representative data from two independent experiments were shown.  
MIP-1a









































** *** *** *** 
** 
*** 
IFN-γ IP-10 MI  
I -1α I -1β 
** 

























































Figure 3.7 FIP-fve significantly induced proliferation of total T cells, 
CD4
+ 
T cells, and CD8
+
 T cells. Purified total T cells, CD4
+
 T cells, CD8
+
 T 
cells were stimulated with 40 µg/ml of FIP-fve, either alone or in co-culture 
with BM-DCs. Two days after stimulation, cells were harvested for [
3
H]-
Thymidine incorporation assay. Stimulation index was calculated by dividing 
the count per minute (cpm) value of FIP-fve stimulated group by the cpm 
value of non-stimulated group (i.e. in medium only). Empty bar represents the 
co-culture of T cells or their subsets in the absence of BM-DCs. Filled-bar 
represents the co-culture of T cells or their subsets in the presence of BM-
DCs. Data were presented as mean±SD. Two-tailed student’s t-test was used 
to calculate the significant difference between the FIP-fve-stimulated and 
medium control groups. *, P<0.05; **, P<0.01; ***, P<0.001. Representative 





































3.2.1.3 Effect of FIP-fve on B cell proliferation 
Besides examining the function of FIP-fve on BM-DCs and T cells, an attempt 
was also made to explore the mitogenic effect of FIP-fve on another major 
type of immune cell, B cells, via in vitro cell proliferation study. Mouse 
splenocytes were labeled with 5 μM of Carboxyfluorescein succinimidyl ester 
(CFSE) and further stimulated with 40 µg/ml of FIP-fve, 2 µg/ml of 
Phytohemagglutinin (PHA) or 1 µg/ml of Lipopolysaccharides (LPS) for 48 
hours. The cells were stained with CD19, CD4, CD8 mAbs and the percentage 
of proliferative B cells, CD4
+
 T and CD8
+
 T cells were analyzed. Results 
showed that the B cell mitogen (LPS), which served as a positive control, 
induced proliferation in 69.85% of B cells. In contrast, as compared to the 
unstimulated cells (i.e. medium alone), the T cell mitogen (PHA) and FIP-fve 
did not induce B cells proliferation (12.26%, 4.27%, and 7.19% of proliferated 
cells for unstimulated, PHA-, and FIP-fve-stimulated B cells respectively) 
(Fig. 3.5A). Furthermore, as expected, both FIP-fve and PHA enhanced the 
percentage of proliferating CD4
+
 T (0.82%, 8.39%, and 28.91% for 
unstimulated, PHA-, and FIP-fve-stimulated CD4
+
 T cells respectively) and 
CD8
+
 T cells (1.87%, 73.24%, and 77.85% for unstimulated, PHA-, and FIP-
fve-stimulated CD8
+
 T cells respectively) (Fig. 3.8). The CFSE assay also 
further confirmed the results of [
3
H]-thymidine incorporation assay showing 
that FIP-fve induced more proliferation of CD8
+
 T cells than that of CD4
+
 T 































Figure 3.8 FIP-fve-stimulated B cells did not proliferate in vitro. C57BL/6J 
mouse splenocytes were labeled with 5 µM of CFSE and cultured for two days 
in medium alone or in the presence of 40 µg/ml of FIP-fve, 2 µg/ml of PHA or 
1 µg/ml of LPS. The cells were stained with anti-CD19, -CD4 and -CD8 
mAbs and the percentage of proliferating B cells (A), CD4
+
 T cells (B), and 
CD8
+
 T cells (C) were analyzed by flow cytomety. The numbers represent the 
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3.2.2 The mitogenic and cytokine/chemokine-inducing effects of FIP-fve 
involved the binding of CD27, OX-40 on T cells and their 
respective ligands, CD70, OX-40L  
3.2.2.1 Treatment of purified total T cells, CD4
+
 T or CD8
+
 T cells 
with anti-CD70 and anti-OX-40L antagonist monoclonal 
antibodies significantly reduced FIP-fve-induced cellular 
proliferation 
Since the surface expressions of 4-1BB, CD27, and OX-40 on T cells were 
shown to be up-regulated upon FIP-fve stimulation, I then hypothesized that 
the binding of these receptors to their respective ligands on APCs or accessory 
cells could be involved in mediating the biological effects of FIP-fve. The role 
of these markers in FIP-fve-induced -T cell proliferation, -cytokine/chemokine 
production were examined using the blocking antibodies against their ligands 
4-1BBL, CD70 or OX-40L. First, purified T cells, CD4
+
 T cells or CD8
+
 T 
cells were co-cultured with BM-DCs and stimulated with FIP-fve in the 
presence or absence of 1 µg/ml or 10 µg/ml of blocking antibodies against 4-
1BBL, CD70 or OX-40L or the respective isotype control. The proliferation of 
cells were measured by [
3
H]-thymidine incorporation assay. When blocking 
antibody was used individually at 1 µg/ml, I found that only the treatment of 
CD8
+
 T cell co-culture with anti-CD70 antibody resulted in significant 
reduction in cellular proliferation as compared to its isotype control (26.2  ± 
3.9 % vs 3.3 ± 2.6 %, P = 0.002). The combination of 1 µg/ml each of -
CD70 and -4-1BBL (14.1 ± 4.1 % vs 1.5 ± 2.3 %, P = 0.02) or -4-1BBL 





 T cells only. More importantly, the combination of 1 
µg/ml of -CD70 and -OX-40L blocking antibodies significantly inhibited 
total T cell (30.8 ± 4.1 % vs 2.2 ± 5.3 %, P = 0.002), CD4
+
 T cell (21.4 ± 6.2 
% vs -0.6 ± 5.3 %, P = 0.0004), and CD8
+
 T cell (37.1 ± 1.2 % vs 3.3 ± 2.6 %, 
P = 0.0003) proliferation. The combination of three antibodies -CD70, -4-
1BBL and -OX40L did not further suppress the proliferation of T and 
subsets of T cells (Fig. 3.9A). While, with the addition of 10 µg/ml of each 
antibody, there was generally a trend of reduction in T cell proliferation. When 
10 µg/ml of anti-4-1BBL antibody was added, there was a significant 
reduction in only CD8
+
 T cell proliferation as compared to the addition of its 
isotype control (13.2 ± 3.9 % vs 2.4 ± 2.4 %, P = 0.02). In the presence of 10 
µg/ml of anti-CD70 antibody, there was a significant inhibition in both CD4
+
 
T cell and CD8
+
 T cell proliferations (15.2 ± 4.6 % vs -7.4 ± 3.2 %, P = 0.003; 
29.9 ±2.8 % vs -3.5 ± 2.1 %, P = 0.0001 for CD4
+
 T cell and CD8
+
 T cell co-
cultures respectively). Whereas, the addition of 10 µg/ml of anti-OX-40L 
antibody resulted in significant reduction in total T cell, CD4
+
 T cell, and 
CD8
+
 T cell proliferations (24.1 ± 3.9 % vs 0.04 ± 10.5 %, P = 0.04; 16.4 ± 
5.5 % vs -7.4 ± 3.2 %, P = 0.006; 16.1 ± 2.9 % vs -3.5 ± 2.1 %, P = 0.001 for 
total T cell, CD4
+
 T cell, and CD8
+
 T cell co-cultures respectively). Blocking 
with 10 g/ml of -CD70, -4-1BBL or -OX40L in any combination 
resulted in significant reduction in total T cell, CD4
+
 T cell, and CD8
+
 T cell 
proliferations (Fig 3.9B). Thus, these results indicate that the binding of CD27 
and OX-40 with their respective ligands may be essential for optimal 
proliferation of T cells upon FIP-fve stimulation. CD27 is in particular 
important for FIP-fve-induced CD8
+
 T cell proliferation. The unprocessed 
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Figure 3.9 FIP-fve-induced T cell proliferation was partly mediated by the 
binding of CD70 and OX-40L to their respective receptors on T cells. 
Total T cells (purple bar), CD4
+
 T cells (blue bar), and CD8
+
 T cells (red bar) 
were stimulated with 40 μg/ml of FIP-fve in the presence of BM-DCs. 
Blocking antibodies against 4-1BBL, CD70, OX-40L or their respective 
isotype control Abs were added at 1 μg/ml (A) or 10 μg/ml (B). The effect of 
blocking Abs on cellular proliferation was measured by [
3
H]-thymidine 
incorporation assay after 48 hours of incubation. Black bar indicated the 
isotype control group. Percentage of inhibition was calculated by the 
following formula: [1-(cpm values in absence of blocking Ab / cpm values in 
the presence of blocking Ab)] x 100%. Statistical analysis was calculated by 
two-tailed student’s t-test. *, P < 0.05; **, P< 0.01; ***, P < 0.001. 
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3.2.2.2 FIP-fve requires the binding of CD70, OX-40L with their 
receptors on T cells to induce an optimal level of 
cytokine/chemokine secretion  
Next, the role of 4-1BB, CD27, and OX-40 in FIP-fve-induced T cell 
cytokine/chemokine secretion was examined. Purified T cells, CD4
+
 T cells or 
CD8
+
 T cells were cultured in the same condition as described in the 
proliferation assay above. The culture supernatants were collected at day 2 and 
day 3 of co-culture to assay for FIP-fve-induced cytokine/chemokine profile. 
Here, I only presented the data from the cells treated with anti-CD70 and anti-
OX-40L antibodies as the treatment with anti-4-1BBL antibody did not 
significantly affect the cytokine/chemokine secretion (data not shown). The 
addition of up to 20 g/ml of IgG2b antibody did not significantly change the 
levels of FIP-fve induced cytokine/chemokine production either (Appendix 3). 
For total T cells and BM-DCs co-culture, the addition of 1 µg/ml of anti-CD70 
antibody into T cell co-culture significantly decrease the levels of IFN-γ 
(389.4 ± 61.9 pg/ml (anti-CD70) vs 747.2 ± 120.1 pg/ml (isotype), P = 0.02), 
IP-10 (402.6 ± 45.9 pg/ml vs 573 ± 25.5 pg/ml , P = 0.01), and MIP-1β (389.4 
± 62 pg/ml  vs 747.2 ± 120.1 pg/ml , P = 0.02) at day 3 of co-culture (Fig. 
3.10A). Though it did not reach statistical significance, single blocking with 
10 µg/ml of anti-CD70 or anti-OX-40L antibody showed a trend of reduction 
in IFN-, MIG, MIP-1, MIP-1β secretion at day 3 of co-culture (Fig. 3.10A). 
When the anti-CD70 and anti-OX-40L antibodies (double blockings) were 
added together into the total T cell co-culture at a dosage of 1 µg/ml or 10 
µg/ml of each antibody, again, results showed that there was a reduction in the 
levels of cytokine/chemokine, particularly at day 3 of co-culture. In the 
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presence of 1 µg/ml of anti-CD70 and anti-OX-40L antibodies, the levels of 
IFN-γ (417.8 ± 38.5 pg/ml vs 747.2 ± 120.1 pg/ml (isotype), P = 0.03), IP-10 
(365 ± 36.4 pg/ml vs 573 ±25.5 pg/ml , P = 0.002), MIP-1α (105.2 ± 8.4 pg/ml 
vs 185.2 ± 30.2 pg/ml , P = 0.04), and MIP-1β (417.8 ± 38.5 pg/ml vs 747.2 ± 
120.1 pg/ml , P = 0.03) were significantly reduced at day 3 of co-culture. The 
levels of IFN-γ, MIG, MIP-1α, and MIP-1β were also showing a trend of 
reduction in the presence of 10 µg/ml of anti-CD70 and anti-OX-40L 
antibodies (Fig. 3.10B).   
Interestingly, when anti-CD70 and anti-OX-40L antibodies were added to 
CD4
+
 T cells and BM-DCs co-culture either separately or in combination, 
there was no significant change in the profile of FIP-fve-induced 
cytokine/chemokine secretion (Fig. 3.11). On the other hand, addition of 1 
μg/ml of anti-CD70 antibody into the CD8+ T cells and BM-DCs co-culture 
significantly decreased the level of IFN-γ (1253.6 ± 279.1 pg/ml vs 2140.1 ± 
114.5 pg/ml (isotype), P = 0.02 at day 2; 1071.2 ± 61.3 pg/ml vs 1762.5 
±439.7 pg/ml , P = 0.04 at day 3) and MIG (535.2 ± 63.1 pg/ml vs 986.4 ± 
172.2 pg/ml , P = 0.03 at day 2; 1092.9 ± 78.9 pg/ml vs 1920.9 ± 249.7 pg/ml , 
P = 0.02 at day 3) in the supernatants of both day 2 and day 3 of co-culture as 
well as significantly decreased the level of MIP-1 (1210.9 ± 114.3 pg/ml vs 
1628.9 ± 111.1 pg/ml , P = 0.01) and MIP-(4318.1 ± 575.6 pg/ml vs 6791.4 
± 533.7 pg/ml , P = 0.005) in the day 2 supernatant. Similar effects were also 
observed with the addition of 10 μg/ml of anti-OX-40L antibody in which the 
levels of IFN-γ and MIG were also significantly reduced at both day 2 and day 
3 of co-culture (Fig. 3.12A). Furthermore, when 1 μg/ml each of anti-CD70 
and anti-OX-40L antibodies were added into CD8
+
 T cells co-culture, there 
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was a decrease in the levels of IFN-γ (829.3 ± 136.4 pg/ml vs 2140.1 ± 114.5 
pg/ml, P = 0.0003 at day 2; 626.9 ± 110.1 pg/ml vs 1762.5 ± 439.7 pg/ml, P = 
0.04 at day 3), MIG (581.6 ± 66.8 pg/ml vs 986.4 ± 172.2 pg/ml, P = 0.04 at 
day 2; 1013.7 ± 172.1 pg/ml vs 1920.9 ± 111.3 pg/ml, P = 0.009 at day 3), 
MIP-1α (1200.1 ± 35.5 pg/ml vs 1628.9 ± 111.1 pg/ml, P = 0.01 at day 2; 
1067.6 ± 86.9 pg/ml vs 1460.3 ± 410.1 pg/ml at day 3), and MIP-1β (4041.4 ± 
852.9 pg/ml vs 6791.4 ± 533.7, P = 0.01 at day 2; 5006.9 ± 1265.9 pg/ml vs 
6031.2 ± 1129.4 pg/ml at day 3) at both day 2 and day 3 of co-culture. Similar 
effects were also observed with the addition of 10 μg/ml each of anti-CD70 
and anti-OX-40L antibodies (Fig. 3.12B). Notably, the anti-CD70 and anti-
OX-40L antibodies had minor effects on the level of IP-10.  
In summary, blocking of CD70 and OX-40L significantly attenuated the 
secretion of cytokine/chemokine by T cells (CD8
+
 T cells in particular); thus, 
providing a stronger evidence on the essential role of CD27 and OX-40 in 
































Figure 3.10 Anti-CD70 and anti-OX40L mAbs suppress cytokines/chemokines 
production by T cells.  Purifed total T cells were co-cultured with BM-DCs in the presence 
of FIP-fve.Cell cultures were separately treated with either 1 µg/ml (blue line) or 10 µg/ml 
(purple line) of anti-CD70 (filled-bar) or anti-OX-40L (square mesh pattern-bar) antibody for 
single blocking (A),. In addition, the similar co-culture setups were also treated with either 1 
µg/ml (blue line) or 10 µg/ml (purple line) of anti-CD70 and anti-OX-40L antibodies in 
combination (filled-bar) for double blockings (B). Isotype control is represented by the empty 
bar. Culture supernatant was collected on day 2 and 3 after stimulation and assayed for the 
level of cytokine/chemokine by multiplex immunoassay. Data were presented as mean±SD. 
Statistical difference was calculated by two-tailed student’s t-test. *, P<0.05; **, P<0.01; ***, 
P<0.001. Representative data from two independent experiments were shown.  
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Figure 3.11 Anti-CD70 and anti-OX40L mAbs suppress cytokines/chemokines 
production by CD4
+
 T cells. Purifed CD4
+
 T cells were cultured and treated with the same 
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Figure 3.12 Anti-CD70 and anti-OX40L mAbs suppress cytokines/chemokines 
production by CD8
+
 T cells.  Purifed CD8
+
 T cells were cultured and treated with the same 
protocols as described in Fig 3.10.  
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 T cells 
As shown in my previous result, T cells alone could be directly activated by 
FIP-fve stimulation. Thus, to gain a deeper insight on the cellular and 
molecular events occurring when T cells were stimulated with FIP-fve, I 
attempted to expand the knowledge on gene expression profile of FIP-fve 
stimulated CD4
+
 T and CD8
+
 T cells by gene array studies. Purified mouse 
CD4
+
 T and CD8
+
 T cells were stimulated with 20 µg/ml of FIP-fve for 2 
hours and 8 hours. Total RNA was then extracted for microarray experiment 
using mouse 8x60K GX array. T cells were stimulated for two hours to 
identify the genes which were expressed at early activation phase, whereas 
eight hours of FIP-fve stimulation were performed to identify the genes which 
were expressed at later activation phase. The heat map analysis showed 
clustering of the gene expression profile according to length of stimulation (2 
hours vs 8 hours), followed by T cell types (CD4
+ 
T cells vs CD8
+
 T cells), and 
finally by type of treatment (FIP-fve vs medium alone) (Fig. 3.13). 
The Venn diagram analysis, based on gene expression with fold change more 
than or equal to two and P-value < 0.05, demonstrated that comparing the 
CD4
+
 T cells stimulated for 2 hours and 8 hours with FIP-fve, 27 genes were 
differentially expressed at 2 hours, 100 genes were differentially expressed at 
8 hours, and 5 genes were differentially expressed at both 2 hours and 8 hours 
(Fig. 3.14A). While, for CD8
+
 T cells, 18 genes were differentially expressed 
at 2 hours, 219 genes were differentially expressed at 8 hours, and 11 genes 
were differentially expressed at both 2 hours and 8 hours (Fig. 3.14B). 
Moreover, comparing the CD4
+
 T and CD8
+
 T cells stimulated with FIP-fve 
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for 2 hours, 26 genes were differentially expressed only in CD4
+
 T cells, 23 
genes were differentially expressed only in CD8
+
 T cells, and 6 genes were 
differentially expressed in both CD4
+
 T and CD8
+
 T cells (Fig. 3.14C). On the 
other hand, after 8 hours of stimulation, 37 genes were differentially expressed 
only in CD4
+
 T cells, 162 genes were differentially expressed only in CD8
+
 T 
cells, and 68 genes were differentially expressed in both CD4
+
 T and CD8
+
 T 
cells (Fig. 3.14D). Overall, the results demonstrated that more genes which 
were differentially expressed in CD8
+
 T cells than that in CD4
+
 T cells, 
especially when stimulated with FIP-fve for 8 hours. 
Moreover, data analysis using the GeneSpring GX software also allowed us to 
determine the cellular and biochemical pathways that were significantly up-
regulated on CD4
+
 T and CD8
+
 T cells after stimulation with FIP-fve for 2 
hours and 8 hours. A list of significantly affected signaling or cellular 
pathways is shown in Table 3.2. Based on the list of genes which were 
differentially expressed after FIP-fve stimulation for 2 hours, the pathways 
involved in inositol phosphate metabolism, mTOR signaling pathway, 
regulation of eIF-4E and p70 S6 kinase as well as PTEN-dependent cell cycle 
arrest and apoptosis were found to be commonly affected in both FIP-fve-
stimulated -CD4
+
 T and -CD8
+
 T cells (highlighted in blue in Table 3.2). 
Similarly, based on the genes that were differentially expressed upon 8 hours 
of FIP-fve stimulation, the pathway involved in folate metabolism, glycine and 
serine metabolism, steroids metabolism, FGF signaling pathway as well as 
pyrimidine nucleotides and nucleosides metabolism were among the 
significantly affected pathways in both FIP-fve-stimulated -CD4
+
 T and -CD8
+
 
T cells (highlighted in green in Table 3.2). 
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Several representative genes from FIP-fve-stimulated -CD4
+
 T and -CD8
+
 T 
cells upon 2 hours and 8 hours of stimulation were selected based on fold 
change greater than or equal to two, P-value < 0.05, and involvement in 
immune functions (Table 3.3). The expressions of these genes were further 
validated by qPCR. The qPCR results showed that FIP-fve stimulation for 2 
hours up-regulated Irf4 and Sh3bp2 on CD4
+
 T cells (Fig. 3.15A), while Ccl3, 
Ir4, and Sh3bp2 were also significantly up-regulated on CD8
+
 T cells (Fig. 
3.15B). Furthermore, FIP-fve stimulation for 8 hours up-regulated Cx3cl1, 
Egr1, Irf4, Sh3bp2, Shmt1, and Tnf on CD4
+
 T cells; however, only the up-
regulation of Egr1, Irf4, and Tnf reached statistical significance (Fig. 3.15C). 
Whereas, for CD8
+
 T cells, the expressions of Ccl4, Shmt1, Tnfrsf9 (4-1BB), 
Xcl1, CD274, Ifng, Stat1, Shmt2, Plk3, Lta, Tnf, Irf4, Egr1, Cxcl10, CD160, 
and Tnfsf14 (LIGHT) were all significantly up-regulated after FIP-fve 
stimulation for 8 hours (Fig. 3.15D). The complete list of differentially 
expressed genes of FIP-fve-stimulated -CD4
+
 T and -CD8
+
 T cells (fold 

























Figure 3.13 Gene expression array of FIP-fve-stimulated CD4
+
 T and 
CD8
+
 T cells – heat map analysis. Mouse CD4+ T cells and CD8+ T cell were 





 T cells were above 94% and 90% respectively. Each T cell 
subset was stimulated with 20 µg/ml of FIP-fve for 2 hours and 8 hours. Heat 
map analysis showed the clustering of gene expression profile based on length 
of stimulation, subset of cells as well as type of treatment (FIP-fve vs medium 
alone). 
  



































Figure 3.14 Gene expression array of FIP-fve-stimulated CD4
+
 T and 
CD8
+
 T cells – Venn diagram analysis. Venn diagrams show the number of 
differentially expressed genes in CD4
+
 T (A) and CD8
+
 T (B) cells upon 
stimulation by FIP-fve for 2 hours and 8 hours. In addition, the number of 
differentially expressed genes comparing CD4
+
 T and CD8
+
 T cells at both 2 
hours (C) and 8 hours (D) of FIP-fve stimulation are also shown. 
.  
CD4+ T cells 
CD8+ T cells 
2 hours 
8 hours 
2 hours 8 hours 27 5 100 
2 hours 8 hours 18 11 219 
CD4+ T cells CD8+ T cells 26 6 23 
CD4+ T cells CD8+ T cells 37 68 162 
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Table 3.2 List of significantly affected signaling or cellular pathways in 
CD4
+
 T and CD8
+




 T cells after 2 hours of FIP-fve stimulation 
Inositol phosphate metabolism ( Inositol phosphate metabolism ) 
mTOR signaling pathway 
Regulation of eIF-4E and p70 S6 kinase 
PTEN-dependent cell cycle arrest and apoptosis 
CD8
+
 T cells after 2 hours of FIP-fve stimulation 
Inositol phosphate metabolism 
mTOR signaling pathway 
Regulation of eIF-4E and p70 S6 kinase 
PTEN-dependent cell cycle arrest and apoptosis 
Rho cell motility signaling pathway 
CCR3 signaling in eosinophils 
Role of mal in rho-mediated activation of srf 
Rac1 cell motility signaling pathway 
CD4
+
 T cells after 8 hours of FIP-fve stimulation 
L-Tetrahydro-folic acid 
+





 H2O ( Folate metabolism ) 
Glycine and Serine metabolism 
Dimethylallyl diphosphate = Isopentenyl diphosphate ( Steroids metabolism ) 
Gene expression of Sprouty1 ( FGF signaling pathway ) 
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides 
and Nucleosides metabolism ) 
Vitamin B6 metabolism 
T cell receptor signaling (PLC gamma, PKC, Ras and IKK-NF-kappaB 
cascade) ( CD4 T cell receptor signaling (NF-kB cascade) ) 
IGF1 signaling pathway ( IGF1 signaling pathway ) 
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IL-2 signaling pathway(JAK1 JAK3 STAT5) ( IL-2 signaling(JAK1 JAK3 
STAT5) ) 
IGF1 signaling pathway ( IGF1 signaling pathway ) 
Role of mitochondria in apoptotic signaling 
Alk in cardiac myocytes 
Apoptotic signaling in response to dna damage 
Opposing roles of aif in apoptosis and cell survival 
IL-2 signaling pathway 
Regulation of bad phosphorylation 
Role of pi3k subunit p85 in regulation of actin organization and cell migration 
Biosynthesis of steroids 
Glycine, serine and threonine metabolism 
Cyanoamino acid metabolism 
Glyoxylate and dicarboxylate metabolism 





BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 
members 
Oligomerization of connexins into connexons 
Gap junction assembly 
CD8
+





 5,10-Methylene-tetrahydro-folic acid = NADH 
+
 5,10-Methenyl-
tetrahydro-folic acid ( Folate metabolism ) 
2-Oxo-glutaric acid 
+
 L-O-Phospho-serine = L-Glutamic acid 
+
 3-Phospho-
hydroxy-pyruvic acid ( Glycine and Serine metabolism ) 
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Dimethylallyl diphosphate = Isopentenyl diphosphate ( Steroids metabolism ) 
Gene expression of Sprouty1 ( FGF signaling pathway ) 
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides 
and Nucleosides metabolism ) 
Vitamin B6 metabolism 
Fatty acid biosynthesis 
Biosynthesis of steroids 
Glycine, serine and threonine metabolism 
Cyanoamino acid metabolism 
One carbon pool by folate 
Methane metabolism 
Terpenoid biosynthesis 
Oligomerization of connexins into connexons 
Gap junction assembly 
 
*The pathways which were affected in both FIP-fve-stimulated -CD4
+
 T and -
CD8
+











Table 3.3 List of representative genes which showed differential 
expression (fold change 2, P < 0.05) in CD4+ T and CD8+ T cells upon 





















0.021 3.43 up Irf4 
Mus musculus interferon 
regulatory factor 4 (Irf4), 
mRNA [NM_013674] 
0.029 3.02 up Sh3bp2 
Mus musculus SH3-domain 
binding protein 2 (Sh3bp2), 















5.25 up Ccl3 
Mus musculus chemokine 
(C-C motif) ligand 3 (Ccl3), 
mRNA [NM_011337] 
0.004 4.36 up Irf4 
Mus musculus interferon 
regulatory factor 4 (Irf4), 
mRNA [NM_013674] 
0.007 2.32 up Sh3bp2 
Mus musculus SH3-domain 
binding protein 2 (Sh3bp2), 













0.004 8.14 up Irf4 
Mus musculus interferon 
regulatory factor 4 (Irf4), 
mRNA [NM_013674] 
0.010 7.05 up Egr1 
Mus musculus early growth 
response 1 (Egr1), mRNA 
[NM_007913] 
0.009 5.96 up Sh3bp2 
Mus musculus SH3-domain 
binding protein 2 (Sh3bp2), 
transcript variant 2, mRNA 
[NM_001145859] 
0.010 5.81 up Shmt1 
Mus musculus serine 
hydroxymethyltransferase 1 




0.022 4.49 up Cx3cl1 
Mus musculus chemokine 





4.01 up Tnf 
Mus musculus tumor 













0.002 20.04 up Xcl1 
Mus musculus chemokine 
(C motif) ligand 1 (Xcl1), 
mRNA [NM_008510] 
0.004 16.44 up Tnfrsf9 
Mus musculus tumor 
necrosis factor receptor 
superfamily, member 9 
(Tnfrsf9), transcript variant 
1, mRNA [NM_011612] 
0.047 13.55 up Ccl4 
Mus musculus chemokine 




0.009 13.53 up Shmt1 
Mus musculus serine 
hydroxymethyltransferase 1 




0.018 12.15 up Tnf 
Mus musculus tumor 
necrosis factor (Tnf), mRNA 
[NM_013693] 
0.026 11.99 up Irf4 
Mus musculus interferon 
regulatory factor 4 (Irf4), 
mRNA [NM_013674] 
0.024 8.46 down Tnfsf15 
Mus musculus tumor 
necrosis factor (ligand) 
superfamily, member 15 
(Tnfsf15), mRNA 
[NM_177371] 
0.001 8.00 up Egr1 
Mus musculus early growth 
response 1 (Egr1), mRNA 
[NM_007913] 
0.046 7.51 up Cxcl10 
Mus musculus chemokine 
(C-X-C motif) ligand 10 
(Cxcl10), mRNA 
[NM_021274] 
0.092 5.88 up Cd160 
Mus musculus CD160 
antigen (Cd160), transcript 
variant 2, mRNA 
[NM_018767] 
0.096 4.72 up Tnfsf14 
Mus musculus tumor 
necrosis factor (ligand) 
superfamily, member 14 
(Tnfsf14), mRNA 
[NM_019418] 
0.037 3.99 up Cd274 
Mus musculus CD274 
antigen (Cd274), mRNA 
[NM_021893] 
0.030 3.77 up Ifng 
Mus musculus interferon 
gamma (Ifng), mRNA 
[NM_008337] 
0.040 3.21 up Stat1 
Mus musculus signal 
transducer and activator of 
transcription 1 (Stat1), 
mRNA [NM_009283] 
0.001 2.64 up Shmt2 
Mus musculus serine 
hydroxymethyltransferase 2 
(mitochondrial) (Shmt2), 
nuclear gene encoding 
mitochondrial protein, 
mRNA [NM_028230] 
0.018 2.46 up Plk3 
Mus musculus polo-like 
kinase 3 (Drosophila) (Plk3), 
mRNA [NM_013807] 
0.012 2.00 up Lta 
Mus musculus lymphotoxin 


























Figure 3.15 Validation of gene expression profile from gene array study 
using real-time qPCR. The list of representative genes (table 3.3) from FIP-
fve-stimulated –CD4+ T and –CD8+ T cells upon 2 hours (A and B 
respectively) and 8 hours (C and D respectively) of stimulation was validated 
by real-time qPCR. qPCR assay for each target gene was performed in 
triplicates. Normalized Ct (ΔCt) values for each target gene were calculated by 
subtracting the Ct value obtained from each target gene with the Ct value 
obtained from the β-actin. Using ΔΔCt values (calculated from ΔCt in FIP-fve-
stimulated group – ΔCt in unstimulated group) and the formula, 2-( ΔΔCt), the 
relative quantity (RQ) of mRNA levels in FIP-fve-stimulated sample and 
unstimulated sample were determined. Statistical difference was calculated by 































































3.2.4 Effect of FIP-fve on antigen-specific CD8
+
 T cell responses 
To further explore the adjuvant effect of FIP-fve on adaptive immune 
responses, I utilize the CD8
+
 T cells from OT-I mice whose T cell receptor 
(TCR) is specific for chicken ovalbumin 257-264 (OVA257-264), in the context 
of H-2K
b
. Purified OT-I CD8
+
 T cells were pre-stimulated with 20 µg/ml or 40 
µg/ml of FIP-fve for 18 hours, followed by thorough washing steps to remove 
the remnant of FIP-fve. The FIP-fve pre-stimulated OT-I CD8
+
 T cells were 
co-cultured with BM-DCs in the presence of various concentrations of 
OVA257-264 peptide for one to five days. The proliferation of OVA257-264 
peptide specific T cells were measured by [
3
H]-thymidine incorporation assay. 
Results indicated that pre-stimulation of OT-I CD8
+
 T cells with FIP-fve led to 
significant enhancement in the proliferation of OVA-specific CD8
+
 T cells, 
particularly from day 1 until day 3 after antigenic stimulation. The effect of 
FIP-fve pre-stimulation appeared to diminish from day 4 onwards. In addition, 
the cell proliferation results also suggested that 10
-5
 μM of OVA257-264 peptide 
could be the optimal concentration to induce OVA-specific CD8
+
 T cell 
proliferation at early time point (Fig. 3.16A).   
Furthermore, I also collected the culture supernatant on day 1, day 2, day 3, 
and day 5 of co-culture to assay and determine the level of IFN-γ produced by 
OVA-specific CD8
+
 T cells. ELISA result indicated that pre-stimulation of 
CD8
+
 T cells with 40 µg/ml of FIP-fve, resulted in significant increase of the 
secretion of IFN-γ by OVA-specific CD8+ T cells (Fig. 3.16B). To further 
examine the function of OVA-specific CD8
+
 T cells, I performed in vitro 
cytotoxic T lymphocyte (CTL) killing assay using Calcein-acetoxymethyl 





 T cells with FIP-fve significantly enhanced their killing activity, as 
shown by the increase in percentage of specific lysis under the condition in 
which there was a low effector to target ratio (Fig. 3.17). Taken together, these 
findings suggest that pre-stimulation or potentiation of antigen-specific CD8
+
 
T cells with FIP-fve significantly speed up as well as enhance the magnitude 
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Figure 3.16 FIP-fve enhanced the magnitude of antigen-specific CD8
+
 T 
cell responses in vitro. Purified OT-I CD8
+
T cells were pre-stimulated with 
either 20 μg/ml (         ) or 40 μg/ml (         ) of FIP-fve for 18 hours. The group 
in medium alone was represented by (       ). After washing, the OT-I CD8
+
 T 
cells were co-cultured with BM-DCs in the presence of 10-fold serial dilution 
of OVA257-264 peptide. At the indicated day upon stimulation, the co-culture 
was harvested to measure OVA-specific CD8
+
 T cell proliferation by [
3
H]-
Thymidine incorporation assay (A). In addition, the culture supernatant was 
also collected and used to assay for the level of IFN-γ by ELISA (B). Data 
were shown as mean ± SEM for 3 to 6 replicate samples and two-tailed 
student’s t-test was used to calculate the significant difference. *, significant 
difference between (       ) and (         ); #, significant difference between  
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Figure 3.17 FIP-fve enhanced the function of antigen-specific CD8
+
 T cells 
in vitro. Unstimulted or pre-stimulated OT-I CD8
+
 T cells (cultured in 40 
μg/ml of FIP-fve for 18 hours) were activated with 0.78 μM of OVA257-264 
peptide and cultured for 7 days. Subsequently, the activated CD8
+
 T cells were 
used as effector cells for in vitro CTL assay. OVA257-264 peptide- pulsed EL4 
cells served as the target cells. Data were presented as mean±SD. Statistical 
difference was calculated by two-tailed student’s t-test. #, P<0.05. 
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In vivo studies from others and our laboratory have shown that FIP-fve can act 
as an adjuvant to enhance the humoral and cellular immune responses against 
allergy and tumor in mouse model (Chang et al., 2010; Ding et al., 2009; 
Hsieh et al., 2003). However the detailed molecular and cellular mechanisms 
by which FIP-fve can modulate the immune response is not fully elucidated. 
Hence, in this chapter, the interaction between FIP-fve and dendritic cells, T 
cells, B cells were dissected via various in vitro studies. Results suggest that T 
cells (or CD8
+
 T cells in particular) are the main and direct target cells of FIP-
fve. 
Dendritic cells (DCs) are known as antigen  presenting cells (APCs) with a 
unique ability to rapidly recognize the pathogen during tissue injury and 
present the associated antigen to the cell of adaptive immunity; thus, inducing 
the activation of immune responses (Fearon and Locksley, 1996; Hoffmann et 
al., 1999; Medzhitov and Janeway). In the present study, DCs were derived 
from mouse bone marrow cells using GM-CSF. Stimulation of BM-DCs with 
FIP-fve did not appear to enhance the surface expression of their activation 
markers, including CD40, I-A
b
, CD80, and CD86. However, interestingly, the 
surface expression of those markers was up-regulated when T cells were 
present in the co-culture during FIP-fve stimulation. Furthermore, when T cells 
were pre-stimulated with FIP-fve and subsequently added to the BM-DCs 
culture, the surface expression of I-A
b
 and CD86 was also enhanced. Hence, it 
appears that FIP-fve may have more pre-dominant effect on T cells and the 
crosstalk between the FIP-fve-stimulated T cells and BM-DCs is essential to 
drive BM-DCs maturation. 
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It has been reported that the crosstalk between activated innate lymphocytes 
including NK cells, NK T cells as well as γδ T cells and DCs may lead to full 
maturation of DCs. α-galactosylceramide-activated NK T cells was shown to 
rapidly mature DCs, as assessed by the up-regulation of CD40, I-A
b
, CD80, 
and CD86 expressions on splenic DCs (Reschner et al., 2008). Moreover, α-
galactosylceramide stimulation in Jα281-/- mice which lacked the NK T cells 
failed to mature the DCs in vivo (Fujii et al., 2003). Munz, et al. postulated 
that the activated innate lymphocytes could induce DCs maturation, 
presumably under the circumstances where DCs were also presenting some 
ligands recognized by innate lymphocytes. Different types of innate 
lymphocytes may mediate DCs activation via cytokines and cell contact-
dependent molecules. The activated DCs may in turn expand the innate 
lymphocytes and elicit the adaptive immunity to processed antigens, (Münz et 
al., 2005).  
The cytokine/chemokine immunoassay (Fig 3.5A) and gene array profile 
(Table 3.3) in the present study have shown that FIP-fve can directly act on T 
cells and enhance the secretion or gene expression of chemokines/cytokines, 
MIP-1, MIP-1, IP-10, IFN-, TNF. Besides, FIP-fve can directly up-
regulate the expression of CD27, CD28, 4-1BB on T cells (Fig 3.3) and hence 
may enhance the interaction between T cells and DCs through the binding of 
these receptors to their counterpart ligands, CD70, CD80/CD86, 4-1BBL on 
DCs. Taken together, a similar mechanism may also be plausible in this study 
in which the FIP-fve- activated T cells may mediate BM-DCs maturation, 
possibly via surface receptors-ligands binding and/or soluble mediators. 
Matured DCs may in turn enhance the adaptive cellular responses and increase 
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the anti-tumor activity as seen in the previous in vivo studies. This hypothesis 
is indirectly proven in the in vitro study showing that co-culture of FIP-fve 
pre-stimulated OT-I CD8
+
 T cells with BM-DCs in the presence of OVA257-264 
peptide stimulation was shown to significantly enhance the magnitude of OVA 
specific immune responses. Moreover, it enhances the cytotoxicity function of 
CD8
+
 T cells (Fig. 3.15). The results suggest that FIP-fve-activated T cells 
could have driven the maturation of BM-DCs in the co-culture via the binding 
of their receptors with the cognate ligands on BM-DCs and/or secretion of 
soluble mediators; hence, resulting in a more effective antigen presentation 
function, and ultimately greater adaptive immune responses. 
Since T cell appears to be the major target cell in response to FIP-fve 
stimulation, the direct effect of FIP-fve stimulation on T cells was 
subsequently examined. Results demonstrated that in the absence of accessory 
cells, FIP-fve could still activate T cells as shown by (1) up-regulation of 
CD137 (4-1BB) on both CD4
+
 T and CD8
+
 T cells, CD27 and CD28 mainly 
on the CD8
+
 T cells as well as CD134 (OX-40) mainly on the CD4
+
 T cells in 
a dose-dependent manner in vitro, (2) enhancement of T cells proliferation and 
(3) elevation of chemokine secretion, MIP-1 and MIP-1. However results 
suggested that the cellular proliferation of T cells induced by FIP-fve was 
significantly dependent on the interaction between T cells and BM-DCs. 
Although FIP-fve could still significantly stimulate the proliferation of purified 
total T cells, CD4
+
 T, and CD8
+
 T cells, the cellular proliferation was robustly 
increased when the BM-DCs were present in the co-culture system during 
FIP-fve stimulation, particularly for CD8
+
 T cells where it could proliferate to 
a stimulation index of 21.5 as compared to only 6.4 in CD4
+
 T cells. Similarly, 
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multiplex assay results also suggested that FIP-fve could increase the secretion 
of IFN-γ, IP-10, and MIG on T cells by six to ten folds in the presence of BM-
DCs. Hence, this data indicate that the biological function of FIP-fve is partly 
dependent on the interaction between T cells and accessory cells (i.e. BM-DCs 
or non-T cells). 
Several members of tumor necrosis factor receptor (TNFR) family, namely 
CD27, CD134 (OX40), CD137 (4-1BB), and CD30 have been shown to play a 
direct role in T cell responses following initial T cell activation (Aizawa et al., 
1997; Arch et al., 1998; Kawamata et al., 1998; Yamamoto et al., 1998). 4-
1BB and OX-40 have been demonstrated to be able to up-regulate the anti-
apoptotic members of Bcl-2 family (Croft, 2009) as well as to play an 
important role in T cell proliferation and sustaining its survival (Shuford et al., 
1997). Furthermore, the interaction of CD27 on T cells with its ligand, CD70, 
on antigen presenting cells (APCs) or B cells was shown to promote T cells 
proliferation and sustain the survival of effector and memory T cells (Denoeud 
and Moser, 2011). In this study, the binding of CD70 and OX-40L to their 
cognate receptors on T cells has also been shown to be essential for the 
optimal FIP-fve-induced T cell proliferation, as the blocking of these ligands 
during FIP-fve stimulation resulted in significant reduction of T cells 
proliferation (Fig.3.9 and appendix 2). Besides promoting T cells proliferation 
and sustaining their survival, the role of CD27, OX-40, and 4-1BB has also 
been shown to be important for the enhancement of secondary expansion as 
well as generation of memory CD8
+
 T cells during Influenza virus infection 
(Hendriks et al., 2005). Moreover, Croft et al. reported that a vaccination 
strategy using a strongly replicating vaccinia virus involved the engagement of 
 106 
 
OX-40 and CD27 which would in turn enhance the generation of memory 
CD8
+
 T cells and confer a protective immunity against the lethal virus 
challenge in the absence of CD4
+
 T cells help (Salek-Ardakani et al., 2011). 
Taken together, it is possible that FIP-fve may drive the expansion and sustain 
the survival of CD8
+
T cells, partly via the engagement of CD27 signaling 
pathway.  
Despite the up-regulation of surface expression on FIP-fve-stimulated T cells 
did not require the helper role from accessory cells; results suggested that the 
cellular proliferation of T cells induced by FIP-fve was significantly dependent 
on the interaction between T cells and BM-DCs. Although FIP-fve could still 
significantly stimulate the proliferation of purified total T cells, CD4
+
 T, and 
CD8
+
 T cells, the cellular proliferation was robustly increased when the BM-
DCs were present in the co-culture system during FIP-fve stimulation, 
particularly for CD8
+
 T cells where it could proliferate to a stimulation index 
of 21.5 as compared to only 6.4 in CD4
+
 T cells. Similarly, multiplex assay 
results also suggested that FIP-fve could increase the secretion of IFN-γ, IP-
10, and MIG on T cells by six to ten folds in the presence of BM-DCs. Hence, 
this data indicate that the biological function of FIP-fve is partly dependent on 
the interaction between T cells and accessory cells (i.e. BM-DCs or non-T 
cells). To date, the tumor necrosis factor (TNF) superfamily is composed of 29 
receptors and 19 ligands which play different roles in the body. The members 
of TNF receptor superfamily are composed of one to six cysteine-rich repeats 
in their extracellular domain; each of which contains three cysteine bridges 
(Naismith and Sprang, 1998). All members of TNF superfamily display pro-
inflammatory activities, partly via activation of the transcription factor NF-κB. 
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While other members of the superfamily show proliferative activity on 
hematopoietic cells, partly via the activation of various mitogen-activated 
kinases. The cellular signaling exerted by most cytokines and growth factors is 
usually mediated via the binding of a soluble ligand and a transmembrane 
receptor. However, several ligands of the TNF receptor superfamily, such as 
FasL, CD70, CD30L, CD40L, OX40L, and 4-1BBL are primarily expressed 
as transmembrane proteins on the cell surface, which resulted in more 
restricted cell signaling effects (Aggarwal, 2011). Since several members of 
this family were found to be up-regulated on T cells upon FIP-fve stimulation, 
the interaction between these molecules and their respective ligands could be 
important for FIP-fve-induced-cellular proliferation and -cytokine/chemokine 
secretion. In general, results demonstrated that the blocking of both CD70 and 
OX-40L at a dose of 1 µg/ml of each antibody resulted in significant reduction 
of FIP-fve-induced -T cell proliferation as well as -cytokine/chemokine 
secretion by CD8
+
 T cells (Fig. 3.9, 3.10C, appendix 2). The TNF receptor 
family members, such as CD70 and OX-40L have a distinct signaling 
mechanism as compared to that of T cell receptor (TCR) or CD28. The 
binding of TNF receptor and its ligand leads to recruitment of TNF receptor 
associated factor (TRAF) family adaptors, namely TRAF2 and TRAF5, to the 
cytoplasmic tail of transmembrane receptor and subsequently results in 
activation of NF-κB and c-Jun kinase signaling pathways (Akiba et al., 1998; 
Gravestein et al., 1995). Further analysis into the proximal signaling events 
initiated by CD27 demonstrated that the NF-κB -inducing kinase and the IKK 
signalosome are recruited to the receptor, which then leads to activation of the 
canonical and alternative NF-κB pathway (Ramakrishnan et al., 2004). The 
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NF-κB pathway has been shown to play some important roles in the control of 
cellular proliferation and apoptosis by regulating the expression of multiple 
genes involved in pro-inflammatory response, including cytokines, 
chemokines, and adhesion molecules (Yamamoto and Gaynor, 2001). Taken 
together, again, it appears that the biological effects of FIP-fve on T cells is 
dependent on the interaction with accessory cells, and partly mediated through 
the binding of CD70 as well as OX-40L with their cognate receptors on T 
cells, which subsequently lead to activation of NF-κB or c-Jun kinase 
signaling pathways and downstream expression of various pro-inflammatory 
cytokines/chemokines. 
A number of studies have demonstrated that one of the mechanisms by which 
adjuvants exert their function is via the enhancement of cytokine/chemokine 
secretion (Lavelle et al., 2003; Mosca et al., 2008; Yan et al., 2007). Some of 
the widely used and approved adjuvants for human vaccines, such as 
aluminum hydroxide and MF59, have been shown to significantly induce the 
secretion of a range of chemoattractants including CCL2 (MCP-1), CCL3 
(MIP-1α), CCL4 (MIP-1β), and CXCL8 (IL-8) by the human immune cells 
(Seubert et al., 2008). These chemokines were all involved in the recruitment 
of cells from the blood into the peripheral tissues. Here, results showed that 
FIP-fve stimulation on the T cells could significantly enhance the secretion of 
IFN-γ, IP-10, MIG, MIP-1α, and MIP-1β. Gamma interferon-inducible protein 
10 (IP-10) and monokine induced by IFN-γ (MIG) are structurally-related 
CXC chemokines which bind to the common CXCR3 receptor on the 
activated T cells and NK cells (Loetscher et al., 1996). The role of IP-10 and 
MIG was shown in several animal models of infection as well as in mice 
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bearing the murine renal adenocarcinoma where the study suggested that the 
intermediate expression of IP-10 and MIG was required to recruit anti-tumor 
effector T cells to the tumor site (Amichay et al., 1996; Tannenbaum et al., 
1998). Furthermore, MIP-1α and MIP-1β were also shown to be important for 
the generation of tumoricidal monocytes from the peripheral blood monocytes 
of healthy women and patients with carcinoma of breast by differentially 
regulating the release of inflammatory cytokines (Nath et al., 2006). Hence, it 
is possible that the underlying mechanisms by which FIP-fve exerts its anti-
tumor effect, as demonstrated in previous in vivo studies (Chang et al., 2010; 
Ding et al., 2009), is via the modulation of cytokine/chemokine secretion 
which may subsequently result in the activation of adaptive immune 
responses. 
Next, to further explore the molecular mechanisms or signaling pathways 
involved in the activation of CD4
+
 T cells and CD8
+
 T cells upon FIP-fve 
stimulation, a gene array study was performed to gain insight into gene 
expression profile of the stimulated cells. Based on current data analysis, some 
of the significant differentially expressed genes, including IFN- γ, CCL3 
(MIP-1α), CCL4 (MIP-1β), CXCL-10 (IP-10), and TNFRSF-9 (CD137 or 4-
1BB) have already been shown to be up-regulated at protein level; thus, 
further assuring the consistency of the results. Moreover, based on the data 
analysis which was presented in Venn diagram, the number of significant 
differentially expressed genes in CD8
+
 T cells was found to be more than that 
of CD4
+
 T cells, particularly at 8 hours upon FIP-fve stimulation. Thus, it 
appears that this phenomenon may be correlated with the higher magnitude of 





 T cells as observed previously. Furthermore, to make 
use of the information regarding the significantly affected pathways on CD8
+
 
T cells during FIP-fve stimulation, I analyzed the signature genes involved in 
the affected pathway. Serine hydroxymethyltransferase -1 and -2 (Shmt1 and 
Shmt2) were shown to be significantly up-regulated at 8 hours upon FIP-fve 
stimulation on CD8
+
 T cells; these genes were known to be involved in folate 
metabolism pathway by providing the largest part of one-carbon units to the 
cells (Stover and Schirch, 1990). Thus, the role of folate metabolism in FIP-
fve-induced T cell proliferation may deserve a further study in future. 
Besides an extensive investigation on the mitogenic effect of FIP-fve on BM-
DCs and lymphocytes, an attempt was also made to investigate the adjuvant 
effect of FIP-fve on antigen-specific T cells, in particular CD8
+
 T cells in 
vitro. Results from this study demonstrated that FIP-fve could significantly 
enhance the priming of antigen-specific CD8
+
 T cells in vitro, particularly at 
early time point. The enhanced priming effects were demonstrated by a 
significant increase in cellular proliferation of pre-stimulated CD8
+
 T cells, 
their IFN-γ secretion as well as killing activity of the pre-stimulated OVA-
specific CD8
+
 T cells towards OVA-pulsed EL4 cells, particularly at a low 
effector to target cells ratio. Hence, it is probable that FIP-fve may potentially 
function as a vaccine adjuvant by accelerating and enhancing the magnitude of 
antigen-specific CD8
+
 T cell responses as well as their cytotoxic function. 
To summarize, FIP-fve can only drive the maturation of BM-DCs indirectly, 
via the receptors and ligands binding between FIP-fve-stimulated T cells and 
BM-DCs respectively as well as the soluble mediators secreted by FIP-fve-
activated T cells. In contrast, FIP-fve is able to directly target and activate T 
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cells, as shown by the up-regulation of their surface markers, increased 
secretion of cytokine/chemokine (by CD8
+
 T cells in particular) as well as 
enhancement of their cellular proliferation. Nonetheless, an optimal biological 
effect of FIP-fve on T cells is still dependent on the presence of accessory cells 
in which the binding of CD70 and OX-40L to their cognate receptors on T 
cells is essential for FIP-fve-induced -cellular proliferation and -
cytokine/chemokine secretion. More importantly, upon FIP-fve stimulation, 
the secretion of various chemokines, such as MIG, IP-10, MIP-1α, and MIP-
1β can attract other immune cell types which may subsequently result in 
activation of adaptive immune responses; this phenomenon may also serve as 
one of the possible mechanisms which underlie the adjuvant properties of FIP-
fve. Furthermore, as demonstrated in this study, pre-stimulation of OT-I CD8
+ 
T cells with FIP-fve may lead to enhanced priming of antigen-specific CD8
+
 T 




Immunomodulatory and adjuvant effects of FIP-fve in vivo 
 
4.1 Introduction 
Having performed extensive investigations on the mitogenic or 
immunomodulatory function of FIP-fve in vitro, I then attempted to examine 
whether the phenomenon that I observed in my in vitro studies could occur in 
the in vivo setting as well. As in vitro study tend to show a simplified version 
of normal physiological environment, it is crucial to choose an appropriate in 
vivo model to validate the in vitro results such that the conclusion from the 
study can be translated into higher organisms or clinical settings. On the other 
hand, in vivo studies are known to pose greater challenges due to the complex 
environment and dynamic interplay among different cell types and their 
subsets as well as various soluble mediators, including growth factors, 
cytokines or chemokines secreted by different cell types at different locations 
in response to various stimuli in the body.  
Nonetheless, to date, the in vitro studies on FIP-fve have been correlated well 
with the in vivo observations from the proof-of-concept studies. The in vitro 
Th1-skewing effect of FIP-fve which showed an increased expression of IFN-γ 
and low level of IL-4 expression on stimulated mouse splenocytes or human 
peripheral blood mononuclear cells (PBMCs) was consistent with subsequent 
in vivo studies which demonstrated that oral feeding of FIP-fve into the mouse 
asthma model resulted in suppressed airway hyperresponsiveness, significant 
 113 
 
lower number of infiltrating inflammatory cells, and decreased Th2 cytokines 
in bronchoalveolar lavage fluid (BALF) and serum (Ko et al., 1995a; Lee et 
al., 2013). Moreover, oral administration of FIP-fve could also inhibit the 
development food-allergic reaction in mice, as demonstrated by reduced level 
of OVA-specific IgE and IL-5 as well as increased level of OVA-specific 
IgG2a and IFN-γ in the serum of the FIP-fve-treated mice (Hsieh et al., 2003) 
In this chapter, I attempted to investigate the mitogenic and adjuvant effects of 
FIP-fve in vivo. I first examined the local immune responses in the draining 
lymph nodes upon footpad injection with FIP-fve. During the activation of 
local immune responses, the cell types which were activated, proliferating or 
infiltrating into the draining lymph nodes in response to FIP-fve stimulation 
were further identified. Subsequently, I also utilized the OVA peptide-
immunized mouse model to investigate whether FIP-fve could exert its 
adjuvant effect by enhancing the priming of antigen-specific CD8
+
 T cells. 
Furthermore, the possibility of the primed antigen-specific CD8
+
 T cells to 
progress to the memory phase was also examined.   
 
 






4.2.1 FIP-fve stimulation activated local immune responses in the 
draining lymph nodes 
In previous chapter, I have shown that FIP-fve stimulated and activated T cells 
in vitro. To investigate whether FIP-fve stimulation could also activate 
immune cells (particularly T cells) in vivo, C57BL/6J mice were given 10 µg 
of FIP-fve on each footpad, popliteal lymph nodes (PLNs) were collected daily 
from day 1 to 5 post injection and the total cell numbers were counted. It was 
noted that the PLNs of FIP-fve-injected mice were bigger in size (Appendix 4) 
and had significantly higher total cell number than that of PBS control group. 
In the FIP-fve-injected mice, the total cell number in the PLNs started to 
increase from day 1 post-injection (2.2 × 10
6
 ± 0.26 × 10
6
 (FIP-fve) vs 0.44 × 
10
6
 ± 0.1 × 10
6 
(PBS), P = 0.003), reached its peak at day 3 post-injection 
(10.9 × 10
6
 ± 1.1 × 10
6
 vs 0.6 × 10
6
 ± 0.4 × 10
6
, P = 0.001), and subsequently 
started to decrease after day 4 post-injection (4.5 × 10
6
 ± 0.25 × 10
6
 vs 0.44 × 
10
6
 ± 0.03 × 10
6
, P = 0.001) ( Fig. 4.1A). The composition of T cells from 
PLNs collected on day 3 post-injection were analyzed by flow cytometry. As 
compared to PBS-injected mice, there was an increase in the percentage of 
CD8
+




 ratio was significantly higher in the 
PLN of FIP-fve-injected mice (0.85 ± 0.06 vs 0.66 ± 0.01, P = 0.03) (Fig. 
4.1B). Though the percentage of CD4
+
 T cellls decreased as compared to the 




 T subsets 
significantly increased in the PLNs of FIP-fve-injected mice. There were about 




 T cells respectively 
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(Fig. 4.1C). Furthermore, immunostaining results revealed that CD28 
expression was up-regulated on both CD4
+
 T (1.2 fold higher, P = 0.002) and 
CD8
+
 T cells (1.9 fold higher, P = 0.003) in the PLN of FIP-fve-injected mice; 
while, CD27 expression was up-regulated mainly on CD8
+
 T cells (2.5 fold 
higher, P = 0.02) (Fig. 4.1D, E). There was no significant change in the 





























































































































































































Figure 4.1 FIP-fve significantly increased T cell number in the draining 
lymph nodes as well as up-regulated the expression of CD27 and CD28 on 
CD8
+
 T cells in vivo. C57BL6/J mice were injected with either PBS (n = 4, 
empty-bar) or 10 μg of FIP-fve (n = 4, filled-bar) on the footpad. At the 
indicated day post-injection, the popliteal lymph nodes (PLNs) were harvested 
and the total cell number was counted (A). At day 3 post-injection, the 
percentages of CD4
+
 T cells, CD8
+
 T cells and the ratio of CD8
+





 cells (B) as well as the numbers of CD4
+
 T cells and CD8
+
 
T cells in the PLNs (C) were determined. Besides, the expressions of CD27, 
CD28, OX40 (CD134), and 4-1BB (CD137) on both CD4
+
 T and CD8
+
 T cells 
at day 3 post-injection were shown in the histograms (D). The solid line and 
dotted line represent the T cell subsets from FIP-fve-injected and PBS-injected 
mice respectively. The grey-filled histogram represents the isotype control. 
Mean fluorescence intensity (MFI) values of the surface expressions were 
shown in bar charts (E). Data were shown as mean ± SD and statistical 
differences were calculated by Mann-Whitney U-test. *, P<0.05; **, P<0.01; 

































































4.2.2  FIP-fve stimulation altered the composition of innate immune cells 
in the draining lymph node  
During the analysis of T cell composition in PLNs, results showed that the 
increased T cell number contributed to less than 50% of total increased cell 
number in the FIP-fve-injected mice. Thus, I then examined the percentage 
and number of different cell types that were present in the draining lymph 
nodes of mice given FIP-fve injection. I found that the percentage of T cells 
(48 ± 2.2 % (FIP-fve) vs 91.5 ± 1.2 % (PBS), P = 8.9 × 10
-7
) was significantly 
decreased, whereas the percentage of B cells (49 ± 3.1 % vs 7 ± 1.3 %, P = 1.1 
× 10
-5










(Macrophages) (1.6 ± 0.2 % vs 0.4 ± 0.3 %, P = 0.006) were significantly 
increased in the popliteal lymph nodes (PLNs) of FIP-fve-injected mice 
compared to that in PBS-injected mice (Fig. 4.2A). The cell number of various 
cell types in the PLNs, including T cells (3.6 × 10
6
 ± 1.1 × 10
6
 (FIP-fve) vs 0.9 
× 10
5
 ± 0.5 × 10
5 
(PBS), P = 0.005), B cells (3.8 × 10
6
 ± 1.2 × 10
6
 vs 0.8 × 10
4
 
± 0.5 × 10
4
, P = 0.006), NK cells (8.9 × 10
4
 ± 2.1 × 10
4
 vs 6.3 × 10
2
 ± 2.8 × 
10
2
, P = 0.03), NK T cells (2.6 × 10
5
 ± 1 × 10
5
 vs 3.3 × 10
3
 ± 1.7 × 10
3





) (2 × 10
5
 ± 0.7 × 10
5
 vs 6.5 × 10
2
 ± 1.7 × 10
2
, P = 




) (1.2 × 10
5
 ± 0.4 × 10
5





, P = 0.04) were all significantly increased in the FIP-fve-injected 


































































Figure 4.2 FIP-fve stimulation modified the composition of immune cells 
in the local lymphoid organ in vivo. C57BL/6J mice were injected with 
either PBS (n = 3) or 10 µg of FIP-fve (n = 3) on their footpads. Three days 
post-injection, the popliteal lymph nodes were harvested and stained. The 
percentages (A) and absolute cell numbers (B) of T-, B-, NK-, NK T- cells, 
dendritic cells (DC) and macrophage were determined. Filled bar represents 
FIP-fve-injected group, empty bar represents PBS control group. Data were 
shown as mean ± SD and Mann-Whitney U-test was used to calculate the 
statistical significance. *, P<0.05; **, P<0.01; ***, P<0.001. Representative 
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4.2.3  FIP-fve significantly enhanced the proliferation of CD4
+
 T and 
CD8
+
 T cells in vivo but not B cells or NK cells 
Having demonstrated that FIP-fve stimulation led to significant increase in the 
number of different cell types, I investigated whether this phenomenon was 
due to increase in proliferation or recruitment of cells into the draining lymph 
nodes. Thus, to identify the proliferating cell types upon FIP-fve stimulation, 
mice were injected with either FIP-fve or PBS on their footpad, followed by 
intraperitoneal injection with BrdU at day 2 post-injection. The PLNs were 









 T cells increased by 3.8- 
fold and 10.9- fold respectively, in the FIP-fve injected mice compared to the 
PBS control group (CD4
+
, 3.35 ± 0.4 % vs 0.89 ± 0.3 %, P = 0.0009; CD8
+
, 
9.37 ± 2 % vs 0.86 ± 0.2 %, P = 0.02) (Fig. 4.3A). While, there was no 
increase in the percentage of BrdU
+ 
B cells (0.67 ± 0.1 % vs 0.25 ± 0.1 %;) or 
BrdU
+ 
NK cells (1.02 ± 0.5 % vs 0.35 ± 0.1 %) in mice injected with FIP-fve 
























Figure 4.3 FIP-fve significantly enhanced the percentage of proliferating 
CD4
+
 T and CD8
+
 T cells but not of NK cells or B cells. C57BL6/J mice 
were injected with either PBS (n = 3) or 10 μg of FIP-fve (n = 3) on the 
footpad. Subsequently, the mice were intraperitoneally (i.p.) injected with 1 
mg of BrdU per mouse for three times at 4 hours at day 2. The popliteal lymph 









 T cells among CD3
+
 T cells (A) and   
BrdU
+
 B cells (B) as well as BrdU
+
 NK cells (C) among gated lymphocyte 
region were then determined. Representative data from two independent 
experiments were shown. Data were shown as mean ± SD and significant 
differences between the FIP-fve-injected (filled bar) and PBS control (empty 





























4.2.4  FIP-fve, as an adjuvant, significantly enhanced antigen-specific 
CD8
+
 T cell responses on day 3 post-immunization in OVA mouse 
model 
I have demonstrated that FIP-fve significantly enhanced the speed, magnitude, 
and function of antigen-specific CD8
+
 T cell responses in vitro in the Chapter 
3. Here, I further investigated whether FIP-fve could potentially be used as an 
adjuvant to boost the responses of antigen-specific CD8
+
 T cells in vivo. To 
address this possibility, 2x10
6
 of purified CD8
+
 T cells from OT-I mice were 
adoptively transferred into C57BL/6J mice. Next day,mice were 
subcutaneously injected with PBS, FIP-fve, OVA peptide (OVAp), FIP-fve + 
OVAp, OVAp in IFA or FIP-fve + OVAp in IFA on the back. Finally, the 
draining lymph nodes were harvested at day 3 post-injection and the 
percentage as well as number of OVA-specific CD8
+
 T cell were determined 
(Fig. 4.4A). 
FIP-fve significantly increased the cell number in the draining lymph nodes 
only when the OVAp was not administered in conjunction with IFA. FIP-fve 
significantly enhanced the total cell number to 27.6 × 10
6
 ± 10.6 × 10
6
 as 
compared to only 8.7 × 10
6
 ± 0.9 × 10
6
 in the OVAp group (Fig. 4.4B). The 
percentage of OVA specific CD8
+
 T cell was then analyzed by flow cytometry 
(Fig 4.4C). Regardless of whether the OVAp was mixed with IFA or not, FIP-
fve significantly increased the percentage and number of OVA-specific CD8
+
 
T cells in the draining lymph nodes. In the absence of IFA, FIP-fve 
significantly increased the percentage and number of OVA-specific CD8
+
 T 
cells to 10.78 ± 2.9 % (among T cells), 18.02 ± 6.3 % (among CD8
+
 T cells), 
and 1.3 × 10
6
 ± 0.7 × 10
6
 cells respectively as compared to 6.04 ± 1.35 % 
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(among T cells), 9.78 ± 2.2 % (among CD8
+
 T cells), and 2.6 × 10
5
 ± 0.5 × 10
5
 
cells respectively in the OVAp control group. While, in the presence of IFA, 
FIP-fve could also increase the percentage and number of OVA-specific CD8
+
 
T cells to 1.6 ± 0.45 % (among T cells), 3.21 ± 1.0 % (among CD8
+
 T cells), 
and 7.5 × 10
4
 ± 1.8 × 10
4
 cells respectively as compared to 0.76 ± 0.15 % 
(among T cells), 1.44 ± 0.3 % (among CD8
+
 T cells) and 2.7 × 10
4
 ± 0.8 × 10
4
 
cells respectively in the OVAp/IFA group (Fig. 4.4C, D). Moreover, results 
also indicated that immunization with FIP-fve alone did not increase the total 
cell number (8.8 × 10
6
 ± 1.9 × 10
6
 (FIP-fve) vs 6.8 × 10
6
 ± 1.8 × 10
6 
(PBS)) 
nor the percentage (0.8 ± 0.05 %  vs 0.73 ± 0.04 %  (among T cells); (1.46 ± 
0.2 %  vs 1.42 ± 0.1 %  (among CD8
+





  vs 3.2 × 10
4
 ± 0.7 × 10
4 
) of antigen-specific CD8
+
 T as compared to 
the PBS group (Fig. 4.4B, C, D, E). 
Next, the T cell activation markers were examined on the OVA-specific CD8
+
 
T cells (Fig. 4.5A). As compared to the PBS group, up-regulation of CD27 
CD28 and CD44 was observed in mice receiving immunization by OVAp 
alone or in combination with either IFA or FIP-fve. Up-regulation of CD69 
was observed in mice receiving OVAp immunization mixed with IFA. There 
was no change in the expression of OX40. Comparing surface expression of T 
cell markers between FIP-fve + OVAp/IFA and OVAp/IFA groups, there were 
no significant difference in the expressions of CD27, CD28, -OX40, and 
CD44; nonetheless, the expression of CD69 was up-regulated (1.8 fold higher, 
P = 0.008) and the expression of CD62L was down-regulated (0.8 fold lower, 
P = 0.03) in FIP-fve + OVAp/IFA group. Comparing FIP-fve + OVAp and 
OVAp groups, there was no significant change in the expressions of CD27, 
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CD28, OX40, CD44, and CD69, except the expression of CD62L was down-
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Figure 4.4 FIP-fve, as an adjuvant, significantly increased the percentage 
and number of antigen-specific CD8
+ 
T cells in vivo. A. C57BL/6J mice 
were first adoptively transferred with 2 × 10
6
 of OT-I CD8
+
 T cells; the next 
day, the mice (n = 5 per group) were subcutaneously injected with PBS, FIP-
fve, OVAp in IFA, FIP-fve + OVAp in IFA, OVAp or FIP-fve + OVAp. The 
draining lymph nodes were then harvested at day 3 post-injection. B.Total cell 
number in the draining lymph nodes from each group was determined. C. Dot 
plots showed the gating and percentage of OVA-specific CD8
+
 T cells among 
the CD3
+
 population for each group. D. The percentages of OVA-specific 
CD8
+
 T cells among the gated CD8
+
 T cells population are shown in a bar 
chart. Number of OVA-specific CD8
+
 T cells (E) were also determined. Data 
were shown as mean ± SD and Mann-Whitney U-test was used to calculate the 
significant differences. *, P<0.05; **, P<0.01. For the multiple comparisons, 




































Figure 4.5 Phenotypes of OVA-specific CD8
+
 T cells at day 3 post-
immunization. A. Mice were immunized as described in Fig 4.4. The 
histograms showed the expressions of CD27, CD28, CD134 (OX-40), CD69, 
CD44, and CD62L on OVA-specific CD8
+
 T cells in the different groups as 
indicated by the corresponding colors. B. MFI values of the surface 
expressions were shown in the bar charts. Data were shown as mean ± SD and 
Mann-Whitney U-test was used to calculate the significant differences. *, 
P<0.05; **, P<0.01. For the multiple comparisons, P was corrected by 




















































































































































































4.2.5  FIP-fve did not further enhance the antigen-specific CD8
+
 T cell 
responses at day 20 post-immunization in the OT-I CD8
+
 T cells 
transfer model 
Short-term immunization study demonstrated FIP-fve could potentially be 
used as an adjuvant to enhance both the percentage and number of antigen-
specific CD8
+
 T cells in the draining lymph nodes at day 3 post-injection. I 
further examined whether the adjuvant effect of FIP-fve could be maintained. 
The spleen and draining lymph nodes were harvested on day 20 post-
immunization. In this long-term experiment, OT-I CD8
+
 T cells recipent mice 
were subcutaneously injected with PBS, OVAp, FIP-fve + OVAp or Poly I:C 
+ OVAp. A diagram of the experimental protocol is shown in Fig. 4.6A. 
Results comparing FIP-fve + OVAp and OVAp groups showed that there was 
no significant enhancement in the percentage (1.68 ± 0.7 % vs 1.47 ± 0.8 %) 
and number (4.6 × 10
4
 ± 2.6 × 10
4
 vs 4.8 × 10
4
 ± 2.8 × 10
4
) of OVA-specific 
CD8
+
 T cells in the spleen of FIP-fve + OVAp group at day 20 post-
immunization (Fig. 4.6B). Similarly, in the draining lymph nodes, there was 
also no significant increase in both percentage (0.39 ± 0.1 % vs 0.48 ± 0.2 %) 
and number (1.2 × 10
4
 ± 0.7 × 10
4
 vs 7.3 × 10
3
 ± 4.1 × 10
3
) of OVA-specific 
CD8
+
 T cells in FIP-fve + OVAp group (Fig. 4.6C). 
Furthermore, the phenotype of OVA-specific CD8
+
 T cells was characterized 
by examining the expression of CD44 and CD62L (Fig 4.7A, B). In the 







 T cells were significantly reduced in three OVAp-injected groups 
compared to the PBS control group (percentage: 6.3 ± 2.6 %, 9.2 ± 6.3 %, 10.6 
± 3.1 %, and 14.9 ± 2.7 % for OVAp, FIP-fve + OVAp, Poly I:C + OVAp, and 
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PBS groups respectively; number: 2.9 × 10
3
 ± 2.1 × 10
3
, 2.9 × 10
3





 ± 1.2 × 10
3
, and 8.1 × 10
3
 ± 2.1 × 10
3







 T cells was increased in the 
OVAp-injected groups, with the highest percentage found in the FIP-
fve+OVAp injected group (13.1 ± 4.9 %, 19.5 ± 4.5 %, 13.3 ± 2.7 %, and 6.8 
± 0.9 % for OVAp, FIP-fve + OVAp, Poly I:C + OVAp, and PBS groups 







cells significantly increased in OVAp-immunized groups compared to that of 
PBS control group (48.7 ± 9.2 %, 46.9 ± 13.2 %, 40.4 ± 8.4 %, and 15.9 ± 1.7 
% for OVAp, FIP-fve + OVAp, Poly I:C + OVAp, and PBS groups 







 T cells were significantly reduced in the OVAp-
immunized groups compared to the PBS control group. (percentage: 31.9 ± 
11.9 %, 24.3 ± 7.4 %, 35.6 ± 3.7 %, and 62.4 ± 2.9 % for OVAp, FIP-fve + 





, 1.1 × 10
4
 ± 0.5 × 10
4
, 1.1 × 10
4
 ± 0.5 × 10
4
, and 3.4 × 10
4
 ± 0.6 × 
10
4
) (Fig. 4.8). An almost similar observation was also found in the draining 







 T cells were significantly reduced in the OVAp-immunized 
groups (percentage: 4.1 ± 2.2 %, 6.3 ± 1.0 %, 3.3 ± 1.1 %, and 14.1 ± 1.2 % 
for OVAp, FIP-fve + OVAp, Poly I:C + OVAp, and PBS groups respectively; 
number: 0.3 × 10
3
 ± 0.2 × 10
3
, 0.7 × 10
3
 ± 0.3 × 10
3
, 0.5 × 10
3





 ± 1.9 × 10
3







 T cells was significantly increased in the OVAp-injected 
groups (44.8 ± 5.1 %, 36.8 ± 5.3 %, 42.1 ± 4.6 %, and 26.9 ± 4.4 % for PBS + 
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OVAp, FIP-fve + OVAp, Poly I:C + OVAp, and PBS groups respectively) 
























Figure 4.6 FIP-fve did not further enhance the percentage and cell 
number of antigen-specific CD8
+
 T cells at day 20 post-immunization. 
C57BL/6J mice were adoptively transferred with 2 × 10
6
 of purified OT-I 
CD8
+
 T cells at one day before immunization. Mice (n = 5 per group) was then 
subcutaneously injected with PBS, OVAp, FIP-fve + OVAp or Poly I:C + 
OVAp. At day 20 post-injection, spleens and draining lymph nodes were 
harvested, stained and analyzed by flow cytometry (A). The percentage and 
cell number of OVA-specific CD8
+
 T cells in the spleen (B) and draining 
lymph nodes (C) were then determined. Data were shown as mean ± SD and 
Mann-Whitney U-test was used to calculate the statistical significance. *, 
























































































































































Day 20  
Harvest spleen and 































Figure 4.7 CD44 and CD62L expressions on OVA-specific CD8
+
 T cells in 
spleen and draining lymph nodes at day 20 post-immunization. Mice were 
immunized as described in Figure 4.6. The expression of CD44 and CD62L on 
the OVA-specific CD8
+
 T cells in the spleen (A) and draining lymph nodes 
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Figure 4.8 Percentages and cell number of naïve, effector, effector 
memory, and central memory OVA-specific CD8
+
 T cells in spleen at day 
20 post-immunization. Mice were immunized as described in Figure 4.6. 
Based on the expression of CD44 and CD62L on OVA-specific CD8
+
 T cells, 
percentage (the left panel) and cell number (the right panel) of effector 
memory, central memory, naïve, and effector OVA-specific CD8
+
 T cells in 
the spleen were subsequently determined. Data were shown as mean ± SD and 
Mann-Whitney U-test was used to calculate the statistical significance. *, 




















































































































































































































































Figure 4.9 Percentages and cell number of naïve, effector, effector 
memory and central memory OVA-specific CD8
+
T cells in draining 
lymph nodes at day 20 post-immunization. Mice were immunized as 
described in Figure 4.6. Based on the expression of CD44 and CD62L on 
OVA-specific CD8
+
 T cells, percentage (the left panel) and cell number (the 
right panel) of effector memory, central memory, naïve and effector OVA-
specific CD8
+
 T cells in the draining lymph nodes were subsequently 
determined. Data were shown as mean ± SD and Mann-Whitney U-test was 
used to calculate the statistical significance. *, P<0.05. Similar data were 

















































































































































































































In this chapter, the responses of immune cells to FIP-fve in vivo were 
examined in the lymph nodes and spleen. Results showed that as similar to the 
findings observed in the previous chapter; the mitogenic activity as well as the 
adjuvant effect of FIP-fve can also be observed in vivo. FIP-fve strongly 
activated T cells as indicated by enhancement of T cell proliferation and up-
regulation of CD27 and CD28 expressions on T cells when FIP-fve was 
administered through footpad injection. Besides, FIP-fve dramatically 
recruited immune cells into the draining lymph nodes. Recently, the Adjuvant 
System AS01, a lipoposome-based adjuvant containing MPL (TLR4 agonist) 
and QS-21, has also been shown to promote the transient recruitment of innate 
cells into the muscle and draining lymph nodes upon intramuscular injection 
of this adjuvant (Didierlaurent et al., 2014). One of the innate immune 
parameters which may explain the ability of AS01 to promote adaptive 
immune responses is the rapid recruitment of naïve T cells into the draining 
lymph nodes; thus, resulting in higher frequency of T and APC interactions 
(Soderberg et al., 2005). Besides, the CXCR3 ligands CXCL9 (MIG) and 
CXCL10 (IP-10), which were associated with Th1 responses (Park et al., 
2002), were also prominently detected in the draining lymph nodes. As shown 
in my previous chapter, the secretion of these two chemokines was also 
significantly elevated upon in vitro stimulation of T cells and BM-DCs co-
culture with FIP-fve. Hence, I speculate that FIP-fve may significantly increase 
the cell number in the draining lymph nodes by inducing the production or 
secretion of different chemokines, such as MIG, IP-10, MIP-1α, and MIP-1β. 
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The elevation in these cell number may subsequently enhance the frequency of 
T and APC interactions; thereby, enhancing the adaptive immune responses. 
My previous in vitro results suggested that FIP-fve stimulation could activate 
the BM-DCs in the presence of T cells, as shown by the up-regulation of 
CD40, I-A
b
, CD80, and CD86. Consistently, several in vivo studies also 
demonstrated that FIP-fve was capable of inducing phenotypic maturation on 
splenic DCs, as indicated by their increased expression of I-A
b
 and CD86 
(Chang et al., 2010; Ding et al., 2009). Activation of innate immunity has 
been associated with a rapid burst of inflammatory cytokines as well as the 
activation of nonclonal responses from APCs, which subsequently leads to 
conditioning of immune system for development of specific adaptive immune 
responses (Pashine et al., 2005). The innate immunity employs various 
invariable receptors to detect the evolutionarily conserved signatures from 
pathogens, known as pathogen-associated molecular patterns (PAMPs) 
(Uematsu and Akira, 2008). The incorporation of these molecular signatures 
into experimental vaccines has resulted in robust and durable adaptive immune 
responses. However, the mechanism underlying the potentiation of these 
immune responses was still not clear until the discovery of pattern-recognition 
receptors (PRRs). The engagement of PRRs on a variety of immune cells, 
including neutrophils, macrophages, dendritic cells, NK cells, B cells, and 
other non-immune cells, such as epithelial and endothelial cells leads to the 
cellular activation and secretion of cytokines/chemokines from these cells as 
well as the maturation and recruitment of other cells. This resulting 
inflammatory environment may subsequently lead to establishment of adaptive 
immune responses (Iwasaki and Medzhitov, 2004). We speculate that FIP-fve 
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exerts its biological function by activating the innate immunity and creating an 
inflammatory environment which is essential for establishment of adaptive 
immune responses. 
Upon footpad injection with FIP-fve, my results showed that the percentage of 
T cells in the draining lymph nodes was significantly reduced; however, in 
term of cell number, they were still significantly higher than that of PBS 
control group. Moreover, I found that the decrease in the percentage of T cells 
was mainly due to the tremendous increase in the percentage and number of B 
cells in the draining lymph nodes upon FIP-fve stimulation. This interesting 
phenomenon suggested that B cells could either proliferate or be recruited into 
the draining lymph nodes after FIP-fve stimulation. Further investigation using 
the in vivo BrdU incorporation assay showed that footpad injection with FIP-
fve significantly increased the the percentage and number of proliferating 
CD4
+
 T and CD8
+
 T cells but not B cells in the popliteal lymph nodes; thus, 
this result indicated that the significant increase in the percentage and number 
of B cells in the draining lymph nodes could be due to the recruitment of B 
cells from the peripheral blood or other lymphoid organs. Nonetheless, the 
role of B cells in response to FIP-fve stimulation in vivo is still not understood. 
In my present study, I did not further address the role and function of B cells 
in mediating the biological effect of FIP-fve due to the time constraint and 
scope limitation of this project. However, this exciting finding may open a 
new avenue for the future direction on the study of FIP-fve. Jiang et al. 
proposed that the activation and expansion of naïve B cells following TLR9 
agonists induction could potentially enhance the interaction of these cells with 
cognate antigens as well as facilitate the cell-mediated immune responses 
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(Jiang et al., 2007). Furthermore, since a number of in vivo studies have 
demonstrated that co-administration of FIP-fve with various antigens 
significantly increased the titer of HPV-16 E7-specific IgG2a antibodies (Ding 
et al., 2009), OVA-specific IgG2a antibodies (Hsieh et al., 2003; Lee et al., 
2013) as well as Der p 2-specific IgG antibodies (Su et al., 2012a), I speculate 
that the increase in the percentage and number of B cells in response to FIP-
fve stimulation may be associated with the significant enhancement in 
antibody production. 
In previous chapter, I have demonstrated that FIP-fve can serve as adjuvant to 
enhance the immune responses of OVA-specific CD8
+
 T cells in vitro. To 
address whether FIP-fve can enhance the immune response of antigen-specific 
CD8
+
 T cell in vivo, the OT-I CD8
+
 T cell transfer model was used. Mice were 
then immunized with peptide AVHAAHAEINEAGSIINFEKL which 
contained an OVA-specific CD4
+
 T epitope AAHAEINEA followed by the 
OVA-specific CD8
+
 T epitope SIINFEKL. My present short-term 
immunization experiment demonstrated that the use of FIP-fve as an adjuvant 
during OVA peptide immunization significantly elevated both the percentage 
and number of OVA-specific CD8
+
 T cells in vivo. This is probably due to the 
enhancement of antigen presenting function and also the cross priming 
function of dendritic cells as a longer peptide sequences were used for 
immunization. Because FIP-fve is not capable of inducing DCs maturation in 
vitro, such enhancement may be mediated via the indirect effect of FIP-fve-
activated T cells. Interestingly, the inclusion of IFA with the OVA peptide 
resulted in significant lower percentage and number of antigen-specific CD8
+
 
T cells in the draining lymph nodes than that of without IFA, albeit it was still 
 139 
 
significantly higher than that of its control group. This phenomenon may be 
due to the slow-release properties of IFA as a depot adjuvant; hence, only a 
small amount of OVA peptide is released from the site of injection and being 
captured in the draining lymph nodes within 3 days of immunization, resulting 
in less extent of expansion on OVA-specific CD8
+
 T cells. Besides, the lower 
percentage and number of OVA-specific CD8
+
 T cells in the group with IFA 
may also be caused by the difference in the kinetic of T cells activaton. This is 
demonstrated by the expression profile of CD69. This early T cell activation 
marker was still up-regulated on OVA-specific CD8
+
 T cells of both groups 
receiving OVAp/IFA immunization. In contrast, the up-regulation of CD69 
could no longer be seen but the up-regulation of CD27 and CD28 were more 
prominent in the two groups receiving OVAp immunization without IFA. 
Since the long-term protective effect and memory responses have always been 
the goal of every vaccination strategy, I also attempted to examine the 
frequency and phenotype of antigen-specific CD8
+
 T cells at day 20 post-
immunization. Unfortunately, my results indicated that the percentage and 
number of OVA-specific CD8
+
 T cells in all the OVA peptide-immunized 
groups were significantly reduced to a level in which there was no longer any 
significant difference as compared to the PBS control group. Furthermore, 
there was no difference in the percentage of OVA-specific effector or memory 
CD8
+
 T cells between OVA peptide and FIP-fve+OVA peptide immunized 
groups. Numerous studies have demonstrated that peptide vaccination, in the 
absence of CD4
+
 helper T cell co-stimulation, could show robust and 
immunoprotective effects in the acute phase; however, the number of antigen-
specific CD8
+
 T cells were rapidly diminished over the time, leaving a poor 
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and low avidity memory response (Alexander-Miller et al., 1996; Bourgeois et 
al., 2002; Bullock et al., 2003; Janssen et al., 2003; Kumaraguru et al., 2002). 
A vaccination strategy using recombinant human hsp70 coupled to the peptide 
(SSIEFARL), an immunodominant peptide epitope recognized by HSV-
specific T cells, demonstrated excellent immunity during a short term 
immunization; however, by day 90 post-immunization, the immunity had 
waned to a level which was significantly less than that of the mice immunized 
with UV-inactivated HSV (Kumaraguru et al., 2002). Several studies using 
murine models of chronic viral infections suggested that CD4
+
 helper T cells 
are essential for maintaining CD8
+
 CTL responses (Shedlock and Shen, 2003; 
Sun and Bevan, 2003). When CD8
+
 T cells were raised in the absence of CD4
+
 







 (Khanolkar et al., 2004). It was suggested that either 
CD4
+
 T cells could provide the help to CD8
+
 T cells via CD40 and CD154 
interaction which would condition the APCs for effective activation of CD8
+
 
T cells or there may be a direct effect of CD40 on the responding CD8
+
 T cells 
(Khanolkar et al., 2004; Lefrançois et al., 1999; Ninomiya et al., 2002). 
Janssen et al. reported that the CD8
+
 T cell responses produced in the absence 
of CD4
+
 helper T cells would still function effectively in the primary phase 
but their deficiencies became more evident in the memory phase; nevertheless, 
the treatment of these memory cells with IL-2 during in vitro restimulation 
was found to restore their functionality (Janssen et al., 2003). Though the 
immunization peptide used in this study contains the epitope of CD4
+
 T helper 
cells, it is possible that the number of activated OVA-specific T helper cells is 
too low as compared to the activated OVA-specific CD8
+





T cells transfer model and hence these OVA-specific T helper cells do not 
provide enough helper function to CD8
+
 T cells. A modified animal model, for 
example transfer of T cells from both OT-I and OT-II mice, is required to 
address whether FIP-fve can enhance the long-term effector or memory 
responses of CD8
+
 T.  
Peptide vaccination has been known to provide the highest safety profile as 
compared to vaccination using the live or attenuated pathogens. However, due 
to the low immunogenicity nature of its antigen, the success of peptide 
vaccination is almost indispensable from the use of adjuvants. One of the 
many approaches which use the combination of synthetic CD8
+
 T cell 
epitopes, toll-like receptor agonists, and co-stimulatory anti-CD40 antibodies 
has successfully induced a large number of long-lasting antigen-specific CD8
+
 
T cells which are capable of recognizing and killing the tumor cells in vivo 
(Cho and Celis, 2009). Toka et al. demonstrated that peptide immunization 
using MHC class-I-restricted epitopes from HSV-1 could not elicit an 
effective CD8
+
 T cell memory immune response. Instead, this vaccination 
strategy led to the generation of functionally impaired memory CD8
+
 T cell 
responses due to the lack of helper CD4
+
 T cell activation. However, co-
administration of rIL-12, pIL-15 or anti-CD40 in combination with the peptide 
and TLR9 ligand at the beginning of immunization led to the generation of 
functional memory CD8
+
 T cells which were several fold higher than 
immunization with peptide alone (Toka et al., 2005). To date, several recent 
studies have modified the peptide immunization protocol and successfully 
induce strong memory T cell populations using the synthetic peptide epitopes. 
Nonetheless, these studies have used high doses of antigen, recombinant 
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cytokines, potent agonistic antibodies for T cell costimulation, as well as 
multiple repeated immunizations; thereby making these strategies not feasible 
for a mass vaccination setting. In this chapter, I demonstrated that FIP-fve 
could activate the local immune responses when injected into the mouse 
footpad as well as successfully enhance the percentage and number of antigen-
specific CD8
+
 T cells in the short term immunization experiment, suggesting 
the potential use of FIP-fve as an adjuvant in the peptide vaccination design 
which aims to boost the antigen-specific CD8
+
 T cell responses. Despite the 
results from current long term immunization experiment failed to demonstrate 
the enhancement of memory antigen-specific CD8
+
 T cells, further 
modification and optimization on current immunization protocol to sustain the 
survival of memory antigen-specific CD8
+
 T cells could still be explored. 
More details on the optimization of current protocol for future studies will be 









Conclusions and future perspectives 
5.1 Conclusions 
Among the members of Fungal Immunomodulatory Proteins (FIPs) family, 
LZ-8 (derived from Ganoderma lucidum), has been shown to promote the 
activation and maturation of human monocyte-derived dendritic cells, as 
shown by the up-regulation of CD80, CD86, CD83, and HLA-DR expressions 
as well as enhanced production of IL-12 p40, IL-10, and IL-23 (Lin et al., 
2009b). On the other hand, our present study demonstrated that FIP-fve did not 
enhance the expressions of CD40, I-A
b
, CD80, and CD86 on mouse bone 
marrow-derived dendritic cells (BM-DCs). Interestingly, when BM-DCs were 
co-cultured with either T cells and FIP-fve or FIP-fve-pre-stimulated T cells, 
the expressions of CD40, I-A
b
, CD80, and CD86 on BM-DCs were shown to 
be up-regulated, suggesting that the main target cell of FIP-fve could be on T 
cells. Indeed, when purified T cells alone were stimulated with FIP-fve, the 
expressions of CD25, CD69, and CD137 (4-1BB) on CD4
+
 T and CD8
+
 T 
cells were vastly enhanced. Moreover, the expressions of CD27 and CD28 
were also up-regulated mainly on CD8
+
 T cells. Hence, this result suggests 
that FIP-fve may directly stimulate and activate T cells in the absence of 
accessory cells. When T cells were co-cultured with BM-DCs, which served 
as accessory cells, a similar surface expression profile was still observed on T 
cells in the presence of FIP-fve. Besides, the expression of CD134 (OX-40) on 
CD4
+
 T cells was also shown to be enhanced in this setup. 
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Besides the surface expression profile, we were also interested in 
cytokine/chemokine as well as cellular proliferation profiles of FIP-fve-
stimulated T cells. The secretion of cytokine/chemokine, such as IFN-γ, IP-10, 
and MIG were shown to be more enhanced in the presence of BM-DCs. More 
importantly, CD8
+
 T cells were found to be the main producer of the 
cytokine/chemokine in response to FIP-fve stimulation since the levels of the 
secreted cytokine/chemokine, including IFN-γ, IP-10, MIG, MIP-1α, and 
MIP-1β were greatly enhanced in this co-culture group as compared to that of 
CD4
+
 T cell co-culture group. Similarly, for the cellular proliferation profile, 
despite FIP-fve could significantly increase the stimulation index of CD4
+
 T 
cell and BM-DCs co-culture group to about 6.4, the stimulation index was 
higher in CD8
+
 T cell and BM-DCs co-culture group, which was about 21.5. 
Hence, these results suggest that FIP-fve preferentially targets at CD8
+
 T cells 
to stimulate the cytokine/chemokine expression and cellular proliferations. 
Next, since we found that FIP-fve stimulation could up-regulate the 
expressions of CD27, CD134 (OX-40), and CD137 (4-1BB) on T cells and the 
interaction between T cells and BM-DCs were important for FIP-fve-induced 
cellular proliferation and cytokine/chemokine secretion, we were interested in 
whether the engagement of these molecules on T cells with their respective 
ligands may play essential role in mediating optimal biological effect of FIP-
fve. For cellular proliferation profile, the addition of anti-CD70 blocking 
antibody significantly reduced the CD8
+
 T cell proliferation. Whereas, the 
simultaneous addition of anti-CD70 and anti-OX-40L antibodies significantly 
decrease the cellular proliferation of total T cell, CD4
+
 T cell, and CD8
+
 T 
cells. Similarly, for cytokine/chemokine profile, the simultaneous of blocking 
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of CD70 and OX-40L in CD8
+
 T cell co-culture group resulted in significant 
attenuation of IFN-γ, MIG, MIP-1α, and MIP-1β secretion. Whereas, for CD4+ 
T cell co-culture group, we did not observe any significant blocking effect, 
mainly due to the low level of cytokine/chemokine being produced in co-
culture group. Thus, our results suggest that the binding of CD27 and CD134 
(OX-40) on T cell with their cognate ligands may be involved in mediating the 
mitogenic activity of FIP-fve on T cell. Moreover, the low level 
cytokine/chemokine in CD4
+
 T cell co-culture group further confirm the 
preferential effect of FIP-fve on CD8
+
 T cells; hence, we then focus on the 
effect of FIP-fve on CD8
+
 T cell function in our subsequent studies. 
Besides its mitogenic activity, we demonstrated that the pre-stimulation of 
OT-I CD8
+
 T cells with FIP-fve could also significantly enhance the kinetics 
of cellular proliferation of antigen-specific CD8
+
 T cells. The secretion of 
IFN-γ was shown to be significantly increased when OT-I CD8+ T cells were 
pre-stimulated with FIP-fve. More importantly, when co-cultured with 
C57BL/6J mouse lymphoma cell line, EL4, the pre-stimulated OT-I CD8
+
 T 
cells exhibited enhanced killing function particularly at low effector to target 
cell ratio. Thus, our results suggest that pre-stimulation of OT-I CD8
+
 T cells 
with FIP-fve significantly accelerate and enhance the magnitude as well as the 
function of antigen-specific CD8
+
 T cells. 
Next, when FIP-fve was injected into the mouse footpad, we found that the 
local immune response was activated, as shown by significant increase in the 





 T cells as well as higher ratio of CD8
+
 T to CD4
+
 T cells, the 
expressions of CD27 and CD28 on CD8
+
 T cells were also significantly up-
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regulated at day 3 post-injection in the FIP-fve-injected mice. In addition to T 









 (macrophages) were also 
significantly enhanced. Further analysis using in vivo BrdU incorporation 
assay suggested that both CD4
+
 T and CD8
+
 T cells could proliferate in 
response to FIP-fve stimulation, whereas other cell types, such as B cells and 
NK cells were most likely being recruited into the draining lymph nodes of 
FIP-fve-injected mice. 
To demonstrate the adjuvant effect of FIP-fve on the enhancement of antigen-
specific CD8
+
 T cell responses in vivo, we performed a peptide immunization 
experiment using the OVA mouse model. In our short term immunization 
regime, we showed that FIP-fve, as an adjuvant, significantly increased both 
the percentage and number OVA-specific CD8
+
 T cells. However, 
unfortunately, at day 20 post-immunization, we found that there was no longer 
any difference in the percentage and number of OVA-specific CD8
+
 T cells 
among the OVA peptide-injected groups and the PBS control group.  
To summarize, we demonstrated that FIP-fve significantly enhanced T cells 
proliferation and their cytokine/chemokine secretion via the up-regulation and 
engagement of T cell co-stimulary molecules CD27 and OX-40. In addition, 
FIP-fve was also shown to accelerate as well as significantly enhance the 
magnitude and function of antigen-specific CD8
+
 T cell responses in vitro. 
More importantly, the use of FIP-fve as an adjuvant in vivo led to a significant 
increase in both the percentage and number of activated antigen-specific CD8
+
 
T cells. To conclude, my results suggest that FIP-fve may exert its function as 
an adjuvant via the potentiation of T cells by up-regulation of co-stimulatory 
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molecules as well as enhancement of T cell proliferation and their 
cytokine/chemokine secretion, thus results in a microenvironment which 
favors the activation of antigen-specific immune responses. Similar 
mechanisms of action by other adjuvants have also been demonstrated in other 
studies where an increase in the antigen-specific T cell proliferation, cytokines 
production as well as up-regulation of T cell co-stimulatory molecules were 
observed (Heal et al., 2001; Ryan et al., 1998). Finally, our findings suggest 
that the FIP-fve, which is derived from a natural product with a long history of 
nutritional and medicinal values, may serve as a potent adjuvant particularly in 
the vaccines that aim for a strong elicitation of antigen-specific CD8
+
 T cells 
response, such as in the cancers and viral-related diseases. 
5.2 Postulated mechanism of action of FIP-fve 
Based on our in vitro and in vivo findings, we suggest that following 
stimulation with FIP-fve, T cells may be activated or potentiated, as indicated 
by the up-regulation of CD25, CD69, and CD137 (4-1BB) expressions on both 
CD4
+
 T and CD8
+
 T cells. In addition, the expressions of CD27 and CD28 
will also be up-regulated, mainly on CD8
+
 T cells. Furthermore, besides the 
enhanced T cell proliferation, the chemokines, including MIP-1α and MIP-1β 
are secreted at a moderate level by the activated T cells.  
Next, in the presence of FIP-fve-stimulated T cells, the expression of CD40, I-
A
b
 and CD86 on dendritic cells (DCs) may also be up-regulated, leading to 
increased efficiency in antigen processing and presentation to T cells. When T 
cells are fully activated via antigen presentation (e.g. OVA257-264 peptide in our 
studies) and co-stimulatory signals (i.e. involving the binding of CD27 and 
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OX-40 with their respective ligands on DCs), the clonal expansion of antigen-
specific T cells will be significantly enhanced. Moreover, the secretion of 
cytokine/chemokines, such as IFN-γ, IP-10, MIG, MIP-1α, and MIP-1β by 
CD8
+
 T cells will also be significantly elevated, resulting in the recruitment of 
other cell types including B cells, NK cells, NK T cells, DCs, and 
macrophages into the draining lymph nodes (Fig. 5.1). As a consequence, this 
will then create a microenvironment which may favor the initiation and 
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Figure 5.1 Postulated mechanism of action of FIP-fve. Upon stimulation 
with FIP-fve, T cells may be potentiated or activated, as indicated by the up-





 T cells. In addition, the expressions of CD27 and CD28 are also up-
regulated, mainly on CD8
+
 T cells. Besides enhancing T cell proliferation, 
FIP-fve may also induce the secretion of some chemokines, including MIP-1α 
and MIP-1β at a moderate level by the activated T cells. Furthermore, in the 
presence of FIP-fve-stimulated T cells, the expression of CD40, I-A
b
 and 
CD86 on dendritic cells (DCs) may also be up-regulated. Next, when T cells 
are further activated via antigen presentation (e.g. OVA257-264 peptide in our 
studies) and co-stimulatory signals (i.e. involving the binding of CD70 and 
OX-40L with their cognate receptors on APCs), the clonal expansion of 
antigen-specific CD8
+
 T cells will be significantly enhanced. Moreover, the 
secretion of cytokine/chemokines, such as IFN-γ, IP-10, MIG, MIP-1α, and 
MIP-1β will also be significantly elevated, resulting in the recruitment of other 
cell types including B cells, NK cells, NK T cells, DCs, and Macrophages. As 
a consequence, this microenvironment may then favor the activation of 








5.3  Future perspectives 
There are several aspects which are worth to be further characterized in future 
studies. 
5.3.1  The mechanisms on how FIP-fve-stimulated T cells may drive the 
maturation of bone marrow-derived dendritic cells (BM-DCs) 
Results demonstrated that FIP-fve failed to drive the maturation of BM-DCs 
by itself. However, the expressions of CD40, I-A
b
, CD80, and CD86 were up-
regulated in the presence of T cells that suggested the phenotypic maturation 
of BM-DCs. One of the hallmarks for FIP-fve stimulation on human peripheral 
blood lymphocytes and mouse lymphocytes is its capability to enhance the 
transcriptional expression and secretion of IFN-γ (Ding et al., 2009; Ko et al., 
1995a). He et al. have shown for the first time that IFN-γ was capable to 
stimulate the maturation of a dendric cell line DC2.4, as indicated by the up-
regulation of I-A
b
, CD40, CD80, and CCR7 as well as the more efficient 
induction of cytotoxic T cell responses and antitumor immunity both in vitro 
and in vivo (He et al., 2007). Hence, we speculate that the IFN-γ secreted by 
FIP-fve-stimulated T cells may drive the maturation of BM-DCs and it is 
feasible to prove this hypothesis by either blocking the IFN-γ in the co-culture 
of T cells and BM-DCs using the anti-IFN-γ blocking antibody or employing 
the T cells from IFN-γ-/- mice. Moreover, since our results showed that the 
interaction between the FIP-fve-pre-stimulated T cells and BM-DCs also 
resulted in BM-DCs maturation, the pre-stimulated T cells may provide some 
co-stimulatory signals to further activate the BM-DCs. Thus, the blocking of 
the co-stimulatory molecules, such as CD27, CD40L, CD134 (OX-40), and 
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CD137 (4-1BB) may also be performed to investigate their roles in mediating 
the BM-DCs maturation upon FIP-fve stimulation.  
5.3.2  Functional assays for the target genes determined by gene 
expression array study 
The gene expression profile from our array study indicated that the transcript 
level of several important genes involved in the regulation of immune system, 
namely signal transducer and activator of transcription 1 (Stat1), CD160, 
TNFSF14, serine hydroxymethyltransferase -1 and -2 (Shmt1 and Shmt2) were 
up-regulated on CD8
+
 T cells upon 8 hours of stimulation with FIP-fve. 
STAT1 signaling has been shown to be required for the clonal expansion and 
the memory formation of CD8
+
 T cells following viral infection in vivo 
(Quigley et al., 2008). A functional assay to block the STAT1 signaling using 
STAT1-specific inhibitor (i.e. fludarabine) during FIP-fve stimulation may be 
performed to investigate whether this signaling may play any significant role 
in mediating FIP-fve-induced-cellular proliferation and -cytokine/chemokine 
secretion on CD8
+
 T cells.  
CD160 is a member of Ig superfamily and expressed on about 10% of CD8
+
 T 
cells (memory phenotype, CD44 high), few CD4
+
 T cells, and about 20% of 
NK cells in mouse splenocytes (Cai and Freeman, 2009). TNFSF14, or known 
as lymphotoxin-like, exhibits inducible expression, and competes with herpes 
simplex virus glycoprotein D for HVEM, a receptor expressed by T 
lymphocytes (LIGHT) is a member of TNF family and expressed mainly on 
activated T cells (Mauri et al.) and immature DCs (Tamada et al., 2000). Both 
CD160 and LIGHT are the ligands for HVEM (herpes virus entry mediator) 
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(TNFR family members) (Cai et al., 2008; Tamada et al., 2000). The 
expression of HVEM and its ligands is extensive and may be expressed on 
either side of T cell/APC interaction (Cai and Freeman, 2009). The binding of 
CD160 to HVEM provides co-inhibitory signal to T cell activation (Cai et al., 
2008), whereas the binding of LIGHT to HVEM  delivers co-stimulatory 
signal to drive T cell activation and expansion (Shaikh et al., 2001). Since FIP-
fve stimulation enhances the transcriptional expression of both CD160 and 
LIGHT, we speculate that this may serve as a bidirectional switch mechanism 
for FIP-fve to regulate T cell activation in a co-stimulatory or co-inhibitory 
manner whose outcome depends on the ligand engaged (Cai and Freeman, 
2009). To prove this hypothesis, the expression of CD160 and LIGHT needs 
to be further examined at protein level by immunostaining or western blot. 
Moreover, a functional study to determine the role of these molecules may be 





 mice for in vivo studies.  
Furthermore, upon analyzing the signature genes involved in the significantly 
affected pathways on CD8
+
 T cells during FIP-fve stimulation, serine 
hydroxymethyltransferas 1 (Shmt1) and 2 (Shmt2) were shown to be 
significantly up-regulated at 8 hours after FIP-fve stimulation on CD8
+
 T cells. 
These two genes were known to be involved in between amino acid and folate 
metabolic pathways by providing the major source of one-carbon units in cells 
for several essential biosynthetic processes, such as thymidylate, purines, 
methionine, etc (Stover and Schirch, 1990). Folate deficiency leads to 
nucleotide imbalance like increased dUMP/dTMP ratios and uracil 
misincorporation into DNA. Folate deficiency also induced cell cycle arrest in 
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cell ratio due to a marked reduction of CD8
+
 T cells proliferation 
(Courtemanche et al., 2004). Thus, the proliferation or activation of CD8
+
 T 
cells are more sensitive to folate deficiency and the significance of SHMT 
enzyme activity on CD8
+
 T cell activation remains to be examined.  
5.3.3  Involvement of TNF signaling pathways in mediating the 
mitogenic effect of FIP-fve on T cells 
The binding of TNF ligands to their receptors has been shown to recruit the 
TNF receptor associated factors (TRAF 2, 5) to the cytoplasmic tail of the 
receptor, followed by subsequent recruitment of NF-κB-inducing kinase, IKK 
signalosome, leading to activation of NF-κB and c-Jun kinase signaling 
pathways (Akiba et al., 1998). The activation of these pathways is essential for 
the survival of effector and memory T cells (Denoeud and Moser, 2011). The 
preliminary result from our laboratory demonstrated that the NF-κB-/- mice 
receiving subcutaneous injection with FIP-fve showed significantly reduced 
IFN-γ in their sera as compared to that of wild type mice receiving the similar 
treatment (data not published). Furthermore, our present result also indicated 
that the binding of CD27 and CD134 (OX-40) on T cells with their respective 
ligands were essential in mediating the optimal biological effect of FIP-fve. 
Taken together, we suggest that the signaling pathway activated by receptors 
of TNF family may play some important role on T cell activation during FIP-
fve stimulation. An in vitro study to block the cytoplasmic molecules, such as 
TRAFs proteins, NF-κB and c-Jun kinase as well as the in vivo study using the 
knockout mice for these molecules may be considered to further investigate 
the role of these pathways on T cells during FIP-fve stimulation. 
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5.3.4  Role of CD27 and OX-40 during in vivo FIP-fve stimulation  
As mentioned earlier, we have shown that CD27 and OX-40 are involved in 
mediating the biological effect of FIP-fve in vitro. Thus, it is imperative to 
further prove this phenomenon in the in vivo setting. In present study, we have 
attempted to block the CD27 and OX-40 in our short-term immunization 
protocol; however, we observed no significant blocking effect in this 
experimental setup (data not shown). Since the role of these molecules is 
mainly to maintain the survival of effector and memory T cells (Hendriks et 
al., 2003), we speculate that the blocking effect of these molecules may only 
be observed in the later stage of immunization regimen. Hence, to further 





 mice to further confirm the role of these 
molecules in mediating the adjuvant effect of FIP-fve. In addition, the role of 
these molecules in mediating the activation of local immune responses upon 
footpad injection of the mice with FIP-fve may also be further investigated.  
5.3.5  Role of B cells in the draining lymph nodes upon FIP-fve 
stimulation  
My present result suggested that B cells could be recruited into the draining 
lymph nodes in response to FIP-fve stimulation, as shown by the significant 
increase in both their percentage and number. The role of B cells in antibody 
production and antigen presentation has been widely known. I hypothesize 
that the recruitment of B cells into the draining lymph nodes may mediate the 
adjuvant effect of FIP-fve via enhancement of antigen presentation to the FIP-
fve-stimulated T cells, which subsequently lead to augmentation of adaptive 
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immune responses. Further investigation on the role of B cells in mediating 
the adjuvant effect of FIP-fve can be carried by performing immunization 
studies on B cell-deficient mice. 
5.3.6  Optimization of long term peptide immunization protocol to 
maintain the survival of effector and memory antigen-specific 
CD8
+
 T cells 
At day 20 post-immunization, our present results indicated that there was no 
longer any significant difference in the percentage and number of OVA-
specific CD8
+
 T cells among the peptide-immunized groups and PBS control 
group. Since Barry T. Rouse and his group demonstrate that the incorporation 
of IL-12, IL-15 or anti-CD40 antibody at the inception of peptide 
immunization is required to rescue the reactivity of memory CD8
+
 T cells 
(Toka et al., 2005), we suggest that our present peptide immunization protocol 
may need to be further optimized by incorporation of these signaling 
molecules, particularly for the long term immunization study. 
5.3.7  Identification of target cellular receptor for FIP-fve binding  
Recent study suggested that the carbohydrate binding module family 34 
(CBM-34) on FIP-fve could bind to the ligand-like glycoproteins on the 
surface of human PBMCs, as demonstrated by the reduced secretion of IFN-γ 
induction upon treatment of human PBMCs with tunicamycin and 
deglycosylation enzymes (Liu et al., 2012). Nevertheless, further screening of 
the candidate oligosaccharides which may mediate the interaction between 
FIP-fve and the target cells is imperative and yet to be accomplished. Hence, 
we proposed that the screening of the target oligosaccharides may be feasible 
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by employing the oligosaccharides array and further functional assay can be 
carried out to examine the effect of a specific oligosaccharide on FIP-fve-
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Appendix 1. Various mushrooms from which the fungal 
immunomodulatory proteins are isolated from. A. Ganoderma lucidum 
(LZ-8) B. Flammulina velutipes (FIP-fve) C. Ganoderma tsugae (FIP-gts) D. 
Ganoderma sinensis (FIP-gsi) E. Poria cocos (FIP-pcp) F. Volvariella 
volvacea (FIP-vvo) G. Antrodia camphorate (FIP-aca) H. Ganoderma 
japonicum (FIP-gja) I. Ganoderma microsporum (FIP-gmi) J. Trametes 
versicolor (FIP-tvc)
A. B. C. 
D. E. F. 




Appendix 2. Attenuation of FIP-fve-induced cellular proliferation upon treatment with anti-4-1BBL, anti-CD70, and  
                     anti-OX-40L antagonist monoclonal antibodies. 
 
 
Blocking antibodies against 













4-1BBL (1 µg/ml) 4632±237 5231±369 13577±672 12241±790 34978±2869 37389±1161 
4-1BBL (10 µg/ml) 4819±559 5303±372 12438±100 12853±601 32660±1464* 36740±914 
CD70 (1 µg/ml) 5025±394 5162±221 11802±521 12766±667 27780±1482** 36398±971 
CD70 (10 µg/ml) 4340±138 5369±567 10766±591** 13641±668 26373±1072*** 38962±794 
OX-40L (1 µg/ml) 4734±461 5162±221 12111±657 12766±667 34822±3673 36398±971 
OX-40L (10 µg/ml) 4074±210* 5369±567 10617±703** 13641±668 31607±1097** 38962±794 
4-1BBL+CD70 (1 µg/ml) 5350±558 5280±369 10898±517* 12498±290 30606±1642 38160±3932 
4-1BBL+CD70 (10 µg/ml) 4326±497 5702±576 11229±752* 13242±535 28850±2693* 38103±1569 
CD70+OX-40L (1 µg/ml) 3718±216* 5071±321 9978±784** 12378±252 23665±470*** 35498±652 
CD70+OX-40L (10 µg/ml) 3691±346** 5103±612 9487±224*** 13161±527 22539±1458*** 36142±526 
4-1BBL+OX-40L (1 µg/ml) 5350±170 5280±369 10898±392** 12498±290 34216±586 38160±3932 
4-1BBL+OX-40L (10 µg/ml) 3566±10* 5702±576 10842±346** 13242±535 32018±2910* 38103±1569 
4-1BBL+CD70+OX-40L (1 µg/ml) 3778±44 5160±286 9356±188*** 12678±320 24020±2041* 37627±492 
4-1BBL+CD70+OX-40L (10 µg/ml) 3258±180* 5376±366 8804±230** 13526±549 22631±2171*** 36792±846 
 
a) Co-cultures of either T cells, CD4+ T cells or CD8+ T cells and BM-DCs were treated with 1 µg/ml or 10 µg/ml of 
anti-4-1BBL, anti-CD70, and anti-OX-40L blocking antibodies either separately or in combination, in the presence 
of 40 µg/ml of FIP-fve. The count per minute (cpm) value of each co-culture was presented as mean±SD. 
Representative data from three independent experiments were shown. The P was calculated by two-tailed student’s t-
test to indicate whether there was a statistically significant reduction in cellular proliferation after blocking with 
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Appendix 3. Cytokine/chemokine profiles of total T cells (A), CD4
+
 T cells 
(B) or CD8
+
 T cells (C) and BM-DCs co-culture in the absence of any 
blocking antibody or in the presence of 1 μg/ml of IgG2b, 2 μg/ml of 
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Appendix 4. Intra-footpad injection of FIP-fve induced the enlargement of 
draining lymph nodes. C57BL6/J mice (n = 3) were injected with phosphate-
buffered saline (PBS) at the left hind footpad and 10 μg of FIP-fve at the right 
footpad. Popliteal lymph nodes from both legs were harvested on day 3. Scale 




















Appendix 5. List of differentially expressed genes from (A) CD4
+
 T cells stimulated with FIP-fve for 2 hours (fold change  2, p < 0.05), 
(B) CD8
+
 T cells stimulated with FIP-fve for 2 hours (fold change  2, p < 0.05), (C) CD4+ T cells stimulated with FIP-fve for 8 hours 
(fold change  2, p < 0.05), and (D) CD8+ T cells stimulated with FIP-fve for 8 hours (fold change  2, p < 0.05). 
 
Gene Symbol Gene Name 
Genbank 
Accession 
Regulation Fold Change P 
Gm9837 predicted gene 9837 XR_035252 up 3.4797056 0.02225
4955 Irf4 interferon regulatory factor 4 NM_013674 up 3.4357455 0.02109
1342 Sh3bp2 SH3-domain binding protein 2 NM_001145859 up 3.0211334 0.02995
6229 4933430I17Rik RIKEN cDNA 4933430I17 gene NM_177607 up 2.829553 0.01991
6415 Ptpn6 protein tyrosine phosphatase, non-receptor type 6 NM_001077705 up 2.7329936 0.00814
0353 Tmem100 transmembrane protein 100 NM_026433 up 2.4213498 .03358
565 Filip1l filamin A interacting protein 1-like NM_001040397 up 2.3752463 0.02124
2324 Pten phosphatase and tensin homolog NM_008960 down 2.3739383 0.00938
8052 Cstad CSA-conditional, T cell activation-dependent protein NM_030137 up 2.2234955 0.03042
697 Lhfpl5 lipoma HMGIC fusion partner-like 5 NM_026571 up 2.2170644 0.02472
132 2900024J01Rik RIKEN cDNA 2900024J01 gene AK013590 down 2.093694 0.01031
6681 4921509J17Rik RIKEN cDNA 4921509J17 gene AK054449 up 2.081829 0.00326
1675 Ccdc126 coiled-coil domain containing 126 NM_175098 up 2.0710483 0.00478
5996 Oxct2b 3-oxoacid CoA transferase 2B NM_181859 up 2.06198 0.01545
8052 Sprr4 small proline-rich protein 4 NM_173070 up 2.0570703 0.01177
0014 Olfr635 olfactory receptor 635 NM_147118 down 2.0419192 .00392












Ccl3 chemokine (C-C motif) ligand 3 NM_011337 up 5.256667 8.61E-05 
Irf4 interferon regulatory factor 4 NM_013674 up 4.367921 0.004046038 
Vmn1r174 vomeronasal 1 receptor 174 NM_207548 up 3.0203142 0.023934016 
Evc Ellis van Creveld gene homolog (human) AK039759 up 2.5953102 0.007224277 
Cnksr1 connector enhancer of kinase suppressor of Ras 1 NM_001081047 up 2.4724708 0.008420905 
Hivep3 
human immunodeficiency virus type I enhancer 
binding protein 3 
NM_010657 up 2.4318874 0.046128303 
Nfib nuclear factor I/B NM_001113209 up 2.3615806 0.005448656 
Sh3bp2 SH3-domain binding protein 2 NM_001145859 up 2.3276072 0.007176471 
A030001D20Rik RIKEN cDNA A030001D20 gene XR_105107 up 2.298684 0.037044495 
Mfsd2a 
major facilitator superfamily domain containing 
2A 
NM_029662 up 2.257764 0.018745128 
Tnfrsf19 
tumor necrosis factor receptor superfamily, 
member 19 
NM_013869 up 2.228792 0.047607522 
1700083H02Rik RIKEN cDNA 1700083H02 gene XR_105493 up 2.195019 0.01616316 
Ptpn6 protein tyrosine phosphatase, non-receptor type 6 NM_001077705 up 2.1842816 0.011437132 
Rxfp3 relaxin family peptide receptor 3 NM_178717 up 2.141611 0.027180376 
Cdc42bpg 
CDC42 binding protein kinase gamma (DMPK-
like) 
NM_001033342 up 2.1177194 0.047938462 
Pten phosphatase and tensin homolog NM_008960 down 2.0666077 0.03992658 





Limk1 LIM-domain containing, protein kinase NM_010717 down 2.0282893 0.028264014 
 
 







Irf4 interferon regulatory factor 4 NM_013674 up 8.140772 0.004190415 
Spire1 spire homolog 1 (Drosophila) NM_194355 down 7.908469 6.12E-04 
Car12 carbonic anyhydrase 12 NM_178396 up 7.676612 0.018706389 
Egr1 early growth response 1 NM_007913 up 7.0512743 0.010342522 
Lad1 ladinin NM_133664 up 6.745348 0.025661122 
Sh3bp2 SH3-domain binding protein 2 NM_001145859 up 5.963758 0.009290759 
Shmt1 serine hydroxymethyltransferase 1 (soluble) NM_009171 up 5.8120494 0.010672449 
Egr2 early growth response 2 NM_010118 up 5.2566724 0.001233879 
Phospho1 phosphatase, orphan 1 NM_153104 up 5.0930963 3.12E-05 
Cx3cl1 chemokine (C-X3-C motif) ligand 1 NM_009142 up 4.494423 0.022517107 
Mfsd2a 
major facilitator superfamily domain containing 
2A 
NM_029662 up 4.374759 0.00423285 
Mettl1 methyltransferase like 1 NM_010792 up 4.1399627 0.029981298 
Tnf tumor necrosis factor NM_013693 up 4.0129695 3.03E-04 
Ankrd33b ankyrin repeat domain 33B NM_026153 up 3.9828992 0.024032865 
Pdgfa platelet derived growth factor, alpha NM_008808 up 3.957803 0.022370454 
Pdgfa platelet derived growth factor, alpha NM_008808 up 3.8516357 0.011569384 





LOC633387 nucleophosmin-like AK088923 up 3.6311033 0.001355297 
Spin2 spindlin family, member 2 NM_001005370 up 3.47032 0.03196626 
Nid1 nidogen 1 NM_010917 up 3.3642967 0.031092815 
Srm spermidine synthase NM_009272 up 3.3148746 0.009805273 
Ccl17 chemokine (C-C motif) ligand 17 NM_011332 up 3.2871373 0.034596816 
Nr4a1 nuclear receptor subfamily 4, group A, member 1 NM_010444 up 3.2534978 0.03437307 
Srm spermidine synthase NM_009272 up 3.1432748 0.016827837 
Spry1 sprouty homolog 1 (Drosophila) NM_011896 up 3.0746431 0.041461393 
Il2 interleukin 2 NM_008366 up 3.0584786 0.019530455 
Tubb3 tubulin, beta 3 NM_023279 up 3.047813 0.015074148 
Slc16a5 
solute carrier family 16 (monocarboxylic acid 
transporters), member 5 
NM_001080934 down 2.9728265 0.016887002 
Npas4 neuronal PAS domain protein 4 NM_153553 up 2.9718938 0.015738506 
Itm2a integral membrane protein 2A NM_008409 up 2.902343 0.0012051 
Il2ra interleukin 2 receptor, alpha chain NM_008367 up 2.803659 0.04446209 
Cdkn2b 
cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4) 
NM_007670 up 2.8028913 2.92E-04 
Rps8 ribosomal protein S8 NM_009098 up 2.7964888 0.00579305 
LOC100505352 hypothetical LOC100505352 XR_105662 down 2.7448459 0.013366438 
Arhgap30 Rho GTPase activating protein 30 NM_001005508 down 2.6525204 0.003635782 
Ptpn6 protein tyrosine phosphatase, non-receptor type 6 NM_001077705 up 2.5330527 0.027656224 
Sspn sarcospan NM_010656 down 2.5209315 9.81E-04 
Trmt61a 
tRNA methyltransferase 61 homolog A (S. 
cerevisiae) 
NM_177374 up 2.4795432 0.03989746 




Tmem100 transmembrane protein 100 NM_026433 up 2.450574 0.00415689 
Idi1 isopentenyl-diphosphate delta isomerase NM_145360 up 2.433004 0.014255975 
Slc2a6 
solute carrier family 2 (facilitated glucose 
transporter), member 6 
NM_172659 up 2.3811362 0.006360101 
Gpatch4 G patch domain containing 4 NM_025663 up 2.3749862 0.008489723 
Tmem97 transmembrane protein 97 BC018156 up 2.369614 0.034593847 
Slc2a6 
solute carrier family 2 (facilitated glucose 
transporter), member 6 
NM_172659 up 2.336041 0.017180905 
Ppa1 pyrophosphatase (inorganic) 1 NM_026438 up 2.3357093 0.006170663 
Cstad 
CSA-conditional, T cell activation-dependent 
protein 
NM_030137 up 2.3189847 0.021252798 
Hcn3 
hyperpolarization-activated, cyclic nucleotide-
gated K+ 3 
NM_008227 up 2.3122 0.006525525 
2610318N02Rik RIKEN cDNA 2610318N02 gene NM_183287 up 2.3115945 0.010434897 
Myc myelocytomatosis oncogene NM_010849 up 2.2850776 0.025386449 
Cd69 CD69 antigen NM_001033122 up 2.2701309 0.035306577 
4921508M14Rik RIKEN cDNA 4921508M14 gene XM_001480797 down 2.2617626 0.02736339 
Rrp15 
ribosomal RNA processing 15 homolog (S. 
cerevisiae) 
NM_026041 up 2.2607 0.004162227 
Slc29a2 
solute carrier family 29 (nucleoside transporters), 
member 2 
NM_007854 up 2.2535505 0.030622924 
Ampd1 adenosine monophosphate deaminase 1 NM_001033303 up 2.2510004 8.80E-04 
Apex1 apurinic/apyrimidinic endonuclease 1 NM_009687 up 2.2369697 0.00224763 
Bcl2l1 BCL2-like 1 NM_009743 up 2.231806 0.038724676 
Grwd1 glutamate-rich WD repeat containing 1 NM_153419 up 2.221313 0.034383718 
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Ap1s3 adaptor-related protein complex AP-1, sigma 3 NM_183027 up 2.2081962 0.032300077 
Sqle squalene epoxidase NM_009270 up 2.2074208 0.028498549 
Sult2b1 sulfotransferase family, cytosolic, 2B, member 1 NM_017465 up 2.2033367 0.004380901 
D430040L24Rik RIKEN cDNA D430040L24 gene AK085126 up 2.1931489 0.017471345 
Tsr1 TSR1, 20S rRNA accumulation, homolog (yeast) NM_177325 up 2.1931002 0.015550312 
Mthfd1 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent), methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthase 
NM_138745 up 2.1855493 0.04960205 
1810029B16Rik RIKEN cDNA 1810029B16 gene NM_025465 up 2.185123 0.034098506 
Pus7 
pseudouridylate synthase 7 homolog (S. 
cerevisiae) 
NM_178403 up 2.162011 0.010530055 
Zcchc12 zinc finger, CCHC domain containing 12 NM_028325 up 2.1568904 0.027311917 
BC035044 cDNA sequence BC035044 AK088258 up 2.141731 0.03922537 
Mrto4 MRT4, mRNA turnover 4, homolog (S. cerevisiae) BC005734 up 2.117711 0.007138579 
Nme1 
non-metastatic cells 1, protein (NM23A) expressed 
in 
NM_008704 up 2.0949047 0.004115156 
Smyd2 SET and MYND domain containing 2 NM_026796 up 2.0928624 0.0174967 
1810029B16Rik RIKEN cDNA 1810029B16 gene NM_025465 up 2.08084 0.009133809 
Ccr4 chemokine (C-C motif) receptor 4 NM_009916 up 2.0678015 0.013503821 
Shmt2 serine hydroxymethyltransferase 2 (mitochondrial) NM_028230 up 2.05301 0.034888152 
Tsr1 TSR1, 20S rRNA accumulation, homolog (yeast) NM_177325 up 2.051847 0.013235289 
Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide NM_013517 up 2.0491948 0.008075465 
Ctps cytidine 5'-triphosphate synthase NM_016748 up 2.0382645 0.02704164 
Mrto4 MRT4, mRNA turnover 4, homolog (S. cerevisiae) NM_023536 up 2.0348485 0.002852731 
Nhp2 NHP2 ribonucleoprotein homolog (yeast) NM_026631 up 2.0335355 0.008995205 
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3110009E18Rik RIKEN cDNA 3110009E18 gene NM_001172074 up 2.0314724 0.016229652 
Btla B and T lymphocyte associated NM_001037719 up 2.0248694 0.011077255 
Pdcd1lg2 programmed cell death 1 ligand 2 NM_021396 up 2.0148518 9.79E-04 
Foxp1 forkhead box P1 BC065386 down 2.0142102 0.035525795 
Dpp9 dipeptidylpeptidase 9 NM_172624 down 2.0123916 0.007034154 
Slc19a1 
solute carrier family 19 (sodium/hydrogen 
exchanger), member 1 
NM_031196 up 2.0118363 0.008395236 
Timm8a1 
translocase of inner mitochondrial membrane 8 
homolog a1 (yeast) 
NM_013898 up 2.001069 0.015499417 
 
 







Xcl1 chemokine (C motif) ligand 1 NM_008510 up 20.045 0.002459959 
Car12 carbonic anyhydrase 12 NM_178396 up 16.48581 0.010780769 
Tnfrsf9 
tumor necrosis factor receptor superfamily, 
member 9 
NM_011612 up 16.440792 0.00418519 
Ccl4 chemokine (C-C motif) ligand 4 NM_013652 up 13.556017 0.047086168 
Shmt1 serine hydroxymethyltransferase 1 (soluble) NM_009171 up 13.5391445 0.009317861 
Nr4a1 nuclear receptor subfamily 4, group A, member 1 NM_010444 up 13.288273 0.002330976 
Spry1 sprouty homolog 1 (Drosophila) NM_011896 up 13.2675495 0.009502939 
Tnf tumor necrosis factor NM_013693 up 12.151814 0.018616967 





Rgs16 regulator of G-protein signaling 16 NM_011267 up 11.732979 0.001545092 
Hivep3 
human immunodeficiency virus type I enhancer 
binding protein 3 
NM_010657 up 10.097288 0.007434807 
Mfsd2a 
major facilitator superfamily domain containing 
2A 
NM_029662 up 9.753259 0.005968136 
Tnfsf15 
tumor necrosis factor (ligand) superfamily, 
member 15 
NM_177371 down 8.461118 0.024600461 
Egr1 early growth response 1 NM_007913 up 8.002019 0.001550117 
Npas4 neuronal PAS domain protein 4 NM_153553 up 7.8499317 0.024911199 
Npw neuropeptide W NM_001099664 up 7.6641006 0.0292544 
Cxcl10 chemokine (C-X-C motif) ligand 10 NM_021274 up 7.514691 0.04615513 
Il2ra interleukin 2 receptor, alpha chain NM_008367 up 7.4328437 0.002570049 
Hk2 hexokinase 2 NM_013820 up 6.9063654 0.03770174 
Egr2 early growth response 2 NM_010118 up 6.5035596 0.023528941 
LOC633387 nucleophosmin-like AK088923 up 5.7941666 0.009638781 
Srm spermidine synthase NM_009272 up 5.601749 0.003224699 
Srm spermidine synthase NM_009272 up 5.561835 0.002714972 
Nr4a2 nuclear receptor subfamily 4, group A, member 2 NM_013613 up 5.5614076 0.018154632 
Aebp1 AE binding protein 1 NM_009636 up 5.455985 0.04196094 
Gm4951 predicted gene 4951 NM_001033767 up 5.4285917 0.049687486 
Slc29a2 
solute carrier family 29 (nucleoside transporters), 
member 2 
NM_007854 up 5.146043 0.006842438 
Spire1 spire homolog 1 (Drosophila) NM_194355 down 5.1432056 6.50E-04 
Sh3bp2 SH3-domain binding protein 2 NM_001145859 up 5.108641 0.02043719 
Fos FBJ osteosarcoma oncogene NM_010234 up 5.067428 0.014389986 
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Adarb1 adenosine deaminase, RNA-specific, B1 NM_001024837 up 4.588621 0.042835355 
Slamf1 
signaling lymphocytic activation molecule family 
member 1 
NM_013730 up 4.577707 0.002457373 
Mpa2l macrophage activation 2 like NM_194336 up 4.4677014 0.01301897 
Mettl1 methyltransferase like 1 NM_010792 up 4.463764 0.001219419 
Itm2a integral membrane protein 2A NM_008409 up 4.2759814 0.008470559 
Lag3 lymphocyte-activation gene 3 NM_008479 up 4.2695155 1.59E-04 
Pdcd1lg2 programmed cell death 1 ligand 2 NM_021396 up 4.2358994 0.024108713 
Palm paralemmin NM_023128 up 4.1622043 0.002261308 
Tgtp2 T-cell specific GTPase 2 NM_001145164 up 4.081973 0.042108793 
Cd274 CD274 antigen NM_021893 up 3.997621 0.037299894 
Sult2b1 sulfotransferase family, cytosolic, 2B, member 1 NM_017465 up 3.9724054 0.035152484 
Cdca7 cell division cycle associated 7 NM_025866 up 3.9537857 0.00555481 
Rps8 ribosomal protein S8 NM_009098 up 3.9299219 0.017928049 
Ppa1 pyrophosphatase (inorganic) 1 NM_026438 up 3.919028 0.006612788 
Spin2 spindlin family, member 2 NM_001005370 up 3.8355954 0.004598794 
Ifng interferon gamma NM_008337 up 3.7782936 0.030295929 
Serpina3f 
serine (or cysteine) peptidase inhibitor, clade A, 
member 3F 
NM_001168294 up 3.663834 0.029035427 
Tmem97 transmembrane protein 97 BC018156 up 3.5707088 0.009874257 
Slc19a1 
solute carrier family 19 (sodium/hydrogen 
exchanger), member 1 
NM_031196 up 3.4125168 0.001288981 
Tgtp1 T-cell specific GTPase 1 NM_011579 up 3.3749835 0.016168108 
Fabp5 fatty acid binding protein 5, epidermal NM_010634 up 3.3628292 0.020304706 
Tmem97 transmembrane protein 97 NM_133706 up 3.3235068 0.015743507 
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Irgm1 immunity-related GTPase family M member 1 NM_008326 up 3.2865977 0.019597333 
Psat1 phosphoserine aminotransferase 1 NM_177420 up 3.276928 9.78E-04 
Stat1 signal transducer and activator of transcription 1 NM_009283 up 3.2118115 0.040126458 
Thop1 thimet oligopeptidase 1 NM_022653 up 3.2072623 0.033955168 
Trmt61a 
tRNA methyltransferase 61 homolog A (S. 
cerevisiae) 
NM_177374 up 3.1844592 0.011621012 
Cd69 CD69 antigen NM_001033122 up 3.1806493 0.006963861 
Zfp799 zinc finger protein 799 NM_177359 down 3.1119468 0.012603028 
2610318N02Rik RIKEN cDNA 2610318N02 gene NM_183287 up 3.1043248 0.04267297 
Sh3gl3 SH3-domain GRB2-like 3 NM_017400 up 3.0976608 0.003683876 
Irgm1 immunity-related GTPase family M member 1 NM_008326 up 3.0695608 0.017934429 
Sqle squalene epoxidase NM_009270 up 3.038444 0.001253718 
Rrp12 
ribosomal RNA processing 12 homolog (S. 
cerevisiae) 
NM_199447 up 3.0179553 0.044703282 
Apex1 apurinic/apyrimidinic endonuclease 1 NM_009687 up 2.990109 0.011433071 
Idi1 isopentenyl-diphosphate delta isomerase NM_145360 up 2.9825127 0.025764558 
Myc myelocytomatosis oncogene NM_010849 up 2.9546292 0.021750174 
Arhgap30 Rho GTPase activating protein 30 NM_001005508 down 2.940713 6.98E-04 
Pcsk4 proprotein convertase subtilisin/kexin type 4 NM_008793 up 2.9274518 0.005251265 
Nolc1 nucleolar and coiled-body phosphoprotein 1 NM_001039352 up 2.8426373 0.014603077 
Rrp15 
ribosomal RNA processing 15 homolog (S. 
cerevisiae) 
NM_026041 up 2.7766376 0.012171356 
Grwd1 glutamate-rich WD repeat containing 1 NM_153419 up 2.751346 0.018345905 
Slc7a5 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 5 




solute carrier family 16 (monocarboxylic acid 
transporters), member 5 
NM_001080934 down 2.7025926 0.024020417 
Nrn1 neuritin 1 NM_153529 up 2.7025023 0.039360143 
Phlda3 
pleckstrin homology-like domain, family A, 
member 3 
NM_013750 up 2.6707354 0.009892793 
Bcl2a1d B-cell leukemia/lymphoma 2 related protein A1d NM_007536 up 2.6539793 0.00323096 
Shmt2 
serine hydroxymethyltransferase 2 
(mitochondrial) 
NM_028230 up 2.6462433 0.001458249 
Tacc2 
transforming, acidic coiled-coil containing 
protein 2 
NM_001004468 up 2.6359475 4.70E-05 
Nhlrc1 NHL repeat containing 1 NM_175340 up 2.5863314 0.03726643 
Ampd1 adenosine monophosphate deaminase 1 NM_001033303 up 2.5826304 0.014416995 
Mthfd1 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent), methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthase 
NM_138745 up 2.581006 4.40E-04 
Mrto4 
MRT4, mRNA turnover 4, homolog (S. 
cerevisiae) 
NM_023536 up 2.5797157 0.015633812 
1810029B16Rik RIKEN cDNA 1810029B16 gene NM_025465 up 2.556316 0.005996791 
Bcl2a1c B-cell leukemia/lymphoma 2 related protein A1c NM_007535 up 2.5534356 0.002917405 
Ptpn6 protein tyrosine phosphatase, non-receptor type 6 NM_001077705 up 2.5083823 8.22E-04 
Gvin1 GTPase, very large interferon inducible 1 NM_029000 up 2.4909472 0.0145393 
Mrto4 
MRT4, mRNA turnover 4, homolog (S. 
cerevisiae) 
BC005734 up 2.4900682 0.011269894 
Irgm2 immunity-related GTPase family M member 2 NM_019440 up 2.4890494 0.043649748 
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) NM_007669 up 2.4788723 0.03381372 
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Id3 inhibitor of DNA binding 3 NM_008321 up 2.4709892 0.008031624 
Plk3 polo-like kinase 3 (Drosophila) NM_013807 up 2.462057 0.018447641 
Mthfd2 
methylenetetrahydrofolate dehydrogenase 
(NAD+ dependent), methenyltetrahydrofolate 
cyclohydrolase 
NM_008638 up 2.4596305 0.010300177 
Timm8a1 
translocase of inner mitochondrial membrane 8 
homolog a1 (yeast) 
NM_013898 up 2.4457116 0.023019517 
Gvin1 GTPase, very large interferon inducible 1 NM_029000 up 2.4396155 0.006844762 
Gpatch4 G patch domain containing 4 NM_025663 up 2.4183915 0.021541437 
Dgat2 diacylglycerol O-acyltransferase 2 NM_026384 up 2.4087539 0.045338858 
Atad3a ATPase family, AAA domain containing 3A NM_179203 up 2.3857121 0.006589732 
Gm4593 predicted gene 4593 AK138221 down 2.3848946 0.018940616 
Gcsh 
glycine cleavage system protein H (aminomethyl 
carrier) 
NM_026572 up 2.3746936 0.016596237 
Crtam cytotoxic and regulatory T cell molecule NM_019465 up 2.3640199 0.003940221 
Smyd5 SET and MYND domain containing 5 NM_144918 up 2.3631485 0.003985385 
Bysl bystin-like NM_016859 up 2.3608692 0.040971376 
Nop2 NOP2 nucleolar protein homolog (yeast) NM_138747 up 2.3575218 0.011538867 
Slc29a1 
solute carrier family 29 (nucleoside transporters), 
member 1 
NM_001199113 up 2.3560774 0.046489414 
Nop16 NOP16 nucleolar protein homolog (yeast) NM_178605 up 2.3461752 0.01603507 
Smyd2 SET and MYND domain containing 2 NM_026796 up 2.3357644 0.035710447 
Hspd1 heat shock protein 1 (chaperonin) NM_010477 up 2.3247085 0.009286335 
LOC674321 
glycine cleavage system H protein, 
mitochondrial-like 
XM_973659 up 2.319473 0.004692658 
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Rufy4 RUN and FYVE domain containing 4 NM_001034060 down 2.316652 0.003157147 
Gpatch4 G patch domain containing 4 NM_025663 up 2.316304 0.026861405 
Gcsh 
glycine cleavage system protein H (aminomethyl 
carrier) 
NM_026572 up 2.3139274 0.003004725 
Vmn1r174 vomeronasal 1 receptor 174 NM_207548 up 2.3109982 0.04157509 
Lrrc32 leucine rich repeat containing 32 NM_001113379 up 2.3095057 0.011775986 
2210411K11Rik RIKEN cDNA 2210411K11 gene NM_029384 up 2.3074267 0.00269434 
Polr1b polymerase (RNA) I polypeptide B NM_009086 up 2.2952795 0.01812196 
Nat10 N-acetyltransferase 10 NM_153126 up 2.2933593 0.019256348 
Ppan peter pan homolog (Drosophila) NM_145610 up 2.2902029 0.012302553 
Ccdc86 coiled-coil domain containing 86 NM_023731 up 2.284328 0.028157113 
Tfrc transferrin receptor NM_011638 up 2.2783825 5.91E-04 
Tfrc transferrin receptor NM_011638 up 2.2739108 0.005956268 
Tsr1 TSR1, 20S rRNA accumulation, homolog (yeast) NM_177325 up 2.2654264 9.22E-04 
Gm4535 predicted gene 4535 NM_001101644 up 2.2509294 0.028429132 
Gstm7 glutathione S-transferase, mu 7 NM_026672 up 2.2374082 0.006943373 
Nme1 
non-metastatic cells 1, protein (NM23A) 
expressed in 
NM_008704 up 2.2222323 0.004716296 
Cstad 
CSA-conditional, T cell activation-dependent 
protein 
NM_030137 up 2.213671 0.007156267 
Rangrf RAN guanine nucleotide release factor NM_021329 up 2.2103572 0.023022408 
Ddx21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 NM_019553 up 2.1972573 0.012942265 
Abcc6 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 6 
NM_018795 up 2.192189 0.021172252 
Timm8a1 translocase of inner mitochondrial membrane 8 NM_013898 up 2.1882493 0.00112417 
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homolog a1 (yeast) 
Ydjc YdjC homolog (bacterial) NM_026940 up 2.185817 0.007364599 
Pecr peroxisomal trans-2-enoyl-CoA reductase NM_023523 up 2.171287 0.031732555 
Dpp9 dipeptidylpeptidase 9 NM_172624 down 2.168815 0.007993945 
Tsr1 TSR1, 20S rRNA accumulation, homolog (yeast) NM_177325 up 2.1630435 0.009908472 
Dph1 DPH1 homolog (S. cerevisiae) NM_144491 up 2.1588042 0.00716082 
Rrp1b 
ribosomal RNA processing 1 homolog B (S. 
cerevisiae) 
NM_028244 up 2.15806 0.030495485 
Mif macrophage migration inhibitory factor NM_010798 up 2.1571026 0.001111944 
Galk1 galactokinase 1 NM_016905 up 2.1564667 0.013887965 
Gm16379 predicted pseudogene 16379 NM_001111330 up 2.1507318 2.11E-04 
Timm10 
translocase of inner mitochondrial membrane 10 
homolog (yeast) 
NM_013899 up 2.1501675 0.003139836 
Nme1 
non-metastatic cells 1, protein (NM23A) 
expressed in 
NM_008704 up 2.142064 0.002999448 
Eif5a eukaryotic translation initiation factor 5A NM_001166589 up 2.1407874 0.023308251 
Acaca acetyl-Coenzyme A carboxylase alpha NM_133360 up 2.139207 0.0433441 
4933416A02Rik RIKEN cDNA 4933416A02 gene AK016828 up 2.1358428 0.023505626 
Ctps cytidine 5'-triphosphate synthase NM_016748 up 2.1348054 0.010590617 
Nop58 NOP58 ribonucleoprotein homolog (yeast) NM_018868 up 2.1336908 0.003754866 





NM_011373 up 2.1191401 0.017234754 




Lap3 leucine aminopeptidase 3 NM_024434 up 2.1175323 0.004291365 
Set SET nuclear oncogene NM_023871 up 2.111692 0.005066021 
2610528E23Rik RIKEN cDNA 2610528E23 gene NM_025599 up 2.1053982 0.008898007 
Pno1 partner of NOB1 homolog (S. cerevisiae) NM_025443 up 2.0941198 0.035090618 
Grwd1 glutamate-rich WD repeat containing 1 NM_153419 up 2.0928404 0.005954872 
Sla src-like adaptor NM_001029841 up 2.092072 0.048941154 
Gpr34 G protein-coupled receptor 34 NM_011823 down 2.0762432 0.046996787 
Ifrd2 interferon-related developmental regulator 2 NM_025903 up 2.0750096 0.010826063 
Hirip3 HIRA interacting protein 3 NM_172746 up 2.0659122 0.011750827 
Mybbp1a MYB binding protein (P160) 1a NM_016776 up 2.0629482 0.038839255 
Mif macrophage migration inhibitory factor NM_010798 up 2.0619664 6.63E-04 
Timm10 
translocase of inner mitochondrial membrane 10 
homolog (yeast) 
NM_013899 up 2.053955 0.005721839 
Lhfpl5 lipoma HMGIC fusion partner-like 5 NM_026571 up 2.0526109 0.023324028 
LOC100505352 hypothetical LOC100505352 XR_105662 up 2.052408 0.007230552 
Urb2 
URB2 ribosome biogenesis 2 homolog (S. 
cerevisiae) 
NM_001029876 up 2.050914 0.031089623 
Mif macrophage migration inhibitory factor BC024895 up 2.0450888 6.97E-04 
LOC100505352 hypothetical LOC100505352 XR_105662 down 2.0421376 0.010597723 
Gm4847 predicted gene 4847 NM_001164312 up 2.0360558 0.00909575 
BC048355 cDNA sequence BC048355 NM_207161 up 2.0359075 6.63E-04 
1700083H02Rik RIKEN cDNA 1700083H02 gene XR_105493 up 2.0301652 0.009033634 
Pa2g4 proliferation-associated 2G4 NM_011119 up 2.0296278 0.009111036 
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Ptp4a3 protein tyrosine phosphatase 4a3 NM_008975 up 2.0280318 0.025235169 
LOC100047671 OX-2 membrane glycoprotein-like XM_003085107 up 2.0270658 0.010950261 
Rcl1 RNA terminal phosphate cyclase-like 1 NM_021525 up 2.026847 0.007582858 
Rangrf RAN guanine nucleotide release factor NM_021329 up 2.0261743 0.012812769 
1300001I01Rik RIKEN cDNA 1300001I01 gene NM_001081158 up 2.0241292 0.031341694 
Slc6a9 
solute carrier family 6 (neurotransmitter 
transporter, glycine), member 9 
NM_008135 up 2.0239275 0.021380704 
Atad3a ATPase family, AAA domain containing 3A NM_179203 up 2.0236843 0.022415906 
Utf1 
undifferentiated embryonic cell transcription 
factor 1 
NM_009482 up 2.0226367 0.039011545 
Dctpp1 dCTP pyrophosphatase 1 NM_023203 up 2.0209544 0.001326682 
Trav7n-5 T cell receptor alpha variable 7N-5 EF154513 up 2.018493 0.018968118 
Mrps28 mitochondrial ribosomal protein S28 NM_025434 up 2.0160968 0.011000129 
Lta lymphotoxin A NM_010735 up 2.0076125 0.012416441 
Nhp2 NHP2 ribonucleoprotein homolog (yeast) NM_026631 up 2.0072896 0.002909734 
Mdn1 midasin homolog (yeast) NM_001081392 up 2.004864 0.008483809 
Hspa9 heat shock protein 9 NM_010481 up 2.0033247 0.023031335 
Trib1 tribbles homolog 1 (Drosophila) NM_144549 up 2.0023227 0.0425038 
 
